

10/572,343 (RCE)



***** Welcome to STN International *****
 ***** STN Columbus *****

FILE 'HOME' ENTERED AT 07:56:06 ON 14 APR 2010

=> file reg

=>

Uploading C:\Program Files\Stnexp\Queries\Queries\10572343_04142010.str



```
chain nodes :
11 13 14 16 17 18 19 23
ring nodes :
1 2 3 4 5 6 7 8 9 10
chain bonds :
7-11 9-13 10-23 13-14 13-16 17-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10
exact/norm bonds :
4-7 5-10 7-8 7-11 8-9 9-10 10-23 13-14 13-16 17-18
exact bonds :
9-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
```

G1:O,N,Cy

G2:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:CLASS 13:CLASS 14:CLASS 16:CLASS 17:Atom 18:CLASS 19:Atom 23:CLASS
 Generic attributes :

17:

Saturation : Unsaturated

=> s l6 sam

L7 45 SEA SSS SAM L6

=> s l6 full

L8 2081 SEA SSS FUL L6

=> file caplus

=> s 18

L9 68 L8

=> s 19 and pd< sept 2002

22860028 PD< SEPT 2002

(PD<20020900)

L11 35 L9 AND PD< SEPT 2002

=> dis l11 1-35 bib abs hitstr

L11 ANSWER 1 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2002:935696 CAPLUS Full-text

DN 138:395808

TI Acute and chronic effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats

AU Inoue, Hirotaka; Yano, Koji; Noto, Tsunehisa; Takagi, Michino; Ikee, Tomihiro; Kikkawa, Kohei

CS Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, 335-8505, Japan

SO Biological & Pharmaceutical Bulletin (2002), 25(11), 1422-1426

CODEN: BPBLEO; ISSN: 0918-6158

PB Pharmaceutical Society of Japan

DT Journal

LA English

AB We examined the hemodynamic property of T-1032 (Me 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate), a novel selective phosphodiesterase type 5 (PDE5) inhibitor, and evaluated the chronic effect of T-1032 on cardiac remodeling and its related death in monocrotaline (MCT)-induced pulmonary hypertensive rats. T-1032 (1, 10, 100 µg/kg, i.v.) significantly reduced mean arterial pressure (MAP) and right ventricular systolic pressure (RVSP) without a change in heart rate. The change in RVSP was more potent than that in MAP with 1 µg/kg T-1032 treatment (RVSP: -8.2±1.2%, mean arterial pressure: -5.7±1.2%), and redns. in RVSP and MAP reached a peak at doses of 1 and 10 µg/kg, resp. In contrast, nitroglycerin (0.1, 1, 10 µg/kg, i.v.) and beraprost (0.1, 1 µg/kg, i.v.) did not cause a selective reduction in RVSP at any dose. When T-1032 (300 ppm in diet) was chronically administered, it delayed the death, and significantly suppressed right ventricular remodeling (T-1032-treated: 0.318±0.021 g, control: 0.401±0.013 g, p<0.05). Our present results suggest that T-1032 selectively reduces RVSP, and resulting in the suppression of right ventricular remodeling with a delay of the death in MCT-induced pulmonary hypertensive rats.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CME C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
 RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2002:816308 CAPLUS [Full-text](#)

DN 138:348489

TI Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure

AU Yamamoto, Takashi; Wada, Atsuyuki; Ohnishi, Masato; Tsutamoto, Takayoshi; Fujii, Masanori; Matsumoto, Takehiro; Takayama, Tomoyuki; Wang, Xinwen; Kurokawa, Kiyoshi; Kinoshita, Masahiko

CS First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Shiga, 520-2192, Japan

SO Clinical Science (2002), 103(Suppl.), 258S-262S

CODEN: CSCIAE; ISSN: 0143-5221

PB Portland Press Ltd.

DT Journal

LA English

AB Endothelin-1 (ET-1) and atrial natriuretic peptide (ANP) play important roles in the regulation of body fluid balance in congestive heart failure (CHF). Renal production of ET-1 increases in CHF and it is a significant independent predictor of sodium excretion. ANP inhibits the ET system through cGMP, a second messenger of ANP. However, in severe CHF, plasma cGMP levels reached a plateau despite the activation of ANP secretion. Thus, ANP does not seem to sufficiently oppose exaggerated ET-1 actions in severe CHF, partially due to the accelerated degradation of cGMP, through phosphodiesterase type 5 (PDE5). We examined the chronic effects of a PDE5 inhibitor, T-1032 (1 mg/kg per day, n = 5), on renal function and renal production of ET-1 in dogs with CHF induced by rapid ventricular pacing (270 beats/min). Vehicle dogs were given a placebo (n = 5) and normal dogs (n = 5) served as normal controls without pacing. In this exptl. produced CHF, plasma levels of ET-1, ANP and cGMP were elevated and renal production of cGMP was increased compared with the normal

10/572,343 (RCE)

group, associated with increases in renal expression of prepro-ET-1 mRNA and the number of ET-1-pos. cells in glomeruli. In the T-1032 group, systemic and renal production of cGMP were further increased compared with the vehicle group despite no significant difference in plasma ANP levels between the two groups. Subsequently, the agent significantly improved urine flow rate, sodium excretion rate and glomerular filtration rate (GFR) associated with redns. in renal expression of prepro-ET-1 mRNA and the number of ET-1-pos. cells compared with the vehicle group. Moreover, there was a significant neg. correlation between the number of ET-1-pos. cells and GFR ($r=-0.802$ and $P < 0.001$, resp.). Our results indicate that chronic PDE5 inhibition ameliorates the antagonistic relationship between renal ANP and ET-1 through the cGMP pathway, subsequently preventing renal dysfunction during the progression of CHF.

IT 212500-03-3, T-1032

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/572,343 (RCE)

L11 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2002:615576 CAPLUS Full-text

DN 137:169431

TI Preparation of isoquinolinones as dipeptidyl peptidase IV inhibitors for the prophylaxis or treatment of diabetes

IN Oi, Satoru; Ikedou, Koji; Takeuchi, Koji; Ogino, Masaki; Banno, Yoshihiro; Tawada, Hiroyuki; Yamane, Taihei

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 600 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062764	A1	20020815	WO 2002-JP831	20020201 <--
	WO 2002062764	A9	20021010		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2437492	A1	20020815	CA 2002-2437492	20020201 <--
	AU 2002230126	A1	20020819	AU 2002-230126	20020201 <--
	JP 2003238566	A	20030827	JP 2002-26185	20020201
	JP 4213390	B2	20090121		
	EP 1355886	A1	20031029	EP 2002-711278	20020201
	EP 1355886	B1	20070711		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	HU 2004000058	A2	20040428	HU 2004-58	20020201
	CN 1500080	A	20040526	CN 2002-807429	20020201
	BR 2002006831	A	20040706	BR 2002-6831	20020201
	AT 366724	T	20070815	AT 2002-711278	20020201
	NO 2003003385	A	20030930	NO 2003-3385	20030729
	US 20040082607	A1	20040429	US 2003-470805	20030801
	US 7034039	B2	20060425		
	MX 2003006918	A	20040524	MX 2003-6918	20030801
	IN 2003KN01086	A	20050708	IN 2003-KN1086	20030827
PRAI	JP 2001-27349	A	20010202		
	JP 2001-292388	A	20010925		
	JP 2001-382232	A	20011214		
	WO 2002-JP831	W	20020201		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:169431

GI



AB Title compds. I [R1, R2 = (un)substituted alkyl or heterocyclic ring; A = (un)substituted 5 to 10-membered aromatic ring; X = bond, O, S, etc.; L = divalent hydrocarbon or a salt], their pharmaceutically acceptable salts and formulations were prepared. For example, acylation of amino isoquinolinone II, followed by BOC deprotection provided claimed isoquinolinone III.HCl. Isoquinolinone III inhibited human dipeptidyl peptidase V with an IC50 = 0.25 μ M. Also, the plasma glucose-lowering (76%) and insulinotropic effects (255%) of III in rat were reported. Compds. I have superior peptidase inhibitory activity and are useful for the prophylaxis or treatment of diabetes.


IT 447423-81-6P 447423-82-7P,
6-Benzylloxy-4-(2-fluorophenyl)-2-isobutyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylic acid 447423-94-1P, Methyl
6-benzylloxy-4-(3-fluorophenyl)-2-isobutyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylate 447424-36-4P, Methyl
6-benzylloxy-4-(4-fluorophenyl)-2-isobutyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylate 447424-37-5P,
6-Benzylloxy-4-(4-fluorophenyl)-2-isobutyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylic acid 447424-57-9P, Methyl
6-benzylloxy-2-isobutyl-4-(4-methylphenyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxylate 447424-58-0P,
6-Benzylloxy-2-isobutyl-4-(4-methylphenyl)-1-oxo-1,2-dihydro-3-isoquinolinecarboxylic acid 447424-73-9P, Methyl
6-benzylloxy-4-(4-chlorophenyl)-2-isobutyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylate 447424-74-0P,
6-Benzylloxy-4-(4-chlorophenyl)-2-isobutyl-1-oxo-1,2-dihydro-3-isoquinolinecarboxylic acid 447425-38-9P, Methyl
6-(benzylloxy)-2-isobutyl-1-oxo-4-(2-thienyl)-1,2-dihydro-3-isoquinolinecarboxylate 447425-33-0P,
6-(Benzylloxy)-2-isobutyl-1-oxo-4-(2-thienyl)-1,2-dihydro-3-isoquinolinecarboxylic acid

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of isoquinolinones as dipeptidyl peptidase IV inhibitors for the treatment of diabetes)


RN 447423-81-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2-fluorophenyl)-1,2-dihydro-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 447423-82-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2-fluorophenyl)-1,2-dihydro-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)- (CA INDEX NAME)




RN 447423-94-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-fluorophenyl)-1,2-dihydro-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 447424-36-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 447424-37-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-2-(2-


10/572,343 (RCE)

methylpropyl)-1-oxo-6-(phenylmethoxy)- (CA INDEX NAME)




RN 447424-57-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-(4-methylphenyl)-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 447424-58-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-(4-methylphenyl)-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)- (CA INDEX NAME)




RN 447424-73-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-chlorophenyl)-1,2-dihydro-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 447424-74-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-chlorophenyl)-1,2-dihydro-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)- (CA INDEX NAME)




RN 447425-38-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)-4-(2-thienyl)-, methyl ester (CA INDEX NAME)



RN 447425-39-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methylpropyl)-1-oxo-6-(phenylmethoxy)-4-(2-thienyl)- (CA INDEX NAME)



IT 447419-55-8, Ethyl 6-chloro-4-(4-methoxyphenyl)-2-methyl-1-oxo-

10/572,343 (RCE)


1,2-dihydro-3-isoquinolinecarboxylate 447419-56-3,
 6-Chloro-4-(4-methoxyphenyl)-2-methyl-1-oxo-1,2-dihydro-3-
 isoquinolinecarboxylic acid 447419-61-6, Ethyl
 6-chloro-4-(3-methoxyphenyl)-2-methyl-1-oxo-1,2-dihydro-3-
 isoquinolinecarboxylate 447419-62-7,
 6-Chloro-4-(3-methoxyphenyl)-2-methyl-1-oxo-1,2-dihydro-3-
 isoquinolinecarboxylic acid 447419-73-0, Ethyl
 6-chloro-4-(4-fluorophenyl)-2-methyl-1-oxo-1,2-dihydro-3-
 isoquinolinecarboxylate 447419-75-2,
 6-Chloro-4-(4-fluorophenyl)-2-methyl-1-oxo-1,2-dihydro-3-
 isoquinolinecarboxylic acid 447419-85-4 447419-87-6
 , 6-Chloro-2-methyl-1-oxo-4-(4-trifluoromethylphenyl)-1,2-dihydro-3-
 isoquinolinecarboxylic acid 447420-02-2, Ethyl
 6-chloro-2-methyl-1-oxo-4-(3-nitrophenyl)-1,2-dihydro-3-
 isoquinolinecarboxylate 447420-03-3,
 6-Chloro-2-methyl-1-oxo-4-(3-nitrophenyl)-1,2-dihydro-3-
 isoquinolinecarboxylic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; preparation of isoquinolinones as dipeptidyl peptidase IV
 inhibitors for the treatment of diabetes)


RN 447419-55-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-4-(4-methoxyphenyl)-2-
 methyl-1-oxo-, ethyl ester (CA INDEX NAME)




RN 447419-56-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-4-(4-methoxyphenyl)-2-
 methyl-1-oxo- (CA INDEX NAME)




RN 447419-61-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-4-(3-methoxyphenyl)-2-
 methyl-1-oxo-, ethyl ester (CA INDEX NAME)




RN 447419-62-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-4-(3-methoxyphenyl)-2-methyl-1-oxo- (CA INDEX NAME)




RN 447419-73-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-oxo-, ethyl ester (CA INDEX NAME)



RN 447419-75-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 6-chloro-4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)



RN 447419-85-4 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-2-methyl-1-oxo-4-[4-(trifluoromethyl)phenyl]-, ethyl ester (CA INDEX NAME)




RN 447419-87-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-2-methyl-1-oxo-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 447420-02-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-2-methyl-4-(3-nitrophenyl)-1-oxo-, ethyl ester (CA INDEX NAME)



RN 447420-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-2-methyl-4-(3-nitrophenyl)-1-oxo- (CA INDEX NAME)



OSC.G 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)
 RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2010 ACS ON STN

AN 2002:417327 CAPLUS [Full-text](#)

DN 138:11262

TI T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters

AU Inoue, Hirotaka; Yano, Koji; Noto, Tsunehisa; Takagi, Michino; Ikee, Tomihiro; Kikkawa, Kohei

CS Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Toda, Saitama, 335-8505, Japan

SO European Journal of Pharmacology (2002), 443(1-3), 179-184

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English

AB To evaluate the influence of T-1032 (Me 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinolinecarboxylate sulfate), a potent and relatively selective phosphodiesterase 5 inhibitor, on chronic heart failure, we examined the acute hemodynamic profile of T-1032 and its chronic effect on the survival of Bio 14.6 cardiomyopathic hamsters. In the acute study, T-1032 (1, 10, 100 µg/kg) was administered i.v. by a dose-escalating procedure in 55-wk-old hamsters. T-1032 significantly reduced both the right and left ventricular end-diastolic pressure in a dose-dependent manner. T-1032 modestly reduced the systemic arterial pressure at the highest dose (100 µg/kg i.v.). T-1032 did not change the heart rate or left ventricular dp/dtmax. In the survival study, chronic administration of T-1032 (50 and 500 ppm in a diet) increased survival, and the survival rate was 24.2%, 45.4% and 48.5% in the control, 50 and 500 ppm-treated groups, resp. The median survival was 55, 58 and 58 wk in control, 50 and 500 ppm-treated groups, resp. Anal. of the survival curves revealed that T-1032 (500 ppm) significantly increased the survival of these hamsters (P<0.05 vs. control). It was concluded that T-1032 had beneficial hemodynamic effects on heart failure in Bio 14.6 cardiomyopathic hamsters, and the favorable hemodynamic changes induced by T-1032 were partly related to the increase in the survival of these hamsters. Phosphodiesterase type 5 inhibitors may have therapeutic potential for the treatment of chronic heart failure.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2002:293485 CAPLUS [Full-text](#)

DN 136:304118

TI Methods and compositions for nucleic acid delivery

IN Donahue, Kevin J.; Marban, Eduardo; Nagata, Koichi; Lawrence, John H.

PA Johns Hopkins University, USA

SO PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030470	A1	20020418	WO 2001-US32274	20011015 <--
	WO 2002030470	A9	20030206		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,			

10/572,343 (RCE)

	GQ, GW, ML, MR, NE, SN, TD, TG		
CA 2425835	A1	20020418	CA 2001-2425835
AU 2002014596	A	20020422	AU 2002-14596
US 20020094326	A1	20020718	US 2001-977865
US 6992070	B2	20060131	
EP 1331950	A1	20030806	EP 2001-983146
EP 1331950	B1	20091014	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004534719	T	20041118	JP 2002-533909
AT 445417	T	20091015	AT 2001-983146
PRAI US 2000-240231P	P	20001013	
WO 2001-US32274	W	20011015	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present provides methods and compns. that enable effective delivery of nucleic to desired cells, including to a solid organ such as a mammalian heart. The methods and compns. enable effective gene transfer and subsequent expression to a majority of cells throughout a solid organ such as the heart. Methods and compns. of the invention preferably provide enhanced vascular permeability that enables increased gene transfer to targeted cells, but without significant degradation or injury to endothelial cell layers. It has been shown that administration of one or more phosphodiesterase (PDE) inhibitors, particularly a PDE-5 inhibitor such as sildenafil can enhance nucleic acid delivery to a solid cell mass by amplifying endogenous cGMP and thereby causing an increase in vascular permeability. It was shown that particularly enhanced nucleic acid delivery resulted from combined administration of a PDE-5 inhibitor and another permeability enhancement agent such as VEGF. It has been shown that.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methods and compns. for nucleic acid delivery using phosphodiesterase inhibitor to increase vascular permeability in relation to use of other agents and low calcium concns.)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9
CMF H2 O4 S



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2002:280087 CAPLUS [Full-text](#)
DN 137:272990

TI Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta
AU Mochida, Hideki; Inoue, Hirotaka; Takagi, Michino; Noto, Tsunehisa; Yano, Koji; Kikkawa, Kohei

CS Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Toda, Saitama, 335-8505, Japan

SO European Journal of Pharmacology (2002), 440(1), 45-52
CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English

AB The vasorelaxant effects of sildenafil and T-1032 [methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinyl methoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate], two phosphodiesterase type 5 inhibitors, were examined in the isolated rat aorta. Sildenafil and T-1032, both of which have almost the same potency and selectivity regarding phosphodiesterase type 5 inhibitory activity, produced a similar, moderate, relaxation at 10-10 to 10-7 M (sildenafil: 66.8±13.7%; T-1032: 77.9±10.8% at 10-7 M). However, sildenafil, but not T-1032, produced further relaxation at the higher concns. (sildenafil: 102.0±0.6%; T-1032: 81.0±7.2% at 10-4 M, P<0.05). Sildenafil also produced a more potent relaxation than did T-1032 at the high concns. (10-5 and 10-4 M) in endothelium-denuded aortic rings and in the presence of NG-nitro-l-arginine Me ester (l-NAME), a nitric oxide synthase inhibitor (3×10-4 M). Moreover, the high concns. of sildenafil, but not of T-1032, caused a rightward shift of the concentration-response curve for calcium chloride in K+-depolarized endothelium-denuded preps. In the ligand binding assay for the l-type Ca2+ channels, the affinities of sildenafil at 10-5 M for binding sites of nitrendipine and (-)-desmethoxy verapamil [(-)-D888] (35.2±3.3% and 35.8±1.9%, resp.) were higher than those of T-1032 (11.8±4.0% and -13.1±1.3%, resp., P<0.05). Regarding cyclic nucleotide levels, both phosphodiesterase type 5 inhibitors increased cGMP levels at 10-6 M. However, sildenafil, but not T-1032, further increased cGMP levels at the higher concns. (sildenafil: 15.7±2.7 pmol/mg protein; T-1032: 5.6±0.6 pmol/mg protein at 10-4 M, P<0.05). These results suggested that high concns. of sildenafil had addnl. vasorelaxant properties through mechanisms other than phosphodiesterase type 5 inhibition. Sildenafil-induced relaxation appears to be due to inhibition of the external Ca2+-dependent cascade for contraction and/or to an increase in cGMP levels. In contrast, T-1032 only showed a vasorelaxant property due to phosphodiesterase type 5 inhibition. In conclusion, T-1032 appears to be a specific phosphodiesterase type 5 inhibitor compared with sildenafil and a useful compound to examine the physiol. function of phosphodiesterase type 5.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); BIOL (Biological study)
 (sildenafil and T-1032 showed a different vasorelaxant property in
 isolated rat aorta)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-
 pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
 (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
 RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2002:241329 CAPLUS [Full-text](#)

DN 136:284433

TI Administration of phosphodiesterase inhibitors for the treatment of
 premature ejaculation

IN Wilson, Leland F.; Doherty, Paul C.; Place, Virgil A.; Smith, William L.;
 Abdel-Hamid, Abdou Ali Ibrahim Aboubakr

PA Vivus, Inc., USA

SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 467,094.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 7

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

10/572,343 (RCE)

PI	US	20020037828	A1	20020328	US	2001-888250	20010621 <--
	US	6403597	B2	20020611			
	US	6037346	A	20000314	US	1998-181070	19981027 <--
	US	6548490	B1	20030415	US	1999-467094	19991210
	CA	2451152	A1	20030103	CA	2002-2451152	20020325
	WO	2003000343	A2	20030103	WO	2002-US9415	20020325
	WO	2003000343	A3	20040325			
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW					
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	AU	2002248712	A1	20030108	AU	2002-248712	20020325
	EP	1418896	A2	20040519	EP	2002-717729	20020325
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP	2005519851	T	20050707	JP	2003-506984	20020325
	AU	2005248938	A1	20060202	AU	2005-248938	20051223
PRAI	US	1997-958816	B2	19971028			
	US	1998-181070	A2	19981027			
	US	1999-467094	A2	19991210			
	AU	2001-22566	A3	20001208			
	US	2001-888250	A	20010621			
	WO	2002-US9415	W	20020325			


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as "as needed" basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided. Zaprinst 1.0, mannitol 1.0, microcryst. cellulose 2.0, and magnesium stearate 10 mg are blended in a suitable mixer and then compressed into sublingual tablets. Each sublingual tablet contains 10 mg zaprinst.

IT 212498-37-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (administration of phosphodiesterase inhibitors for treatment of premature ejaculation)

RN 212498-37-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

L11 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2002:51984 CAPLUS Full-text

DN 136:96106

TI Method for stimulating liver regeneration by use of nitric oxide donor

IN Lautt, Wilfred Wayne

PA Can.

SO U.S. Pat. Appl. Publ., 20 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020006930	A1	20020117	US 2001-888171	20010622 <--
	CA 2351250	A1	20011222	CA 2001-2351250	20010622 <--
PRAI	US 2000-213514P	P	20000622		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention provides an NO donor for use in regenerating the liver. Also provided is a pharmaceutical for liver regeneration including an effective amount of the chemical which promotes liver regeneration and a pharmaceutically acceptable carrier. Also provided is a method of stimulating liver regeneration by administering an effective amount of an NO donor or a chemical which stimulates cGMP production

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nitric oxide donors for liver regeneration)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



L11 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2001:467698 CAPLUS [Full-text](#)

DN 135:298499

TI T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats

AU Inoue, H.; Yano, K.; Ikeo, T.; Noto, T.; Kikkawa, K.

CS Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Toda, Saitama, Kawagishi, 335-8505, Japan

SO European Journal of Pharmacology (2001), 422(1-3), 109-114

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English

AB Nitric oxide (NO) donors including organic nitrates dilate capacitance vessels. As inhibition of phosphodiesterase type 5 results in the accumulation of guanosine 3'-5'-cyclic monophosphate (cGMP), specific phosphodiesterase type 5 inhibitors are expected to have a vasodilator property similar to that of NO donors. To test this hypothesis, we examined the effect of methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel specific phosphodiesterase type 5 inhibitor, on mean arterial pressure and mean circulatory filling pressure (an index of venodilation) compared with that of nitroglycerin and diltiazem in mecamlamine- and noradrenaline-treated anesthetized rats. I.v. infusion of T-1032 (0.1, 1, 10 µg/kg/min) dose-dependently decreased mean arterial pressure (-3.8±0.3%, -9.1±0.8%, -16.8±1.5% at doses of 0.1, 1 and 10 µg/kg/min, resp.) and mean circulatory filling pressure (-6.1±0.9%, -12.5±0.7%, -18.6±3.0% at doses of 0.1, 1 and 10 µg/kg/min, resp.). The mean circulatory filling pressure-mean arterial pressure relationship revealed that T-1032 had a selective action on the mean circulatory filling pressure compared with diltiazem (10, 100 µg/kg/min) and a similar or more selective effect than nitroglycerin (0.3, 3 and 30 µg/kg/min). In the next study, we

calculated venous compliance and unstressed volume from the mean circulatory filling pressure-volume relationship. I.v. infusion of T-1032 (3 µg/kg/min) increased venous compliance (3.35±0.40 in T-1032 vs. 2.31±0.15 mL/kg/mm Hg in vehicle, P<0.05) without changing the unstressed volume (37.2±2.80 in T-1032 vs. 42.6±2.37 mL/kg in vehicle, P>0.05). It was concluded that T-1032 increased venous capacitance by increasing venous compliance, and that this selective phosphodiesterase type 5 inhibitor appeared to have a different vasodilator action from that of an NO donor and a Ca²⁺ channel antagonist in that it had a selective action on the mean circulatory filling pressure.

IT 212500-03-3, T 1032

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2001:355514 CAPLUS [Full-text](#)

DN 135:76771

TI Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and


biological activities of a series of 4-aryl-1-isoquinolinone derivatives
 AU Ukita, Tatsuzo; Nakamura, Yoshinori; Kubo, Akira; Yamamoto, Yasuo;
 Moritani, Yasunori; Saruta, Kunio; Higashijima, Takanori; Kotera, Jun;
 Takagi, Michino; Kikkawa, Kohei; Omori, Kenji
 CS Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., Yodogawa Osaka,
 532-8505, Japan
 SO Journal of Medicinal Chemistry (2001), 44(13), 2204-2218
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 135:76771
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A novel class of potent and selective phosphodiesterase 5 (PDE5) inhibitors, the hydrochlorides of 4-aryl-1-isoquinolinone derivs. such as I (R = H, cyclopentyl, morpholino, etc.) designed by the comparison of the structure of cGMP and a previously reported 1-arylnaphthalene lignan, was disclosed. 4-Aryl-1-isoquinolinone derivs. such as the hydrochlorides of I (R = H, cyclopentyl, morpholino, etc.) were prepared and studied as potent and selective inhibitors of phosphodiesterase 5 (PDE5). I were designed by anal. of the structures of cGMP and a previously reported 1-arylnaphthalene lignan. Among these compds., the dihydrochloride of Me 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate (II) exhibited potent PDE5 inhibitory activity (IC₅₀ = 1.0 nM) with high isoenzyme selectivities (IC₅₀ ratio: PDE1/PDE5 = 1300, PDE2/PDE5 > 10 000, PDE3/PDE5 > 10 000, PDE4/PDE5 = 4700, PDE6/PDE5 = 28). Compound II also showed the most potent relaxant effect on isolated rabbit corpus cavernosum (EC₃₀ = 7.9 nM). Isoquinolinone compound III (T-1032), the sulfate salt of II, was selected for further biol. and pharmacol. evaluation of erectile dysfunction.

IT 212488-77-2P 212488-83-0P 212498-37-8P
 347423-79-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of arylisoquinolinone derivs. as selective inhibitors of phosphodiesterase 5 and as potential agents for the treatment of erectile dysfunction)


RN 212488-77-2 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212488-83-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetamino)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-37-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 347423-79-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-[2-(2-pyridinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




IT	212488-86-3P	212488-89-6P	212489-16-5P
	212489-18-4P	212489-24-2P	212489-27-5P
	212489-31-1P	212489-49-1P	212489-68-4P
	212489-94-6P	212490-26-1P	212493-73-4P
	212496-29-8P	212496-33-4P	212499-02-0P
	212499-81-5P	212500-13-5P	212500-15-7P
	260407-28-1P	260407-29-2P	347423-72-7P
	347423-73-3P	347423-75-0P	347423-78-3P
	347423-96-7P	347423-99-8P	347424-00-4P
	347424-01-5P	347424-02-6P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of arylisoquinolinone derivs. as selective inhibitors of phosphodiesterase 5 and as potential agents for the treatment of erectile dysfunction)


RN 212488-86-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[(4-(methylamino)phenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester] (CA INDEX NAME)




RN 212488-89-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(1-piperidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-16-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-18-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-chlorophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-24-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-cyclopentyl-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-27-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(phenylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212489-31-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-(dimethylamino)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212489-49-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-68-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-94-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-methyl-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212490-26-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212492-73-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-29-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212498-33-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-02-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-81-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212500-13-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-4-(3-hydroxy-4,5-dimethoxyphenyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212500-15-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-4-(4-hydroxy-


10/572,343 (RCE)

3,5-dimethoxyphenyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260407-28-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-hydroxyphenyl)-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-29-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 347423-72-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-cyclohexyl-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 347423-73-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-(4-methoxyphenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 347423-75-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(3-aminophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 347423-78-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA


INDEX NAME)



● HCl

RN 347423-98-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, ethyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 347423-99-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:2) (CA INDEX NAME)




RN 347424-00-4 CAPLUS

CN 3-Isoquinolinecarboxamide, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:2) (CA INDEX NAME)




RN 347424-01-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 2-(4-aminophenyl)-1,2-dihydro-N-methyl-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:2) (CA INDEX NAME)



RN 347424-02-6 CAPLUS

CN 3-Isoquinolinecarboxamide, 2-(4-aminophenyl)-1,2-dihydro-N,N-dimethyl-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


IT 212500-02-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of arylisoquinolinone derivs. as selective inhibitors of phosphodiesterase 5 and as potential agents for the treatment of erectile dysfunction)

RN 212500-02-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



IT 212489-07-1P 212490-22-7P 212490-62-5P
 212492-66-7P 212492-78-9P 212498-25-4P
 212498-31-2P 212498-35-6P 212498-80-1P
 212499-17-7P 212499-67-7P 260407-27-0P
 347423-74-9P 347423-76-1P 347423-77-2P
 347423-82-9P 347423-83-0P 347423-84-1P
 347423-85-2P 347423-86-3P 347423-87-4P
 347423-88-5P 347423-89-6P 347423-90-9P
 347423-91-0P 347423-92-1P 347423-93-2P
 347423-94-3P 347423-95-4P 347423-96-5P
 347423-97-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylisoquinolinone derivs. as selective inhibitors of phosphodiesterase 5 and as potential agents for the treatment of erectile dysfunction)

RN 212489-07-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-

trimethoxyphenyl)- (CA INDEX NAME)




RN 212490-22-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-62-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-68-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-78-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-25-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-31-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-35-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-80-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-bromo-3,5-dimethoxyphenyl)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212499-17-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-67-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260407-27-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-[4-(phenylmethoxy)phenyl]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 347423-74-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[3-[(1,1-dimethylethoxy)carbonylamino]phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 347423-76-1 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 347423-77-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 347423-82-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-[3,4-dimethoxy-5-(methoxymethoxy)phenyl]-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 347423-83-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)]- (CA INDEX NAME)




RN 347423-84-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)]-, ethyl ester (CA INDEX NAME)




RN 347423-85-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methoxymethyl ester (CA INDEX NAME)



RN 347423-86-3 CAPLUS


CN Carbamic acid, [4-[3-(aminocarbonyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 347423-87-4 CAPLUS


10/572,343 (RCE)

CN Carbamic acid, [4-[3-[(methylamino)carbonyl]-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 347423-88-5 CAPLUS

CN Carbamic acid, [4-[3-[(dimethylamino)carbonyl]-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 347423-89-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 347423-90-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methoxymethyl ester (CA INDEX NAME)



RN 347423-91-0 CAPLUS


CN Carbamic acid, [4-[3-(aminocarbonyl)-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 347423-92-1 CAPLUS


10/572,343 (RCE)

CN Carbamic acid, [4-[7-hydroxy-3-[(methylamino)carbonyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 347423-93-2 CAPLUS

CN Carbamic acid, [4-[3-[(dimethylamino)carbonyl]-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 347423-94-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 347423-95-4 CAPLUS

CN Carbamic acid, [4-[3-(aminocarbonyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 347423-96-5 CAPLUS

CN Carbamic acid, [4-[3-[(methylamino)carbonyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 347423-97-6 CAPLUS

CN Carbamic acid, [4-[3-[(dimethylamino)carbonyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 212500-03-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of arylisoquinolinone derivs. as selective inhibitors of phosphodiesterase 5 and as potential agents for the treatment of erectile dysfunction)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
 RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2001:125308 CAPLUS [Full-text](#)

DN 134:261216

TI Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum

AU Takagi, Michino; Mochida, Hideki; Noto, Tsunehisa; Yano, Koji; Inoue, Hirota; Ikeo, Tomihiro; Kikkawa, Kohei

CS Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, 335-8505, Japan

SO European Journal of Pharmacology (2001), 411(1/2), 161-168

CODEN: EJPHAZ; ISSN: 0014-2999

PB Elsevier Science B.V.

DT Journal

LA English

AB This study was designed to examine the pharmacol. properties of T-1032 (methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate), a novel phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. T-1032 (3+10⁻¹¹ to 3+10⁻⁷ M) caused an endothelium-dependent relaxation in the isolated rat aorta precontracted with phenylephrine, and the relaxation was accompanied by an increase in cGMP but not cAMP levels. The T-1032-induced relaxation was attenuated by NG-nitro-L-arginine Me ester (L-NAME) (10⁻³ M), a nitric oxide (NO) synthase inhibitor, or 1 H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (10⁻⁵ M), a guanylyl cyclase inhibitor. T-1032 (10⁻⁹, 10⁻⁸ M) produced a potentiation of the relaxation induced by sodium nitroprusside, but not of the relaxation induced by isoproterenol. In the isolated rabbit corpus cavernosum precontracted with phenylephrine, the elec. field stimulation-induced relaxation was attenuated by treatment with tetrodotoxin (10⁻⁶ M) as well as L-NAME (10⁻⁴ M). The L-NAME-inhibited relaxation was restored by treatment with L-arginine (5+10⁻⁴

M). T-1032 (10⁻⁹ to 10⁻⁶ M) and sildenafil (10⁻⁹ to 10⁻⁶ M) produced a potentiation of the elec. field stimulation-induced relaxation as well as a decrease in basal tension in a concentration-dependent manner. It was concluded that T-1032 had potentiating effects on the NO/cGMP signaling pathway in isolated tissues, probably through specific blockade of phosphodiesterase type 5. T-1032 would be a useful compound to examine the physiol. functions of phosphodiesterase type 5 in mammalian tissues.

IT 212500-03-3, T-1032

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmacol. profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2001:122957 CAPLUS [Full-text](#)

DN 134:232211

TI Phosphodiesterase Inhibitor-mediated Potentiation of Adenovirus Delivery to Myocardium

AU Nagata, Koichi; Marban, Eduardo; Lawrence, John H.; Donahue, Kevin J.

CS Institute of Molecular Cardiology, Johns Hopkins University School of
Medicine, Baltimore, MD, 21205, USA
SO Journal of Molecular and Cellular Cardiology (2001), 33(3),
575-580
CODEN: JMCDAJ; ISSN: 0022-2828

PB Academic Press

DT Journal

LA English

AB Current gene therapy models are limited by inadequate vector delivery. Increases in microvascular permeability have been shown to improve adenovirus-mediated gene transfer to ex vivo and in vivo models. We explored the intracellular mechanism underlying the permeabilizing effects of vascular endothelial growth factor (VEGF). Using an ex vivo model of coronary perfusion in rabbits, we found a dose-response relationship between VEGF and the efficiency of adenoviral gene transfer. Inhibitors of nitric oxide synthase and guanylate cyclase prevented the VEGF effect, and analogs of nitric oxide and cGMP mimicked the effect. Co-administration of phosphodiesterase-5 inhibitors and VEGF caused a synergistic increase in gene delivery. These results can be readily applied to existing models to further optimize vector delivery for gene therapy. (c) 2001 Academic Press.

IT 212500-03-3, T 1032

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery of VEGF gene therapy to myocardium of rabbits)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9


CMF H2 O4 S



OSC.G 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
 RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2000:712977 CAPLUS Full-text
 DN 133:281699
 TI Preparation of isoquinoline derivatives as phosphodiesterase V inhibitors
 IN Ukita, Shinzo; Yamada, Koichiro; Ohmori, Kenji; Yoshikawa, Kohei
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 49 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000281654	A	20001010	JP 1999-83022	19990326 <--
PRAI	JP 1999-83022		19990326		
OS	MARPAT 133:281699				
GI					



AB The title compds. I [ring A = benzene ring with substituents; ring B = (un)substituted benzene ring; R1 = (un)substituted alkoxy, halo, etc.; R2 = CO2R3, etc.; R3 = H, etc.], useful as phosphodiesterase V inhibitors (no data), are prepared For example, the title compound II was prepared

IT 299170-56-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (effect of isoquinoline derivs. with phosphodiesterase V inhibiting activity)

RN 299170-56-2 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




IT 299170-53-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoquinoline derivs. as phosphodiesterase V inhibitors)

RN 299170-53-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(2-pyridinyloxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




IT 299170-51-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isoquinoline derivs. as phosphodiesterase V inhibitors)

RN 299170-51-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



L11 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2000:677058 CAPLUS [Full-text](#)

DN 134:13583

TI Characterization and effects of methyl-2-

(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5)

AU Kotera, J.; Fujishige, K.; Michibata, H.; Yuasa, K.; Kubo, A.; Nakamura, Y.; Omori, K.

CS Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, 335-8505, Japan

SO Biochemical Pharmacology (2006), 60(9), 1333-1341
CODEN: BCPCA6; ISSN: 0006-2952

PB Elsevier Science Inc.

DT Journal

LA English

AB An isoquinolone derivative, methyl-2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), was found to be a novel potent inhibitor of cyclic GMP (cGMP)-binding cGMP-specific phosphodiesterase (PDE5). We investigated the inhibitory effects of T-1032 on six PDE isoenzymes isolated from canine tissues. T-1032 specifically inhibited the hydrolysis of cGMP by PDE5 partially purified from canine lung, at a low concentration (ic50 = 1.0 nM, Ki = 1.2 nM), in a competitive manner. In contrast, the ic50 values of T-1032 for PDE1, PDE2, PDE3, and PDE4 were more than 1 µM. T-1032 also inhibited PDE6 from canine retina with an ic50 of 28 nM, which is of the same order of magnitude as the ic50 of sildenafil. cGMP hydrolytic activities of two alternative splice variants of canine PDE5 expressed in COS-7 cells were inhibited by this compound to a similar extent. T-1032 increased the intracellular concentration of cGMP in cultured rat vascular smooth muscle cells in the presence and absence of C-type natriuretic peptide, an activator of membrane-bound guanylate cyclase, whereas the compound did not change cAMP levels. These data indicated that T-1032, which belongs to a new structural class of PDE5 inhibitors, is a potent and selective PDE5 inhibitor. This compound may be useful in pharmacol. studies to examine the role of a cGMP/PDE5 pathway in tissues.

IT 212500-03-3, T-1032

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(characterization and effects of T-1032, novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)
 RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2000:614435 CAPLUS Full-text

DN 133:276299

TI Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs

AU Noto, Tsunehisa; Inoue, Hirotaka; Ikeo, Tomihiro; Kikkawa, Kohei

CS Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, Japan

SO Journal of Pharmacology and Experimental Therapeutics (2000), 294(3), 870-875

CODEN: JPETAB; ISSN: 0022-3565

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

AB We examined the mechanism underlying the potentiation of penile tumescence by Me 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a new potent and selective phosphodiesterase type V inhibitor. In vivo, pelvic nerve stimulation induced a penile tumescence together with increase of total nitric oxide metabolite levels within the corpus cavernosa of anesthetized dogs. I.V. (1-100 µg/kg) and intraduodenal (3, 30, 300 µg/kg) treatment with T-1032 dose dependently potentiated the tumescence. The potency of T-1032 was equivalent to that of sildenafil. T-1032 did not influence the intracavernous pressure when the pelvic nerve stimulation was absent. The potentiation of tumescence was more pronounced by intracavernous than i.v. injection. Intracavernous NG-nitro-L-arginine, a nitric-oxide synthase inhibitor, but not NG-nitro-D-arginine diminished the effects of T-1032 on the tumescence. Furthermore, i.v. T-1032 augmented the tumescence induced by sodium nitroprusside (SNP) but not by vasoactive intestinal polypeptide (VIP). In vitro, in isolated preps. of canine corpus cavernosum precontracted with phenylephrine, SNP (0.01-100 µM) and VIP (0.01-1 µM) produced a dose-dependent relaxation accompanied by an increase in cGMP and cAMP levels, resp. T-1032 augmented the relaxation induced by SNP but not by VIP. These data suggest that oral treatment with T-1032 has potential to improve erectile dysfunction through the inhibition of phosphodiesterase type V in the smooth muscles of corpus cavernosa.

IT 12500-03-3, T 1032

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

10/572,343 (RCE)

(potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 16 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2000:151479 CAPLUS Full-text

DN 132:194298

TI 4-Phenylisoquinolinone derivatives as cGMP phosphodiesterase inhibitors

IN Ukita, Shinzou; Ohmori, Kenji; Ikeo, Tomihiro

PA Tanabe Seiyaku Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 54 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 2000072751	A	20000307	JP 1998-240837	19980826 <--
FRAI	JP 1998-240837		19980826		
OS	MARPAT 132:194298				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title derivs. I [ring A = Q, Q1 [A1 = (1) OH or (2) lower alkoxy which is substituted with (carboxy)phenyl, (lower hydroxyalkyl)pyridyl, (lower alkyl)pyrimidinyl, pyrazinyl]; benzene ring B may be substituted; R1 = (1) lower alkyl which may be substituted with (lower alkyl)pyridyl, OH, lower alkoxy, CO₂H, lower alkoxy carbonyl, CONH₂, (2) Ph which is substituted with lower alkoxy, lower hydroxyalkyl, (un)protected lower aminoalkyl, CO₂H, lower alkoxy carbonyl, (3) (un)protected amino, (4) (un)protected lower alkylamino, (5) di(lower alkyl)amino; R₂ = CO₂R₃, CONR₄R₅; R₃ = H, ester residue; NR₄R₅ = (un)substituted aliphatic heterocyclyl] or their pharmacol. acceptable salts are prepared I inhibit cGMP phosphodiesterase (phosphodiesterase V) (no data) and are useful for prevention and treatment of chronic cardiac failure, angina pectoris, impotence, hypertension, pulmonary hypertension, atherosclerosis, restenosis after PTCA, etc. 7-Benzyloxy-3-hydroxy-4-(3,4,5-trimethoxyphenyl)-3,4-dihydroisocoumarin-3-carboxylic acid (preparation given) was treated with 1,3-dimethyl-2-imidazolidinone, N-methylmorpholine, and H₂N(CH₂)₃OH at 80° for 3 h to give 7-benzyloxy-3-carboxy-2-(3-hydroxypropyl)-4-(3,4,5-trimethoxyphenyl)-1(2H)-isoquinolinone. This was dissolved in DMF and the solution was treated with K₂CO₃ and MeI at room temperature overnight to give 7-benzyloxy-2-(3-hydroxypropyl)-3-methoxycarbonyl-4-(3,4,5-trimethoxyphenyl)-1(2H)-isoquinolinone.


IT	260262-98-4P	260263-01-2P	260263-02-3P
	260263-12-5P	260263-21-6P	260263-27-2P
	260263-41-0P	260263-47-6P	260263-56-7P
	260263-67-0P	260263-71-6P	260263-78-3P
	260264-17-3P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of phenylisoquinolinones as cGMP phosphodiesterase inhibitors)


RN 260262-98-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-01-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-(hydroxymethyl)phenyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-02-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(methoxycarbonyl)phenyl]-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-12-5 CAPLUS

CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 260263-21-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-2-[3-(methoxycarbonyl)phenyl]-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260263-27-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-41-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-(3-hydroxypropyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-47-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-56-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2-dihydro-8-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260263-67-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-71-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(methoxycarbonyl)phenyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester,


10/572,343 (RCE)

hydrochloride (1:1) (CA INDEX NAME)




RN 260263-78-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(3-hydroxypropyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260264-17-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-carboxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)



IT	260262-99-5P	260263-00-1P	260263-04-5P
	260263-06-7P	260263-06-5P	260263-10-3P
	260263-13-6P	260263-14-7P	260263-15-8P
	260263-16-9P	260263-17-0P	260263-18-1P
	260263-19-2P	260263-20-5P	260263-22-7P
	260263-23-8P	260263-24-9P	260263-25-0P
	260263-28-3P	260263-29-4P	260263-30-7P
	260263-31-8P	260263-32-9P	260263-33-0P
	260263-35-2P	260263-36-3P	260263-37-4P
	260263-38-5P	260263-39-6P	260263-40-9P
	260263-42-1P	260263-43-2P	260263-44-3P
	260263-45-4P	260263-46-5P	260263-48-7P
	260263-49-8P	260263-50-1P	260263-51-2P
	260263-52-3P	260263-53-4P	260263-54-5P
	260263-55-6P	260263-57-8P	260263-58-9P
	260263-59-0P	260263-60-3P	260263-61-4P
	260263-62-5P	260263-63-6P	260263-64-7P
	260263-65-8P	260263-66-9P	260263-68-1P
	260263-69-2P	260263-70-5P	260263-72-7P
	260263-73-8P	260263-74-9P	260263-75-0P
	260263-76-1P	260263-77-2P	260263-79-4P
	260263-80-7P	260263-81-8P	260263-82-9P
	260263-83-0P	260263-84-1P	260263-85-2P
	260263-86-3P	260263-87-4P	260263-88-5P
	260263-89-6P	260263-90-9P	260263-91-0P
	260263-92-1P	260263-93-2P	260263-94-3P
	260263-95-4P	260263-96-5P	260263-97-6P
	260263-98-7P	260263-99-8P	260264-00-4P
	260264-01-5P	260264-02-6P	260264-03-7P
	260264-04-8P	260264-05-9P	260264-06-0P
	260264-07-1P	260264-08-2P	260264-09-3P
	260264-10-6P	260264-12-8P	260264-13-9P
	260264-14-0P	260264-15-1P	260264-16-2P
	260264-18-4P	260264-19-5P	260264-20-8P
	260264-21-9P	260264-22-0P	260264-23-1P
	260264-24-2P	260264-25-3P	260264-26-4P
	260264-27-5P	260264-28-6P	260264-29-7P
	260264-30-0P	260264-31-1P	260264-32-2P
	260264-33-3P	260264-34-4P	260264-35-5P
	260264-36-6P	260264-37-7P	260264-38-8P
	260264-39-9P	260264-40-2P	260264-41-3P
	260264-42-4P	260264-43-5P	260264-44-6P
	260264-45-7P	260264-46-8P	260264-47-9P
	260264-48-0P	260264-49-1P	260264-50-4P
	260264-51-5P	260264-52-6P	260264-53-7P
	260264-54-8P	260264-55-9P	260264-56-0P
	260264-57-1P	260264-58-2P	260264-59-3P
	260264-60-6P	260264-61-7P	260264-62-8P
	260264-63-9P	260264-64-0P	260264-65-1P
	260264-66-2P	260264-67-3P	260264-68-4P
	260264-69-5P	260264-70-8P	260264-71-9P
	260264-72-0P	260264-73-1P	260264-74-2P
	260264-75-3P	260264-76-4P	260264-77-5P
	260264-78-6P	260264-79-7P	260264-80-0P
	260264-81-1P	260264-82-2P	260264-83-3P
	260264-84-4P	260264-85-5P	260264-86-6P
	260264-87-7P	260264-88-8P	260264-89-9P
	260264-90-2P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


10/572,343 (RCE)

BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylisoquinolinones as cGMP phosphodiesterase inhibitors)


RN 260262-99-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-00-1 CAPLUS

CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-04-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methoxyethyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-06-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260263-08-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[1,1-dimethylethoxy]carbonyl]methylamino]-1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-10-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-13-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-14-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260263-15-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-16-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-17-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-18-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(4-pyridinylmethyl)-, methyl ester (CA INDEX NAME)




RN 260263-19-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-2-[4-(3-hydroxypropyl)phenyl]-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260263-20-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(3-pyridinylmethyl)-, methyl ester (CA INDEX NAME)




RN 260263-22-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-23-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(4-pyridinylmethyl)-, methyl ester (CA INDEX NAME)




RN 260263-24-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-8-(phenylmethoxy)-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-25-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-8-(phenylmethoxy)-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-28-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[(1,1-dimethylethoxy)carbonylamino]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260263-29-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-([(1,1-dimethylethoxy)carbonyl]methylamino)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-30-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-carboxyphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 260263-31-8 CAPLUS

CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 260263-32-9 CAPLUS

CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 260263-33-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-carboxyphenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, 3-methyl ester (CA INDEX NAME)




RN 260263-35-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-36-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-amino-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-37-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(methylamino)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-38-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-2-(methylamino)-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260263-39-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-amino-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260263-40-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-[3-(hydroxymethyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-42-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-1-oxo-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-43-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-(2-methoxyethyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-44-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-1-oxo-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-45-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-[3-(methoxycarbonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-46-5 CAPLUS

CN 2(1H)-Isoquinolinepropanoic acid, 7-hydroxy-3-(methoxycarbonyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 260263-48-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-hydroxy-1-oxo-2-(4-pyridinylmethyl)-, methyl ester (CA INDEX NAME)




RN 260263-49-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-hydroxy-2-(3-hydroxypropyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-50-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-hydroxy-1-oxo-2-(3-pyridinylmethyl)-, methyl ester (CA INDEX NAME)




RN 260263-51-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-52-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-hydroxy-2-[3-(methoxycarbonyl)phenyl]-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-53-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-2-(4-pyridinylmethyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-54-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-2-(3-hydroxypropyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-55-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-57-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-hydroxy-2-(3-hydroxypropyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-58-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-hydroxy-1-oxo-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-59-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-hydroxy-1-oxo-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-60-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-61-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-62-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-63-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-1,2-dihydro-8-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-64-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260263-65-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 260263-66-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-2-[4-


10/572,343 (RCE)

[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 260263-68-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260263-69-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(hydroxymethyl)phenyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260263-70-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methoxyethyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260263-72-7 CAPLUS


CN 2(1H)-Isoquinolinepropanoic acid, 3-(methoxycarbonyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260263-73-8 CAPLUS

CN 2(1H)-Isoquinolinepropanoic acid, 7-[(3-carboxyphenyl)methoxy]-3-(methoxycarbonyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 260263-74-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260263-75-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-2-[3-(methoxycarbonyl)phenyl]-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260263-76-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-2-(methylamino)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260263-77-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260263-79-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(3-hydroxypropyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260263-80-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260263-81-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260263-82-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(4-pyridinylmethyl)-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260263-83-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(hydroxymethyl)phenyl]-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl

RN 260263-84-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[(6-(hydroxymethyl)-2-pyridinyl)methoxy]-2-(2-methoxyethyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260263-85-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methoxyethyl)-1-oxo-7-(2-pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260263-86-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(3-pyridinyl)-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 260263-87-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 260263-88-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(3-pyridinylmethyl)-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260263-89-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-[3-(methoxycarbonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260263-90-9 CAPLUS

CN 2-(1H)-Isoquinolinepropanoic acid, 7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-3-(methoxycarbonyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 260263-91-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 260263-92-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 260263-93-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-2-(4-pyridinylmethyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260263-94-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(4-pyridinylmethyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260263-95-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(3-hydroxypropyl)-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 260263-96-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-

10/572,343 (RCE)


dihydro-1-oxo-7-(2-pyridinylmethoxy)-2-(3-pyridinylmethyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260263-97-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(3-pyridinylmethyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 260263-98-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 260263-99-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 260264-00-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-[16-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(4-pyridinylmethyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260264-01-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-((4-pyridinylmethoxy)-2-(4-pyridinylmethyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260264-02-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(3-hydroxypropyl)-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260264-03-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-4-(4-chloro-3,5-

10/572,343 (RCE)

dimethoxyphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 260264-04-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


● 2 HCl

RN 260264-05-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-1-oxo-7-(2-

10/572,343 (RCE)


pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 260264-06-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260264-07-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-08-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-

10/572,343 (RCE)


pyridinyl]methoxy]-2-(methylamino)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260264-09-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(methylamino)-1-oxo-7-(2-pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260264-10-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(methylamino)-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 260264-12-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-1,2-dihydro-1-oxo-8-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



●2 HCl

RN 260264-13-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-8-(2-pyridinylmethoxy)-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 260264-14-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-8-(2-pyridinylmethoxy)-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester,


10/572,343 (RCE)

hydrochloride (1:2) (CA INDEX NAME)




RN 260264-15-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(methylamino)-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 260264-16-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(methylamino)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260264-18-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-carboxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl



RN 260264-19-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-carboxyphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)


PAGE 1-A






RN 260264-20-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-carboxyphenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 260264-21-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-methoxyphenyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-22-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-methoxyphenyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-23-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methoxyphenyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-24-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-25-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-26-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-methoxyphenyl)-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-27-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-methoxyphenyl)-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-28-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-29-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-30-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-31-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-32-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-33-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-34-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-3-oxopropyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-35-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-36-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-37-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-38-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-3-oxopropyl)-1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-39-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-40-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-(3-methoxyphenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-41-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-(4-methoxyphenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-42-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-1-oxo-2-(2-methoxy-4-(3,4,5-trimethoxyphenyl)-1-oxo-2-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-43-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-44-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-45-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-methyl-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-46-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-47-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-48-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-3-oxopropyl)-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260264-49-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-hydroxy-2-(3-methoxyphenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-50-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-hydroxy-2-methyl-1-oxo-4-


10/572,343 (RCE)

(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-51-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-8-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-52-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-hydroxy-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-53-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-hydroxy-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-54-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-hydroxy-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-55-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-3-oxopropyl)-1,2-dihydro-8-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-56-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-8-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-57-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-methoxyphenyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 260264-58-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-2-(3-methoxyphenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 260264-59-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-methoxyphenyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260264-60-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260264-61-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260264-62-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-2-[(2-pyridinyl)methyl]-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 260264-63-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-2-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 260264-64-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-65-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-66-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-67-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-7-(2-pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-68-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 260264-69-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-70-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-7-(2-pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260264-71-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-3-oxopropyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260264-72-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-1,2-dihydro-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-73-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-74-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-methoxyphenyl)-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-75-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-methoxyphenyl)-7-[(6-methyl-4-pyrimidinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-76-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-methoxyphenyl)-7-[(2-methyl-4-pyrimidinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 260264-77-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 260264-78-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260264-79-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260264-80-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260264-81-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(methyamino)-1-oxo-7-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260264-82-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-methoxyphenyl)-1-oxo-8-(2-

10/572,343 (RCE)

pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride
(1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● HCl

RN 260264-83-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride
(1:1) (CA INDEX NAME)




● HCl

RN 260264-84-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-8-(2-


10/572,343 (RCE)

pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride
(1:1) (CA INDEX NAME)




RN 260264-85-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride
(1:1) (CA INDEX NAME)




RN 260264-86-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-3-pyridinyl)methyl]-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 260264-87-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(6-methyl-3-pyridinyl)methyl]-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 260264-88-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 260264-89-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-3-oxopropyl)-1,2-dihydro-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260264-90-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




IT 260262-97-3P 260263-03-4P 260263-05-6P
 260263-09-0P 260263-11-4P 260263-26-1P
 260263-34-1P 260264-11-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of phenylisoquinolinones as cGMP phosphodiesterase inhibitors)


RN 260262-97-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 260263-03-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-methoxyethyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 260263-05-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2-dihydro-1-oxo-7-(phenylmethoxy)- (CA INDEX NAME)




RN 260263-09-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-7-(phenylmethoxy)-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 260263-11-4 CAPLUS

CN 2-(1H)-Isoquinolinepropanoic acid, 3-carboxy-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, 2-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 260263-26-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 260263-34-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 260264-11-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-1,2-dihydro-1-oxo-8-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



L11 ANSWER 17 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2000:151451 CAPLUS Full-text
 DN 132:207769
 TI Preparation of isoquinolinones as effective component in medicine
 IN Ukita, Shinzo; Ohmori, Kanji; Ikeo, Tomihiro
 PA Tanabe Selyaku Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 148 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000072675	A	20000307	JP 1998-240446	19980826 <--
PRAI	JP 1998-240446		19980826		
OS	MARPAT 132:207769				
GI					



AB Title compds. [I; ring A and ring B equivalent or different, substituted or unsubstituted benzene ring; R1 = H, N(CH3)2, 4-H2NC6H4, 4-CH3OCOC6H4, alkyl, cycloalkyl, aryl, complex cyclic; R2 = COOH, COOCH3, COOCH2CH3, COOCH2C6H5, COO(CH2)3CH3] and pharmaceutical acceptable salts are prepared and tested as PDEV inhibitors. The title compound II was prepared


IT 212487-20-2P 212488-77-2P 212489-68-4P
 212489-86-6P 212490-16-9P 212490-26-1P
 212492-25-6P 212492-32-5P 212492-48-3P
 212492-51-8P 212492-54-1P 212492-87-0P
 212492-91-6P 212492-96-1P 212493-77-1P
 212496-03-2P 212496-81-6P 212496-86-1P
 212498-05-0P 212498-07-2P 212498-29-8P
 212498-33-4P 212498-37-8P 212498-41-4P
 212498-47-0P 212498-53-8P 212498-55-0P
 212498-57-2P 212498-74-3P 212498-75-4P

212498-61-2P	212498-92-5P	212498-93-6P
212498-94-7P	212498-95-8P	212498-96-1P
212498-99-2P	212499-00-8P	212499-01-9P
212499-02-0P	212499-03-1P	212499-04-2P
212499-05-3P	212499-06-4P	212499-07-5P
212499-11-1P	212499-15-5P	212499-20-2P
212499-21-3P	212499-27-9P	212499-31-5P
212499-32-6P	212499-33-7P	212499-34-8P
212499-35-9P	212499-44-0P	212499-45-1P
212499-46-2P	212499-51-9P	212499-52-0P
212499-53-1P	212499-54-2P	212499-55-3P
212499-79-1P	212499-80-4P	212499-81-5P
212499-82-6P	212499-84-8P	212499-85-9P
212499-88-2P	212499-90-6P	212499-92-8P
212499-94-0P	212500-03-3P	212501-73-0P
260407-34-9P	260414-73-1P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isoquinolinones as effective component in medicine)

RN 212487-20-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212488-77-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212489-68-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-86-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(4-thiomorpholinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-16-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212490-26-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212492-25-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212492-32-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-, methyl ester (CA INDEX NAME)



RN 212492-48-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212492-51-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212492-54-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212492-87-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212492-91-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212492-96-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(3-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212493-77-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212496-03-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3-aminophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212496-81-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212496-86-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-05-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2,5-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl




RN 212498-07-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212498-29-8 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 212498-33-4 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212498-37-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212498-41-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(3-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-47-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-53-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212498-55-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212498-57-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-

10/572,343 (RCE)

dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212498-74-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-diaminophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●3 HCl


RN 212498-75-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(1H-benzimidazol-2-ylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 212498-81-2 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-92-5 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[[3-(dimethylamino)phenyl]methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212498-93-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212498-94-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


PAGE 1-A



● HCl


RN 212498-95-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2,5-dimethoxyphenyl)methoxyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212498-98-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212498-99-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-00-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-01-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-quinolinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-02-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-03-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-04-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212499-05-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-

10/572,343 (RCE)

dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-quinolinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 212499-06-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● HCl

RN 212499-07-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3-aminophenyl)methoxy]-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212499-11-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-((2,5-dimethoxyphenyl)methoxy)-1,2-dihydro-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl



RN 212499-15-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-(1-isoquinolinylmethoxy)-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 212499-20-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-diaminophenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●3 HCl

RN 212499-21-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(6-(hydroxymethyl)-2-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212499-27-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(4-carboxyphenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl

RN 212499-31-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-((3-carboxyphenyl)methoxy)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212499-32-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




●2 HCl

RN 212499-33-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

●2 HCl

RN 212499-34-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[3-(methylamino)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-35-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[2-(hydroxymethyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-44-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212499-45-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 212499-46-2 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212499-51-9 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(1H-benzimidazol-2-ylmethoxy)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

RN 212499-52-0 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 212499-53-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212499-54-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212499-55-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-(2-furanylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-79-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212499-80-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-81-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-82-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-quinolinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212499-84-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-

10/572,343 (RCE)


methylphenyl)-1,2-dihydro-7-(1-isoquinolinylmethoxy)-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212499-85-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-diaminophenyl)methoxy]-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-, methyl ester, hydrochloride (1:3) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

RN 212499-88-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-90-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[3-(methylamino)phenyl]methoxy]-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-92-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[2-(hydroxymethyl)phenyl]methoxy]-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212499-94-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-, methyl ester,

10/572,343 (RCE)

hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2


CRN 7664-93-9

CMF H2 O4 S




RN 212501-73-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonylamino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-34-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 260414-73-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(1-oxido-2-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


IT 212487-25-7P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)

(preparation of isoquinolinones as effective component in medicine)

RN 212487-25-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



IT	212487-16-6P	212487-17-7P	212487-23-5P
	212487-27-9P	212487-29-1P	212487-33-7P
	212487-35-9P	212487-38-2P	212487-40-6P
	212487-42-8P	212487-44-0P	212487-50-8P
	212487-52-0P	212487-57-5P	212487-59-7P
	212487-61-1P	212487-64-4P	212487-68-8P
	212487-71-3P	212487-73-5P	212487-76-8P
	212487-77-9P	212487-79-0P	212487-80-4P
	212487-81-5P	212487-82-6P	212487-83-7P
	212487-84-8P	212487-85-9P	212487-86-0P
	212487-87-1P	212487-89-3P	212487-90-6P
	212487-91-7P	212487-92-8P	212487-95-1P
	212487-97-3P	212487-98-4P	212487-99-5P
	212488-00-1P	212488-01-2P	212488-02-3P
	212488-03-4P	212488-05-6P	212488-06-7P
	212488-07-8P	212488-08-9P	212488-09-0P
	212488-10-3P	212488-11-4P	212488-12-5P
	212488-13-6P	212488-15-8P	212488-17-0P
	212488-19-2P	212488-21-6P	212488-23-8P
	212488-25-0P	212488-27-2P	212488-29-4P
	212488-31-8P	212488-33-0P	212488-35-2P
	212488-37-4P	212488-39-6P	212488-41-0P
	212488-43-2P	212488-45-4P	212488-46-5P
	212488-48-7P	212488-51-2P	212488-53-4P
	212488-56-7P	212488-58-9P	212488-60-3P
	212488-62-5P	212488-64-7P	212488-65-8P
	212488-67-0P	212488-69-2P	212488-71-6P
	212488-73-8P	212488-75-0P	212488-80-7P
	212488-83-0P	212488-86-3P	212488-89-6P
	212488-92-1P	212488-98-7P	212489-01-8P
	212489-07-1P	212489-10-6P	212489-13-9P
	212489-16-2P	212489-18-4P	212489-21-9P


212489-24-2P 212489-27-5P 212489-31-1P
 212489-34-4P 212489-37-7P 212489-40-2P
 212489-43-5P 212489-46-8P 212489-49-1P
 212489-52-6P 212489-55-9P 212489-59-3P
 212489-64-0P 212489-72-0P 212489-75-3P
 212489-78-6P 212489-81-1P 212489-84-4P
 212489-89-9P 212489-91-3P 212489-94-6P
 212489-97-9P 212490-01-2P 212490-04-5P
 212490-07-8P 212490-11-4P 212490-19-2P
 212490-30-7P 212490-33-0P 212490-36-3P
 212490-39-6P 212490-41-0P 212490-43-2P
 212490-45-4P 212490-47-6P 212490-49-8P
 212490-51-2P 212490-53-4P 212490-55-6P
 212490-58-9P 212490-60-3P 212490-62-5P
 212490-66-9P 212490-68-1P 212490-70-5P
 212490-73-8P 212490-75-0P 212490-77-2P
 212490-79-4P 212490-81-8P 212490-83-0P
 212490-85-2P 212490-87-4P 212490-89-6P
 212490-91-0P 212490-93-2P 212490-95-4P
 212490-97-6P 212490-99-8P 212491-02-6P
 212491-04-8P 212491-06-0P 212491-08-2P
 212491-11-7P 212491-14-0P 212491-16-4P
 212491-22-0P 212491-25-2P 212491-32-2P
 212491-34-4P 212491-38-8P 212491-41-3P
 212491-43-5P 212491-46-8P 212491-49-1P
 212491-51-5P 212491-55-9P 212491-59-3P
 212491-64-0P 212491-68-4P 212491-72-0P
 212491-75-3P 212491-79-7P 212491-82-2P
 212491-85-5P 212491-88-8P 212491-91-3P
 212491-94-6P 212491-97-9P 212492-00-7P
 212492-03-0P 212492-06-3P 212492-09-6P
 212492-11-0P 212492-15-4P 212492-19-8P
 212492-23-0P 212492-35-8P 212492-39-2P
 212492-42-7P 212492-45-0P 212492-51-4P
 212492-60-9P 212492-68-7P 212492-73-4P
 212492-78-9P 212492-82-5P 212493-08-8P
 212493-10-0P 212493-22-6P 212493-28-2P
 212493-32-8P 212493-38-4P 212493-42-0P
 212493-47-5P 212493-51-1P 212493-57-7P
 212493-70-4P 212493-82-8P 212493-88-4P
 212493-94-2P 212493-99-7P 212494-05-8P
 212494-10-5P 212494-14-3P 212494-16-3P
 212494-23-0P 212494-28-5P 212494-33-2P
 212494-39-8P 212494-45-6P 212494-50-0P
 212494-56-9P 212494-61-6P 212494-66-1P
 212494-71-8P 212494-76-3P 212494-81-0P
 212494-95-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoquinolinones as effective component in medicine)


RN 212487-16-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-17-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-6-methoxy-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-23-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-27-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



●2 HCl

RN 212487-29-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212487-33-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-thienylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212487-35-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-38-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 212487-40-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-ethoxy-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 212487-42-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, phenylmethyl ester (CA INDEX NAME)




RN 212487-44-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-[3,5-dimethoxy-4-(phenylmethoxy)phenyl]-1,2-dihydro-1-oxo-2-phenyl-, phenylmethyl ester (CA INDEX NAME)




RN 212487-50-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2-chlorophenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-52-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-naphthalenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-57-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-nitrophenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-59-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-61-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[4-(methoxycarbonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-64-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-carboxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 212487-68-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[4-(4-morpholinylcarbonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-71-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[2-[(1,1-dimethylethoxy)carbonyl]hydrazinyl]carbonyl]phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-73-5 CAPLUS

10/572,343 (RCE)


CN 3-Isoquinolinecarboxylic acid, 2-[4-(hydrazinylcarbonyl)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212487-76-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[cis-4-[(1,1-dimethylethoxy)carbonyl]amino]cyclohexyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)


Relative stereochemistry.



RN 212487-77-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[trans-4-[(1,1-dimethylethoxy)carbonyl]amino]cyclohexyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)


Relative stereochemistry.



RN 212487-78-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(cis-4-aminocyclohexyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 212487-80-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(trans-4-aminocyclohexyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 212487-81-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[1-[(1,1-dimethylethoxy)carbonyl]-3-pyrrolidinyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-82-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(3-pyrrolidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212487-83-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminosulfonyl)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-84-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-85-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(4-piperidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-86-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[3-amino-5-(methoxycarbonyl)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-87-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-5-carboxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 212487-89-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,3-dihydro-1H-inden-2-yl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-90-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,3-dihydro-1H-inden-5-yl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-91-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(1-methyl-4-piperidinyl)methyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-92-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetylamino)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-95-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212487-97-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3,4-dimethoxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-98-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-99-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-4-methoxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212488-00-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(tetrahydro-2-oxo-3-furanyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-01-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(2-oxo-3-pyrrolidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-02-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,3-dihydro-1H-indol-6-yl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212488-03-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-cyclopropyl-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-05-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-06-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-[1-(phenylmethyl)-4-piperidinyl]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-07-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-[3-(trifluoromethyl)phenyl]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-08-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(1H-indazol-5-yl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-09-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(1-piperidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-10-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-11-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(1-piperazinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212488-12-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-13-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-15-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-[4-[[[(phenylmethoxy)carbonyl]amino]methyl]phenyl]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-17-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212488-19-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[(1,2-dihydro-6-methyl-2-oxo-3-pyridinyl)methyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-21-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-23-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[3-(dimethylamino)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212488-25-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(6-methoxy-3-pyridinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212488-27-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(methoxycarbonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-29-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-carboxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 212488-31-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212488-33-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-35-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-amino-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-37-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(acetylamino)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-39-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(diacetylamino)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-41-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(methylamino)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-43-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-hydroxyethyl)amino]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-45-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[2-(acetyloxy)ethyl]amino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-46-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(propylamino)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-48-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(ethylamino)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)


10/572,343 (RCE)



RN 212488-51-2 CAPLUS


CN 2(1H)-Isoquinolineacetic acid, 3-(methoxycarbonyl)-1-oxo-α-(phenylmethyl)-4-(3,4,5-trimethoxyphenyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 212488-53-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(1-methyl-1H-benzotriazol-6-yl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-56-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-fluorophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-58-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-amino-3-methoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-60-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[4-(2-hydroxyethyl)phenyl]-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-62-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxyphenyl)-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-64-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-(methylamino)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-65-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[cis-4-(methoxycarbonyl)cyclohexyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)


Relative stereochemistry.



RN 212488-67-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-carboxycyclohexyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)

(NAME)




RN 212488-69-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2-(furanymethyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-71-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,3-dimethylphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-73-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2,4-bis(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-75-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-80-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[bis(methylsulfonyl)amino]phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-83-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetamino)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-86-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[(methylamino)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-89-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(1-methylpiperidin-4-yl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-92-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-98-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(1,3-benzodioxol-5-yl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-04-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-[2-(1-piperidinyl)ethyl]-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212489-07-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 212489-10-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 212489-13-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-(4-methyl-1-piperazinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-16-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-18-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-chlorophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-21-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-chlorophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-24-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-cyclopentyl-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-27-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(phenylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212489-31-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-(dimethylamino)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212489-34-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[4-(4-morpholinyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl




RN 212489-37-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(1H-imidazol-1-yl)propyl]-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-40-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(hydroxymethyl)phenyl]-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-43-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[4-(2-methoxy-2-oxoethyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-46-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(carboxymethyl)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, sodium salt (1:1) (CA INDEX NAME)




RN 212489-49-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212489-52-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212489-55-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(cyclopropylmethyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

10/572,343 (RCE)



RN 212489-59-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212489-64-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212489-72-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-(4-hydroxy-3,5-dimethoxyphenyl)-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-, methyl ester (CA INDEX NAME)



RN 212489-75-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(2-pyridinylamino)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212489-78-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[3-(methylthio)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-81-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[3-(methylsulfonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-94-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-methyl-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-97-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-methyl-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212490-01-2 CAPLUS

CN 1(2H)-Isoquinolinone, 6,7-dimethoxy-2-methyl-3-(4-morpholinylcarbonyl)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212490-04-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[2-(1H-imidazol-5-yl)ethyl]-6,7-dimethoxy-2-methyl-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212490-07-8 CAPLUS

CN 1(2H)-Isoquinolinone, 3-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-6,7-dimethoxy-2-methyl-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212490-11-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-amino-3-methoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, (trimethylsilyl)methyl ester (CA INDEX NAME)




RN 212490-19-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-1-oxo-2-(tetrahydro-2H-pyran-4-yl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-30-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-33-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonylmethylamino]phenyl]-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212490-36-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-2-[4-(methylamino)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212490-39-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-1-oxo-2-(4-(phenylmethoxy)phenyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-41-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-2-(4-hydroxyphenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-43-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methyl-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-45-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-47-6 CAPLUS

CN 1,3-Dioxolo[4,5-g]isoquinoline-7-carboxylic acid, 5,6-dihydro-5-oxo-6-phenyl-8-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-49-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-methoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-51-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 8-chloro-1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-53-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-methoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-55-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-58-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 8-chloro-2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212490-60-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-8-chloro-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212490-62-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-66-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl- (CA INDEX NAME)




RN 212490-68-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-, methyl ester (CA INDEX NAME)




RN 212490-70-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl- (CA INDEX NAME)




RN 212490-73-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-N-methyl-1-oxo-2-phenyl- (CA INDEX NAME)




RN 212490-75-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-(4-bromo-3-methylphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212490-77-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminocarbonyl)phenyl]-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212490-79-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[3-(aminocarbonyl)phenyl]-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)

NAME)




RN 212490-81-8 CAPLUS

CN 2-(1H)-Isoquinolineacetic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-6,7-dimethoxy-3-(methoxycarbonyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212490-83-0 CAPLUS

CN 2-(1H)-Isoquinolineacetic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-6,7-dimethoxy-3-(methoxycarbonyl)-1-oxo-, ethyl ester (CA INDEX NAME)




RN 212490-85-2 CAPLUS

CN 2-(1H)-Isoquinolineacetic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-6,7-dimethoxy-3-(methoxycarbonyl)-1-oxo- (CA INDEX NAME)




RN 212490-87-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-[(2-(2-hydroxyethoxy)ethyl)-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212490-89-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-[(2-(2-pyridylethoxy)ethyl)-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212490-91-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[[[(1,1-dimethylethoxy)carbonylamino]ethyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212490-93-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(2-aminoethyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212490-95-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(5-methyl-3-isoxazolyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212490-97-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-(phenylamino)-, methyl ester (CA INDEX NAME)




RN 212490-99-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(3-nitrophenyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-02-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(2-methoxyethyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-04-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-(3-carboxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, 3-methyl ester (CA INDEX NAME)




RN 212491-06-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-[(2-[(1,1-dimethylethoxy)carbonyl]hydrazinyl]carbonyl]phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-08-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-(hydrazinylcarbonyl)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-11-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[3-(2-methoxy-2-oxoethoxy)phenyl]-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-14-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-(carboxymethoxy)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, 3-methyl ester (CA INDEX NAME)




RN 212491-18-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[3-(2-[[3-(4-morpholinyl)propyl]amino]-2-oxoethoxy)phenyl]-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-22-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-aminophenyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-25-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-(formylamino)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212491-32-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-34-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[2-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]ethyl]-1,2-dihydro-6,7-


10/572,343 (RCE)

dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212491-38-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[2-(1-piperazinyl)ethyl]-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212491-41-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[2-(4-morpholinyl)ethyl]-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212491-43-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)

dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-46-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-(3-hydroxypropyl)-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-49-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[3-[(3-pyridinylcarbonyl)oxy]propyl]-, methyl ester (CA INDEX NAME)




RN 212491-51-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-butyl-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-55-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2-amino-2-oxoethyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-59-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-(6-quinolinyl)-, methyl ester (CA INDEX NAME)




RN 212491-64-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[(tetrahydro-2-furanyl)methyl]-, methyl ester (CA INDEX NAME)




RN 212491-68-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-(3-quinolinyl)-, methyl ester (CA INDEX NAME)




RN 212491-72-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-[2-hydroxy-1-(hydroxymethyl)ethyl]-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-75-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-(dimethylamino)propyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-79-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-[[1,1-dimethylethoxy]carbonyl]amino]propyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-82-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(3-methoxypropyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-85-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[1-(phenylmethyl)-4-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 212491-88-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-(phenylmethyl)-, methyl ester (CA INDEX NAME)




RN 212491-91-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-propyl-, methyl ester (CA INDEX NAME)




RN 212491-94-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(6-amino-3-pyridinyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212491-97-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminobutyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212492-00-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[(1R,2S)-2-aminocyclohexyl]-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1), rel- (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 212492-03-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminocyclohexyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester,

10/572,343 (RCE)


hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212492-06-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetamino)phenyl]-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212492-09-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212492-11-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[4-(phenylmethoxy)carbonyl]-1-piperazinyl-, methyl ester (CA INDEX NAME)



RN 212492-15-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-[4-(2-hydroxyethyl)-1-piperazinyl]-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212492-19-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[4-(phenylmethyl)-1-piperazinyl]-, methyl ester (CA INDEX NAME)



RN 212492-29-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212492-35-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212492-39-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-4-(2,3,4-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-42-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-45-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-57-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-[(1H-pyrrol-2-ylcarbonyl)oxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-60-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(2-thienylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-68-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-73-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212492-78-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212492-82-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212493-08-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-7-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212493-18-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(cyclopentyloxy)-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-22-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(cyclopentyloxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212493-28-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[2-(dimethylamino)ethoxy]-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-32-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[2-(dimethylamino)ethoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212493-38-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-42-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl


RN 212493-47-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-7-ethoxy-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-51-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-ethoxy-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212493-57-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[1,1-


10/572,343 (RCE)

dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-(2-methoxyethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212493-70-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212493-82-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-88-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212493-94-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-99-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212494-05-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-(2-hydroxyethoxy)-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-10-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-(2-hydroxyethoxy)-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212494-14-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-18-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212494-23-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-


10/572,343 (RCE)

dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-oxo-2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212494-28-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-oxo-2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212494-33-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-(2-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212494-39-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(2-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212494-45-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(3-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-50-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(3-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212494-56-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(cyclohexylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212494-61-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-(2-methoxy-2-oxoethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212494-66-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-(2-methoxy-2-oxoethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212494-71-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[(3,4-dichlorophenyl)methoxy]-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212494-76-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,4-dichlorophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212494-81-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(4-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-85-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(4-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



IT	212494-89-8P	212494-93-4P	212494-97-8P
	212495-00-6P	212495-03-9P	212495-06-2P
	212495-09-5P	212495-12-0P	212495-16-4P
	212495-20-0P	212495-24-4P	212495-27-7P
	212495-31-3P	212495-34-6P	212495-38-0P
	212495-42-6P	212495-48-2P	212495-54-0P
	212495-57-3P	212495-62-0P	212495-66-4P
	212495-66-6P	212495-71-1P	212495-74-4P
	212495-77-7P	212495-80-2P	212495-83-5P
	212495-86-8P	212495-90-4P	212495-93-7P
	212495-96-0P	212496-00-9P	212496-06-5P
	212496-07-6P	212496-08-7P	212496-09-8P
	212496-10-1P	212496-11-2P	212496-12-3P
	212496-13-4P	212496-14-5P	212496-16-7P
	212496-18-9P	212496-24-7P	212496-29-2P
	212496-36-1P	212496-41-6P	212496-46-3P
	212496-52-1P	212496-58-7P	212496-62-3P
	212496-67-8P	212496-72-5P	212496-76-9P
	212496-91-8P	212496-96-3P	212497-01-3P
	212497-05-7P	212497-10-4P	212497-15-9P
	212497-21-7P	212497-27-3P	212497-33-1P
	212497-38-6P	212497-42-2P	212497-46-6P
	212497-49-9P	212497-52-4P	212497-54-6P
	212497-56-8P	212497-58-0P	212497-60-4P
	212497-63-7P	212497-66-0P	212497-69-3P
	212497-72-8P	212497-75-1P	212497-78-4P
	212497-81-9P	212497-85-3P	212497-93-3P
	212497-96-6P	212497-98-8P	212498-01-6P
	212498-03-8P	212498-09-4P	212498-11-8P
	212498-13-0P	212498-19-6P	212498-22-1P
	212498-25-4P	212498-31-2P	212498-35-6P
	212498-39-0P	212498-43-6P	212498-45-8P
	212498-49-2P	212498-51-6P	212498-53-4P
	212498-60-7P	212498-62-9P	212498-64-1P
	212498-65-2P	212498-67-4P	212498-68-5P
	212498-70-9P	212498-72-1P	212498-73-2P
	212498-76-5P	212498-77-6P	212498-78-7P
	212498-79-8P	212498-80-1P	212498-82-3P
	212498-83-4P	212498-84-5P	212498-85-6P
	212498-86-7P	212498-87-8P	212498-88-9P
	212498-89-0P	212498-90-3P	212498-91-4P
	212498-96-9P	212498-97-0P	212499-09-7P
	212499-13-3P	212499-17-7P	212499-19-9P
	212499-22-4P	212499-23-5P	212499-25-7P
	212499-29-1P	212499-36-0P	212499-37-1P
	212499-38-2P	212499-39-3P	212499-41-7P
	212499-42-8P	212499-43-9P	212499-47-3P
	212499-46-4P	212499-49-5P	212499-50-6P
	212499-56-4P	212499-57-5P	212499-58-6P
	212499-59-7P	212499-60-0P	212499-61-1P
	212499-62-2P	212499-64-4P	212499-67-7P
	212499-70-2P	212499-73-5P	212499-76-8P
	212499-96-2P	212499-98-4P	212500-00-0P
	212500-05-5P	212500-07-7P	212500-10-2P
	212500-13-5P	212500-15-7P	260407-15-6P
	260407-16-7P	260407-17-8P	260407-18-9P
	260407-19-0P	260407-20-3P	260407-21-4P
	260407-22-5P	260407-29-2P	260407-30-5P

10/572,343 (RCE)


260407-31-6P 260407-32-7P 260407-35-0P
 260407-39-4P 260407-40-7P 260407-41-8P
 260407-42-9P 260407-43-0P 260407-44-1P
 260407-45-2P 260407-46-3P 260407-48-5P
 260408-67-1P 260414-65-1P 260414-71-9P
 260414-72-0P 260415-47-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoquinolinones as effective component in medicine)


RN 212494-89-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-([1,1'-biphenyl]-4-ylmethoxy)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-93-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-([1,1'-biphenyl]-4-ylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212494-97-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[[3-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212495-00-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-
[[3-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-,
methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-03-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-7-[(2-fluorophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-06-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2-fluorophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212495-09-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-(1-naphthalenylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 212495-12-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-(1-naphthalenylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-16-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-(2-naphthalenylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-20-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-(2-naphthalenylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



10/572,343 (RCE)


RN 212495-24-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-propen-1-yloxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212495-27-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-propen-1-yloxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212495-31-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(4-carboxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212495-34-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[[4-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212495-38-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinyloxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-42-6 CAPLUS

10/572,343 (RCE)


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-oxo-7-(2-pyridinyloxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212495-48-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[[[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-54-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[[[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

10/572,343 (RCE)




RN 212495-57-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(benzoyloxy)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212495-62-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(benzoyloxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-66-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-[(1H-pyrrol-2-ylcarbonyl)oxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-68-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-[2-(2-pyridinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-71-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-[2-(2-pyridinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212495-74-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(3-thienylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-77-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-thienylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212495-80-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-


dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(4-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

$$\text{MeO}-\overset{\overset{\text{O}}{\parallel}}{\text{C}}-\text{R}$$

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[[(3-methylphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212495-90-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-
[(3-methylphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester,
hydrochloride (1:1) (CA INDEX NAME)



RN 212495-93-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 7-[(2-chloro-5-nitrophenyl)methoxy]-2-[4-
[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-
(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-96-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2-chloro-5-
nitrophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-
trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

● HCl


RN 212496-00-9 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-
 [(3-methoxyphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl
 ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212496-06-5 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(cyclopentylmethoxy)-
 1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester,
 hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl


RN 212496-07-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-7-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-08-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-piperidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212496-09-8 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-[2-(1-piperidinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212496-10-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-[2-(1-piperidinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212496-11-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-12-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-
[[4-methyl-1-piperazinyl]carbonyloxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-,
methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl


RN 212496-13-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[[4-(diethylamino)carbonyloxy]-2-[[4-[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212496-14-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-
 [[diethylamino]carbonyloxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-
 trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212496-16-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-
 dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(4-
 morpholinylcarbonyl)oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester
 (CA INDEX NAME)




10/572,343 (RCE)



● HCl


RN 212496-36-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(1-oxido-4-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-41-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(1-oxido-4-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212496-46-3 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(1-oxido-3-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212496-52-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(1-oxido-3-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212496-58-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(1-oxido-2-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212496-62-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(1-oxido-2-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212496-67-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(2-amino-2-oxoethoxy)-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-72-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 7-(2-amino-2-oxoethoxy)-2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212496-76-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3-carboxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212496-91-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212496-96-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-hydroxy-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212497-01-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212497-05-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-hydroxy-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212497-10-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-15-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl


RN 212497-21-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-6-ethoxy-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-27-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-6-ethoxy-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212497-33-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-


10/572,343 (RCE)

dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-6-(2-methoxyethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212497-38-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-6-(2-methoxyethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212497-42-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-(2-hydroxyethoxy)-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212497-46-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-(2-hydroxyethoxy)-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212497-49-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-52-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212497-54-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-56-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212497-58-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-60-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212497-63-7 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 6-(cyclopentyloxy)-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-66-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-6-(cyclopentyloxy)-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212497-69-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-[2-(2-pyridinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

10/572,343 (RCE)




RN 212497-72-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-[2-(2-pyridinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 212497-75-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-, methyl ester (CA INDEX NAME)




RN 212497-78-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,4-dichlorophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-, methyl ester (CA INDEX NAME)



RN 212497-81-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212497-85-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-((1H-indazol-6-yl)amino)-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212497-93-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-((2,2,2-trifluoroacetyl)amino)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212497-96-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dibromo-4-methoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-, methyl ester (CA INDEX NAME)



RN 212497-98-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(4-aminophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212498-01-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(1,3-benzodioxol-5-ylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-03-8 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2,4-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● HCl

RN 212498-09-4 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,4-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 212498-11-8 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2,3-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 212498-13-0 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(2-methoxyphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl

RN 212498-19-6 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(1H-benzimidazol-2-ylmethoxy)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


●2 HCl

RN 212498-22-1 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(4-methylphenyl)sulfonyl]oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212498-25-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-31-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-35-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-39-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(4-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-43-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(2-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-45-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-bromo-3,5-dimethoxyphenyl)-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212498-49-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212498-51-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-59-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-quinolinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212498-60-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-62-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-64-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-65-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212498-67-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(4-

10/572,343 (RCE)


pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride
(1:1) (CA INDEX NAME)



● HCl


RN 212498-68-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(4-methyl-1H-imidazol-5-yl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-70-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(cyclopropylmethoxy)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-72-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(cyclopropylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-73-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212498-76-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,6-dioxo-4-piperidinyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-77-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-78-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-79-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-8-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-80-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-bromo-3,5-dimethoxyphenyl)-2-[[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212498-82-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212498-83-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-84-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-85-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-86-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-87-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(4-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212498-88-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212498-89-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212498-90-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-91-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-96-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212498-97-0 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212499-09-7 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A

● HCl

RN 212499-13-3 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-(cyanomethoxy)-1,2-dihydro-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl

RN 212499-17-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-19-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[9H-fluoren-9-ylmethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)


PAGE 1-A






RN 212499-22-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-[[4-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212499-23-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[4-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212499-25-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-[[3-


10/572,343 (RCE)

(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-29-1 CAPLUS

CN 3-Isiquinolinecarboxylic acid, 7-[(3-carboxyphenyl)methoxy]-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)



RN 212499-36-0 CAPLUS


CN 3-Isiquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(3-(hydroxymethyl)phenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-37-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(4-(hydroxymethyl)phenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212499-38-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetamino)phenyl]-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-39-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-[(1-oxido-2-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-41-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[(3-aminophenyl)methoxy]-1,2-dihydro-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212499-42-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(1H-benzimidazol-2-ylmethoxy)-1,2-dihydro-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-43-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-8-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212499-47-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212499-48-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212499-49-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-(1H-

10/572,343 (RCE)


imidazol-5-ylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212499-50-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[[4-(aminomethyl)phenyl]methoxy]-1,2-dihydro-2-[4-[(methylsulfonyl)amino]phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-56-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 212499-57-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212499-58-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212499-59-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-60-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-61-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-62-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-64-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-quinolinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212499-67-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]aminophenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 212499-70-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212499-73-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212499-76-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-96-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-98-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212499-96-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 212500-00-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 212499-96-2

CMF C32 H29 N3 O7



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 212500-05-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 212500-07-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo- (CA INDEX NAME)




RN 212500-10-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212500-13-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-4-(3-hydroxy-4,5-dimethoxyphenyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl



RN 212500-15-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-4-(4-hydroxy-3,5-dimethoxyphenyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 260407-15-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(3-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-16-7 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-butylphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260407-17-8 CAPLUS
 CN 1,3-Benzenedicarboxylic acid, 5-[3-(methoxycarbonyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-2(1H)-isoquinolinyl]-, 1,3-dimethyl ester (CA INDEX NAME)



RN 260407-18-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(cis-4-hydroxycyclohexyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 260407-19-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl)methylamino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-20-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl](2-hydroxyethyl)amino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-21-4 CAPLUS


CN 2 (1H)-Isoquinolineacetic acid, 3-(methoxycarbonyl)-1-oxo-α-(phenylmethyl)-4-(3,4,5-trimethoxyphenyl)-, phenylmethyl ester, (αS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 260407-22-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-29-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260407-30-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(2-methyl-4-pyrimidinyl)-1-oxo-, methyl ester (CA INDEX NAME)



RN 260407-31-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-(3-aminopropyl)-1-piperazinyl]-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260407-32-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-7-[[2-(methoxycarbonyl)-1-methyl-1H-pyrrol-3-yl]methoxy]-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-35-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260407-39-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(cyclohexylmethoxy)-2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260407-40-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-[(1H-pyrrol-2-ylcarbonyl)oxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260407-41-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(3-methoxyphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260407-42-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-7-[[[3-[(ethoxycarbonyl)amino]phenyl]methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260407-43-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(cyclopentylmethoxy)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260407-44-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[(3-carboxyphenyl)methoxy]-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 260407-45-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(1-methyl-1H-indol-6-yl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260407-46-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(4-methoxyphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260407-48-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[(4-carboxyphenyl)methoxy]-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 260408-67-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(butoxycarbonyl)amino]phenyl]-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260414-65-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-butoxy-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-2-phenyl-, butyl ester (CA INDEX NAME)



RN 260414-71-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-(2-methoxyethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 260414-72-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, butyl ester (CA INDEX NAME)



RN 260415-47-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L11 ANSWER 18 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2000:137239 CAPLUS [Full-text](#)

DN 132:194292

TI Preparation of medicine composition containing pyridylamines

IN Ukita, Tatsuzo; Sugawara, Masakatsu; Ikezawa, Ichiro; Yoshikawa, Hideo;

Naito, Kazuaki
 PA Tanabe Seiyaku Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 41 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000063275	A	20000229	JP 1999-164565	19990611 <--
PRAI	JP 1998-164045	A	19980612		
OS	MARPAT 132:194292				
GI					


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; Q = N containing substituted benzoheterocyclic ring; Q1 = N containing substituted benzoheterocyclic ring], stereoisomers, pharmaceutical acceptable salts are prepared as active components in antiasthmatics. The title compound II was prepared

IT 209262-35-1P 259822-65-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyridylamines as antiasthmatics)


RN 209262-35-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(4-pyridinyl)-, methyl ester (CA INDEX NAME)



RN 259822-65-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(4-pyridinyl)- (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L11 ANSWER 19 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1999:583201 CAPLUS Full-text
 DN 131:228725
 TI Preparation of triazoles as tachykinin NK1 receptor antagonists
 IN Okamoto, Yoshinori; Kubota, Koichi; Takeuchi, Makoto; Ikeda, Masaru;
 Isomura, Yasuo
 PA Yamanouchi Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 14 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11246559	A	19990914	JP 1998-43109	19980225 <--
PRAI	JP 1998-43109		19980225		
OS	MARPAT 131:228725				
GI					




I

AB Title compds. [I; R = H, CH3, C6H5; R1 = H, F; X = CH, N] are prepared and tested as tachykinin NK1 receptor antagonists on treatment and prevention of respiratory tract disease, central neurol. disease, pain, inflammatory diseases, vomit, and migraine. Thus, the title compound I (X = CH; R = H; R1 = H) was prepared

IT 159817-82-0P 243133-59-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of triazoles as tachykinin NK1 receptors antagonists)


RN 159817-82-0 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-1,2-dihydro-N-methyl-1-oxo- (CA INDEX NAME)



RN 243133-59-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-1-oxo- (CA
INDEX NAME)



L11 ANSWER 20 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1998:608601 CAPLUS Full-text

DN 129:216521

OREF 129:44019a,44022a

TI Preparation of 1-isoquinolinone-3-carboxylates as PDE V inhibitors

IN Ukita, Tatsuzo; Omori, Kenji; Ikeo, Tomihiro

PA Tanabe Seiyaku Co., Ltd., Japan

SO PCT Int. Appl., 299 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9838168	A1	19980903	WO 1998-JP715	19980223 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
IN 1998MA00345	A	20050304	IN 1998-MA345	19980220
AU 9862300	A	19980918	AU 1998-62300	19980223 <--
JP 10298164	A	19981110	JP 1998-44139	19980226 <--
PRAI JP 1997-44408	A	19970227		
WO 1998-JP715	W	19980223		
OS MARPAT 129:216521				
GI				



I



II

AB Title compds. [I; R = H or substituent(s); R1 = H, NH2, (cyclo)alkyl, heterocyclyl, aryl, etc.; R2 = (esterified) CO2H, CONH2, N-attached

10/572,343 (RCE)

heterocyclylcarbonyl, etc.; R3 = (un)substituted Ph] were prepared as PDE V inhibitors (no data). Thus, 5-benzyloxy-4-methoxy-2-(3,4,5-trimethoxybenzoyl)benzoic acid was cyclocondensed with CH₂(CO₂Me)₂ and the hydrated product cyclocondensed with 4-(H₂N)C₆H₄NHCO₂Me₃ to give, in 4 addnl. steps, title compound II [R1 = C₆H₄(NH₂)-4, R3 = C₆H₂(OMe)₃-3,4,5, R4 = 2-pyridylmethoxy].


IT 260407-19-0 260407-20-3 260407-21-4
 260407-22-5 260407-23-4 260407-41-8
 260407-43-0 260407-44-1 780737-74-8
 1026587-91-6 1098785-16-0 1098785-17-1
 1098785-18-2 1098785-19-3 1098785-21-7
 1098785-23-9

RL: PRPH (Prophetic)

(Preparation of 1-isquinolinone-3-carboxylates as PDE V inhibitors)


RN 260407-19-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-20-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl](2-hydroxyethyl)amino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-21-4 CAPLUS


CN 2(1H)-Isoquinolineacetic acid, 3-(methoxycarbonyl)-1-oxo- α -(phenylmethyl)-4-(3,4,5-trimethoxyphenyl)-, phenylmethyl ester, (α S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 260407-22-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]methylamino]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-39-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 7-(cyclohexylmethoxy)-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 260407-41-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(3-methoxyphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester

(CA INDEX NAME)




RN 260407-43-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(cyclopentylmethoxy)-2-[4-[(1,1-dimethylethoxy)carbonylamino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 260407-44-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[(3-carboxyphenyl)methoxy]-2-[4-[(1,1-dimethylethoxy)carbonylamino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 780737-74-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,(3-dihydro-1H-indol-6-yl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 1026587-91-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-[3,4-dimethoxy-5-(methoxymethoxy)phenyl]-2-[4-[(1,1-dimethylethoxy)carbonylamino]phenyl]-1,2-dihydro-1-oxo-7-(2-pyridinyimethoxy)-, methyl ester (CA INDEX NAME)




RN 1098785-16-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]propylamino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 1098785-17-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-7-[[3-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 1098785-18-2 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

10/572,343 (RCE)




RN 1098785-19-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


PAGE 1-A



PAGE 2-A




RN 1098785-21-7 CAPLUS
CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-[1-
[(phenylmethoxy)carbonyl]-2-piperazinyl]-4-(3,4,5-trimethoxyphenyl)-,
methyl ester (CA INDEX NAME)



RN 1098785-23-9 CAPLUS

CN 3,7-Isoquinolinedicarboxylic acid,
2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl 7-(1H-pyrrol-2-yl) ester (CA INDEX NAME)




IT 212493-05-5F

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 1-isoquinolinone-3-carboxylates as PDE V inhibitors)

RN 212493-05-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




IT	212487-16-6P	212487-17-7P	212487-20-2P
	212487-22-5P	212487-25-7P	212487-27-9P
	212487-29-1P	212487-31-5P	212487-33-7P
	212487-35-9P	212487-39-2P	212487-40-6P
	212487-42-8P	212487-44-0P	212487-46-2P
	212487-48-4P	212487-50-6P	212487-52-0P
	212487-54-2P	212487-56-4P	212487-57-5P
	212487-59-7P	212487-61-1P	212487-64-4P
	212487-68-8P	212487-71-3P	212487-73-5P
	212487-76-8P	212487-77-9P	212487-78-0P
	212487-80-4P	212487-81-5P	212487-82-6P
	212487-83-7P	212487-84-8P	212487-85-9P
	212487-86-0P	212487-87-1P	212487-89-3P
	212487-90-6P	212487-91-7P	212487-92-8P
	212487-95-1P	212487-97-3P	212487-98-4P
	212487-99-5P	212488-00-1P	212488-01-2P
	212488-02-3P	212488-03-4P	212488-04-5P
	212488-05-6P	212488-06-7P	212488-07-8P
	212488-08-9P	212488-09-0P	212488-10-3P
	212488-11-4P	212488-12-5P	212488-13-6P
	212488-15-8P	212488-17-0P	212488-19-2P
	212488-21-6P	212488-23-8P	212488-25-0P
	212488-27-2P	212488-29-4P	212488-31-8P
	212488-33-0P	212488-35-2P	212488-37-4P
	212488-39-6P	212488-41-0P	212488-43-2P
	212488-45-4P	212488-46-5P	212488-48-7P
	212488-51-2P	212488-53-4P	212488-56-7P
	212488-58-9P	212488-60-3P	212488-62-5P
	212488-64-7P	212488-65-8P	212488-67-0P
	212488-69-2P	212488-71-6P	212488-73-8P
	212488-75-0P	212488-77-2P	212488-80-7P
	212488-83-0P	212488-86-3P	212488-89-6P
	212488-92-1P	212488-98-7P	212489-04-8P
	212489-07-1P	212489-10-6P	212489-13-9P
	212489-16-2P	212489-18-4P	212489-21-9P
	212489-24-2P	212489-27-5P	212489-31-1P
	212489-34-4P	212489-37-7P	212489-40-2P
	212489-43-5P	212489-46-8P	212489-49-1P
	212489-52-6P	212489-55-9P	212489-59-3P
	212489-64-0P	212489-68-4P	212489-72-0P
	212489-75-3P	212489-78-6P	212489-81-1P
	212489-84-4P	212489-86-6P	212489-89-9P
	212489-91-3P	212489-94-6P	212489-97-9P
	212490-01-2P	212490-04-5P	212490-07-8P
	212490-11-4P	212490-16-9P	212490-19-2P
	212490-22-7P	212490-26-1P	212490-30-7P
	212490-33-0P	212490-36-3P	212490-39-6P
	212490-41-0P	212490-43-2P	212490-45-4P
	212490-47-6P	212490-49-8P	212490-51-2P
	212490-53-4P	212490-55-6P	212490-58-9P
	212490-60-3P	212490-62-5P	212490-64-7P
	212490-66-9P	212490-68-1P	212490-70-5P
	212490-73-8P	212490-75-0P	212490-77-2P
	212490-79-4P	212490-81-8P	212490-83-0P
	212490-85-2P	212490-87-4P	212490-89-6P
	212490-91-0P	212490-93-2P	212490-95-4P
	212490-97-6P	212490-99-8P	212491-02-6P
	212491-04-8P	212491-06-0P	212491-08-2P

212491-11-7P	212491-14-6P	212491-18-4P
212491-22-0P	212491-25-3P	212491-29-7P
212491-32-2P	212491-34-4P	212491-38-8P
212491-41-3P	212491-43-5P	212491-46-8P
212491-49-1P	212491-51-5P	212491-55-9P
212491-59-3P	212491-64-0P	212491-68-4P
212491-72-0P	212491-75-3P	212491-79-7P
212491-82-2P	212491-85-5P	212491-88-8P
212491-91-3P	212491-94-6P	212491-97-9P
212492-00-7P	212492-03-0P	212492-06-3P
212492-09-6P	212492-11-0P	212492-15-4P
212492-19-8P	212492-22-3P	212492-25-6P
212492-29-0P	212492-32-5P	212492-35-8P
212492-39-2P	212492-42-7P	212492-45-0P
212492-49-3P	212492-51-8P	212492-54-1P
212492-57-4P	212492-60-9P	212492-65-4P
212492-68-7P	212492-73-4P	212492-78-9P
212492-82-5P	212492-87-0P	212492-91-6P
212492-96-1P	212493-01-1P	212493-08-6P
212493-13-5P	212493-16-0P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-isoquinolinone-3-carboxylates as PDE V inhibitors)


RN 212487-16-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-17-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-6-methoxy-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-20-2 CAPLUS

10/572,343 (RCE)


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212487-23-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-25-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-27-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212487-29-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 212487-31-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[9H-fluoren-9-


10/572,343 (RCE)

ylmethoxy)carbonyl]aminophenyl]-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 212487-33-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-thienylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HC1

RN 212487-35-9 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-38-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, ethyl ester (CA INDEX NAME)




RN 212487-40-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-ethoxy-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-2-phenyl-, ethyl ester (CA INDEX NAME)




RN 212487-42-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, phenylmethyl ester (CA INDEX NAME)




RN 212487-44-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-[3,5-dimethoxy-4-(phenylmethoxy)phenyl]-1,2-dihydro-1-oxo-2-phenyl-, phenylmethyl ester (CA INDEX NAME)




RN 212487-46-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 212487-48-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-butoxy-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-2-phenyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 212487-50-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2-chlorophenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-52-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(2-naphthalenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-54-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(1,1-dimethylethyl)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-56-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[3,5-bis(1,1-dimethylethyl)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-57-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-nitrophenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-59-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(dimethylamino)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-61-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[4-(methoxycarbonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-64-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-carboxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)



RN 212487-68-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[4-(4-morpholinylcarbonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-71-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[2-[(1,1-dimethylethoxy)carbonyl]hydrazinyl]carbonyl]phenyl]-1,2-dihydro-1-oxo-4-


10/572,343 (RCE)

(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-73-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-(hydrazinylcarbonyl)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212487-76-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[cis-4-[(1,1-dimethylethoxy)carbonyl]amino)cyclohexyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)


Relative stereochemistry.



RN 212487-77-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[trans-4-[(1,1-dimethylethoxy)carbonyl]amino]cyclohexyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)


Relative stereochemistry.



RN 212487-78-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(cis-4-aminocyclohexyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 212487-80-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(trans-4-aminocyclohexyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 212487-81-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[1-[(1,1-dimethylethoxy)carbonyl]-3-pyrrolidinyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-82-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(3-pyrrolidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212487-83-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminosulfonyl)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-84-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-85-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(4-piperidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-86-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[3-amino-5-(methoxycarbonyl)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-87-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-5-carboxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)



RN 212487-89-3 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 2-(2,3-dihydro-1H-inden-2-yl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-90-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,3-dihydro-1H-inden-5-yl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-91-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(1-methyl-4-piperidinyl)methyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-92-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetamino)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212487-95-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212487-97-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3,4-dimethoxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-98-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212487-99-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-amino-4-methoxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212488-00-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(tetrahydro-2-oxo-3-furanyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-01-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(2-oxo-3-pyrrolidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-02-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,3-dihydro-1H-indol-6-yl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212488-03-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-cyclopropyl-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-04-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(trans-4-hydroxycyclohexyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

Relative stereochemistry.




RN 212488-05-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-ethyl-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-06-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-[1-(phenylmethyl)-4-piperidinyl]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-07-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-[3-(trifluoromethyl)phenyl]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-08-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(1H-indazol-5-yl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-09-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(1-piperidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-10-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxypropyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-11-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(1-piperazinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212488-12-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-13-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-15-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-[4-
[[(phenylmethoxy) carbonyl] amino] methyl] phenyl]-4-(3,4,5-trimethoxyphenyl)-
methyl ester (CA INDEX NAME)




RN 212488-17-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminomethyl)phenyl]-1,2-dihydro-1-oxo-
4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX
NAME)




RN 212488-19-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[(1,2-dihydro-6-methyl-2-oxo-3-pyridinyl)methyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-21-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-23-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[3-(dimethylamino)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212488-25-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(6-methoxy-3-pyridinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212488-27-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(methoxycarbonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-29-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-carboxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 212488-31-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212488-33-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-35-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-amino-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-37-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(acetamino)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-39-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(diacetamino)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-41-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(methylamino)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-43-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[(2-hydroxyethyl)amino]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-45-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[2-(acetyloxy)ethyl]amino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-46-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(propylamino)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-48-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(ethylamino)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)


10/572,343 (RCE)



RN 212488-51-2 CAPLUS


CN 2(1H)-Isoquinolineacetic acid, 3-(methoxycarbonyl)-1-oxo-α-(phenylmethyl)-4-(3,4,5-trimethoxyphenyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 212488-53-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(1-methyl-1H-benzotriazol-6-yl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-56-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-fluorophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-58-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-amino-3-methoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-60-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[4-(2-hydroxyethyl)phenyl]-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-62-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(3-hydroxyphenyl)-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-64-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-(methylamino)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-65-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[cis-4-(methoxycarbonyl)cyclohexyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)


Relative stereochemistry.



RN 212488-67-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-carboxycyclohexyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)

(NAME)




RN 212488-69-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2-(2-furanylmethyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-71-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,3-dimethylphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-73-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2,4-bis(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-75-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212488-77-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212488-80-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[bis(methylsulfonyl)amino]phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-83-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetamino)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-86-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[4-(methylamino)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-89-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(1-piperidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-92-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(1,3-benzodioxol-5-ylmethyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212488-98-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(1,3-benzodioxol-5-yl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-04-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-[2-(1-piperidinyl)ethyl]-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212489-07-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 212489-10-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 212489-13-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-(4-methyl-1-piperazinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-16-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-18-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-chlorophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-21-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-chlorophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-24-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-cyclopentyl-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-27-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(phenylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212489-31-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-(dimethylamino)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212489-34-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[4-(4-morpholinyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212489-37-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(1H-imidazol-1-yl)propyl]-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-40-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-[3-(hydroxymethyl)phenyl]-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-43-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[4-(2-methoxy-2-oxoethyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-46-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(carboxymethyl)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, sodium salt (1:1) (CA INDEX NAME)




RN 212489-49-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212489-52-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(4-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212489-55-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(cyclopropylmethyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212489-59-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(3-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212489-64-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(2-pyridinylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212489-68-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-72-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-(4-hydroxy-3,5-dimethoxyphenyl)-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-, methyl ester (CA INDEX NAME)



RN 212489-75-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(2-pyridinylamino)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212489-78-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[3-(methylthio)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-81-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[3-(methylsulfonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-84-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-[3-(methylsulfonyl)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-86-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(4-thiomorpholinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-89-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(1,1-dioxido-4-thiomorpholinyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-91-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-(1-oxido-4-thiomorpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-94-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-methyl-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212489-97-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-2-methyl-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212490-01-2 CAPLUS

CN 1(2H)-Isoquinolinone, 6,7-dimethoxy-2-methyl-3-(4-morpholinylcarbonyl)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212490-04-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[2-(1H-imidazol-5-yl)ethyl]-6,7-dimethoxy-2-methyl-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212490-07-8 CAPLUS

CN 1(2H)-Isoquinolinone, 3-[[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl]-6,7-dimethoxy-2-methyl-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212490-11-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-amino-3-methoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, (trimethylsilyl)methyl ester (CA INDEX NAME)




RN 212490-16-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-19-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-1-oxo-2-(tetrahydro-2H-pyran-4-yl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-22-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212490-26-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212490-30-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-33-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]methylamino]phenyl]-6,7-diethoxy-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212490-36-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-2-[4-(methylamino)phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212490-39-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-1-oxo-2-(4-(phenylmethoxy)phenyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-41-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6,7-diethoxy-1,2-dihydro-2-(4-hydroxyphenyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-43-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methyl-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-45-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-47-6 CAPLUS

CN 1,3-Dioxolo[4,5-g]isoquinoline-7-carboxylic acid, 5,6-dihydro-5-oxo-6-phenyl-8-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-49-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-methoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-51-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 8-chloro-1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-53-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-8-methoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-55-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-58-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 8-chloro-2-[[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212490-60-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-8-chloro-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212490-62-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-64-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212490-66-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl- (CA INDEX NAME)




RN 212490-68-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-, methyl ester (CA INDEX NAME)




RN 212490-70-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl- (CA INDEX NAME)




RN 212490-73-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-N-methyl-1-oxo-2-phenyl- (CA INDEX NAME)




RN 212490-75-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-(4-bromo-3-methylphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212490-77-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(aminocarbonyl)phenyl]-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212490-79-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[3-(aminocarbonyl)phenyl]-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212490-81-8 CAPLUS

CN 2(1H)-Isoquinolineacetic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-6,7-dimethoxy-3-(methoxycarbonyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212490-83-0 CAPLUS

CN 2(1H)-Isoquinolineacetic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-6,7-dimethoxy-3-(methoxycarbonyl)-1-oxo-, ethyl ester (CA INDEX NAME)




RN 212490-85-2 CAPLUS

CN 2-(1H)-Isoquinolineacetic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-6,7-dimethoxy-3-(methoxycarbonyl)-1-oxo- (CA INDEX NAME)




RN 212490-87-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-[2-(2-hydroxyethoxy)ethyl]-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212490-89-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-(1H-pyrrol-1-yl)-, methyl ester (CA INDEX NAME)




RN 212490-91-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212490-93-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(2-aminoethyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212490-95-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(5-methyl-3-isoxazolyl)-1-oxo-, methyl ester (CA INDEX NAME)



RN 212490-97-6 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-(phenylamino)-, methyl ester (CA INDEX NAME)




RN 212490-99-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(3-nitrophenyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-02-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(2-methoxyethyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-04-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-(3-carboxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, 3-methyl ester (CA INDEX NAME)




RN 212491-06-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-[(2-[(1,1-dimethylethoxy)carbonyl]hydrazinyl]carbonyl]phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-08-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-(hydrazinylcarbonyl)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-11-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[3-(2-methoxy-2-oxoethoxy)phenyl]-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-14-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-(carboxymethoxy)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, 3-methyl ester (CA INDEX NAME)




RN 212491-18-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[3-[2-[[3-(4-morpholinyl)propyl]amino]-2-oxoethoxy]phenyl]-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-22-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(3-aminophenyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-25-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-(formylamino)phenyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212491-29-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[3-(2-methyl-4-pyrimidinyl)phenyl]-1-oxo-, methyl ester (CA INDEX NAME)



RN 212491-32-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[3-(1-methyl-1H-pyrazol-3-yl)phenyl]-1-oxo-, methyl ester

(CA INDEX NAME)




RN 212491-34-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[2-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]ethyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212491-38-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[2-(1-piperazinyl)ethyl]-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212491-41-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-[2-(4-morpholinyl)ethyl]-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212491-43-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-amino-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-46-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-(3-hydroxypropyl)-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-49-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[3-[(3-pyridinylcarbonyl)oxy]propyl]-, methyl ester (CA INDEX NAME)




RN 212491-51-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-butyl-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-55-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2-amino-2-oxoethyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-59-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-(6-quinolinyl)-, methyl ester (CA INDEX NAME)




RN 212491-64-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[(tetrahydro-2-furanyl)methyl]-, methyl ester (CA INDEX NAME)




RN 212491-68-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-(3-quinoliny)-, methyl ester (CA INDEX NAME)




RN 212491-72-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-[2-hydroxy-1-(hydroxymethyl)ethyl]-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-75-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-(dimethylamino)propyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-79-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-2-[3-[(1,1-dimethylethoxy)carbonyl]amino]propyl]-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-82-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(3-methoxypropyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212491-85-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[1-(phenylmethyl)-4-piperidinyl]-, methyl ester (CA INDEX NAME)




RN 212491-88-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-(phenylmethyl)-, methyl ester (CA INDEX NAME)




RN 212491-91-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-propyl-, methyl ester (CA INDEX NAME)




RN 212491-94-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(6-amino-3-pyridinyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212491-97-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminobutyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212492-00-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[(1R,2S)-2-aminocyclohexyl]-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1), rel- (CA INDEX NAME)


Relative stereochemistry.



● HCl

RN 212492-03-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminocyclohexyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212492-06-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetamino)phenyl]-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212492-09-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212492-11-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[4-(phenylmethoxy)carbonyl]-1-piperazinyl-, methyl ester (CA INDEX NAME)



RN 212492-15-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-[4-(2-hydroxyethyl)-1-piperazinyl]-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212492-19-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-[4-(phenylmethyl)-1-piperazinyl]-, methyl ester (CA INDEX NAME)



RN 212492-22-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(3-aminopropyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212492-25-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212492-29-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl


RN 212492-32-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212492-35-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-2-(4-morpholinyl)-1-oxo-, methyl ester (CA INDEX NAME)




RN 212492-39-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-4-(2,3,4-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-42-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-45-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212492-48-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212492-51-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212492-54-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212492-57-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(1H-pyrrol-2-ylcarbonyl)oxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-60-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(2-thienylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212492-65-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-7-[[5-(methoxycarbonyl)-1-methyl-1H-pyrrol-3-yl]methoxy]-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212492-68-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212492-73-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl


RN 212492-78-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212492-82-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212492-87-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-

10/572,343 (RCE)


quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212492-91-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212492-96-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(3-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212493-01-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212493-08-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-7-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-13-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(carboxymethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212493-18-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(cyclopentyloxy)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




IT	212493-22-6P	212493-28-2P	212493-32-8P
	212493-38-4P	212493-42-0P	212493-47-5P
	212493-51-1P	212493-57-7P	212493-63-5P
	212493-70-4P	212493-77-1P	212493-82-6P
	212493-88-4P	212493-94-2P	212493-99-7P
	212494-05-8P	212494-10-5P	212494-14-9P
	212494-18-3P	212494-23-0P	212494-28-5P
	212494-33-2P	212494-39-8P	212494-45-6P
	212494-50-3P	212494-56-9P	212494-61-6P
	212494-66-1P	212494-71-8P	212494-76-3P
	212494-81-0P	212494-85-4P	212494-89-8P
	212494-93-4P	212494-97-8P	212495-00-6P
	212495-03-9P	212495-06-2P	212495-09-5P
	212495-12-0P	212495-16-4P	212495-20-0P
	212495-24-4P	212495-27-7P	212495-31-3P
	212495-34-6P	212495-38-0P	212495-42-6P
	212495-48-2P	212495-54-0P	212495-57-3P
	212495-62-0P	212495-66-4P	212495-68-3P
	212495-71-1P	212495-74-4P	212495-77-7P
	212495-80-2P	212495-83-5P	212495-86-8P
	212495-90-4P	212495-93-7P	212495-96-0P
	212496-00-9P	212496-03-2P	212496-06-5P

212496-07-6P 212496-08-7P 212496-09-8P
 212496-10-1P 212496-11-2P 212496-12-3P
 212496-13-4P 212496-14-5P 212496-16-7P
 212496-18-9P 212496-24-7P 212496-29-2P
 212496-36-1P 212496-41-8P 212496-46-3P
 212496-52-1P 212496-59-7P 212496-62-3P
 212496-67-8P 212496-72-5P 212496-76-9P
 212496-81-6P 212496-86-1P 212496-91-8P
 212496-96-3P 212497-01-3P 212497-05-7P
 212497-10-4P 212497-15-9P 212497-21-7P
 212497-27-3P 212497-33-1P 212497-38-6P
 212497-42-2P 212497-46-6P 212497-49-9P
 212497-52-4P 212497-54-6P 212497-56-8P
 212497-58-0P 212497-60-4P 212497-63-7P
 212497-66-0P 212497-69-3P 212497-72-8P
 212497-75-1P 212497-78-4P 212497-81-9P
 212497-85-3P 212497-89-7P 212497-93-3P
 212497-96-6P 212497-99-8P 212498-01-6P
 212498-03-8P 212498-05-0P 212498-07-2P
 212498-09-4P 212498-11-8P 212498-13-0P
 212498-16-3P 212498-19-6P 212498-22-1P
 212498-25-4P 212498-29-8P 212498-31-2P
 212498-33-4P 212498-35-6P 212498-37-8P
 212498-39-0P 212498-41-4P 212498-43-6P
 212498-45-8P 212498-47-0P 212498-49-2P
 212498-51-6P 212498-53-8P 212498-55-0P
 212498-57-2P 212498-59-4P 212498-60-7P
 212498-62-9P 212498-64-1P 212498-65-2P
 212498-67-4P 212498-68-5P 212498-70-9P
 212498-72-1P 212498-73-2P 212498-74-3P
 212498-75-4P 212498-76-5P 212498-77-6P
 212498-78-7P 212498-79-8P 212498-80-1P
 212498-81-2P 212498-82-3P 212498-83-4P
 212498-84-5P 212498-85-6P 212498-86-7P
 212498-87-8P 212498-88-9P 212498-89-0P
 212498-90-3P 212498-91-4P 212498-92-5P
 212498-93-6P 212498-94-7P 212498-95-8P
 212498-96-9P 212498-97-0P 212498-98-1P
 212498-99-2P 212499-00-8P 212499-01-9P
 212499-02-0P 212499-03-1P 212499-04-2P
 212499-05-3P 212499-06-4P 212499-07-5P
 212499-09-7P 212499-11-1P 212499-13-3P
 212499-15-5P 212499-17-7P 212499-19-9P
 212499-20-2P 212499-21-3P 212499-22-4P
 212499-23-5P 212499-25-7P 212499-27-9P
 212499-29-1P 212499-31-5P 212499-32-6P
 212499-33-7P 212499-34-8P 212499-35-9P
 212499-36-0P 212499-37-1P 212499-38-2P
 212499-39-3P 212499-40-6P 212499-41-7P
 212499-42-8P 212499-43-9P 212499-44-0P
 212499-45-1P 212499-46-2P 212499-47-3P
 212499-48-4P 212499-49-5P 212499-50-8P
 212499-51-9P 212499-52-0P 212499-53-1P
 212499-54-2P 212499-55-3P 212499-56-4P
 212499-57-5P 212499-58-6P 212499-59-7P
 212499-60-0P 212499-61-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1-isoquinolinone-3-carboxylates as PDE V inhibitors)

RN 212493-22-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(cyclopentyloxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212493-28-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 7-[2-(dimethylamino)ethoxy]-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-32-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[2-(dimethylamino)ethoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



● 2 HCl


RN 212493-38-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-42-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212493-47-5 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-7-ethoxy-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212493-51-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-ethoxy-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212493-57-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-(2-methoxyethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212493-63-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-(2-methoxyethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-70-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212493-77-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-

10/572,343 (RCE)


oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212493-82-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-88-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212493-94-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212493-99-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 212494-05-8 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-(2-hydroxyethoxy)-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212494-10-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-(2-hydroxyethoxy)-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212494-14-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-18-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212494-23-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-oxo-2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-28-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-oxo-2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212494-33-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(2-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-39-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(2-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212494-45-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(3-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-50-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(3-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212494-56-9 CAPLUS

10/572,343 (RCE)


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(cyclohexylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212494-61-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-(2-methoxy-2-oxoethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-66-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-(2-methoxy-2-oxoethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212494-71-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[(3,4-dichlorophenyl)methoxy]-2-[[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-76-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,4-dichlorophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl




RN 212494-81-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(4-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212494-85-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(4-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212494-89-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-([1,1'-biphenyl]-4-ylmethoxy)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212494-93-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-([1,1'-biphenyl]-4-ylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212494-97-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[[3-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-00-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[[3-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212495-03-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-7-[(2-fluorophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-06-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2-fluorophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212495-09-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-(1-naphthalenylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 212495-12-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-(1-naphthalenylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-16-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-(2-naphthalenylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212495-20-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-(2-naphthalenylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-24-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-propen-1-yloxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-27-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-[(2-propen-1-yloxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212495-31-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(4-carboxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212495-34-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[[4-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212495-38-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinyloxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-42-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinyloxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212495-48-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[[[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)]-, methyl ester (CA INDEX NAME)




RN 212495-54-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[[[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-57-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(benzoyloxy)-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)]-, methyl ester (CA INDEX NAME)




RN 212495-62-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(benzoyloxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-66-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-[(1H-pyrrol-2-ylcarbonyl)oxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-68-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-[2-(2-pyridinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-71-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-[2-(2-pyridinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212495-74-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(3-thienylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

10/572,343 (RCE)




RN 212495-77-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-thienylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212495-80-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(4-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212495-83-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 212495-86-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(3-methylphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212495-90-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(3-methylphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212495-93-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 7-[(2-chloro-5-nitrophenyl)methoxy]-2-[[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212495-96-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2-chloro-5-nitrophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A


● HCl

RN 212496-00-9 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(3-methoxyphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212496-03-2 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3-aminophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212496-06-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(cyclopentylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212496-07-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-7-[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-08-7 CAPLUS

10/572,343 (RCE)


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-piperidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212496-09-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-[2-(1-piperidinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-10-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-[2-(1-piperidinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



● 2 HCl


RN 212496-11-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(4-methyl-1-piperazinyl)carbonyl]oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212496-12-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(4-methyl-1-piperazinyl)carbonyl]oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212496-13-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 7-[[[(diethylamino)carbonyl]oxy]-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-14-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[[[(diethylamino)carbonyl]oxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl


RN 212496-16-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(4-morpholinylcarbonyl)oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-18-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(4-morpholinylcarbonyl)oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212496-24-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2H-tetrazol-5-ylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-29-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2H-tetrazol-5-ylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212496-36-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(1-oxido-4-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212496-41-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(1-oxido-4-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212496-46-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(1-oxido-3-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-52-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-
[(1-oxido-3-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl
ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212496-58-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[(1-oxido-2-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA
INDEX NAME)



RN 212496-62-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-
[(1-oxido-2-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl
ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212496-67-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(2-amino-2-oxoethoxy)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212496-72-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(2-amino-2-oxoethoxy)-2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212496-76-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3-

10/572,343 (RCE)


carboxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212496-81-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212496-86-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212496-91-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212496-96-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-hydroxy-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-01-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212497-05-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-hydroxy-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212497-10-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-], methyl ester (CA INDEX NAME)



RN 212497-15-9 CAPLUS

10/572,343 (RCE)


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212497-21-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-6-ethoxy-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-27-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-6-ethoxy-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212497-33-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-6-(2-methoxyethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-38-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-6-(2-methoxyethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212497-42-2 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-(2-hydroxyethoxy)-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212497-46-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-(2-hydroxyethoxy)-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212497-49-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-52-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212497-54-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-56-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212497-58-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-60-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



● 2 HCl


RN 212497-63-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-(cyclopentyloxy)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-66-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-6-(cyclopentyloxy)-1,2-dihydro-7-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212497-69-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-


10/572,343 (RCE)

dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-methoxy-1-oxo-6-[2-(2-pyridinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212497-72-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-methoxy-1-oxo-6-[2-(2-pyridinyl)ethoxy]-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212497-75-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-, methyl ester (CA INDEX NAME)



RN 212497-78-4 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 4-(3,4-dichlorophenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-, methyl ester (CA INDEX NAME)



RN 212497-81-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212497-85-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-2-(1H-indazol-6-yl)-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212497-89-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(1H-indol-1-yl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212497-93-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-[(2,2,2-trifluoroacetyl)amino]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212497-96-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dibromo-4-methoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-2-phenyl-, methyl ester (CA INDEX NAME)



RN 212497-98-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(4-aminophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



● 2 HCl

RN 212498-01-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(1,3-benzodioxol-5-ylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212498-03-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2,4-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


PAGE 1-A



● HCl

RN 212498-05-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2,5-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212498-07-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● HCl

RN 212498-09-4 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,4-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● HCl

RN 212498-11-8 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2,3-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● HCl

RN 212498-13-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-
[(2-methoxyphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl
ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-16-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-
[(4-methoxyphenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl
ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-19-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(1H-benzimidazol-2-
ylmethoxy)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester,
hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212498-22-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[4-methylphenyl)sulfonyl]oxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-25-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-29-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212498-31-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-33-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212498-35-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-37-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



● 2 HCl

RN 212498-39-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(4-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-41-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(3-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-43-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(2-nitrophenyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-45-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-bromo-3,5-dimethoxyphenyl)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 212498-47-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-49-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212498-51-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-53-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212498-55-0 CAPLUS

10/572,343 (RCE)


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212498-57-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212498-59-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-quinolinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212498-60-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-62-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-64-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-65-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HC1

RN 212498-67-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HC1


RN 212498-68-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-7-[(4-methyl-1H-imidazol-5-yl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-70-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(cyclopropylmethoxy)-2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-72-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(cyclopropylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HC1

RN 212498-73-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(6-(hydroxymethyl)-2-pyridinyl)methoxy]-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HC1

RN 212498-74-3 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-diaminophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 3 HCl

RN 212498-75-4 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(1H-benzimidazol-2-ylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl


RN 212498-76-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(2,6-dioxo-4-piperidiny)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-77-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-78-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-79-8 CAPLUS

10/572,343 (RCE)


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-8-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-80-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(4-bromo-3,5-dimethoxyphenyl)-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)



RN 212498-81-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl


RN 212498-82-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212498-83-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-84-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(phenylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212498-85-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-7-hydroxy-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212498-86-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212498-87-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(4-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212498-88-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212498-89-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212498-90-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-7-(2-

10/572,343 (RCE)


pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 212498-91-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-(4-morpholinyl)-1-oxo-7-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212498-92-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[[3-(dimethylamino)phenyl]methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212498-93-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212498-94-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-dimethoxyphenyl)methoxyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




PAGE 1-A

PAGE 2-A

● HCl


RN 212498-95-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2,5-dimethoxyphenyl)methoxyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212498-96-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212498-97-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)



RN 212498-98-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212498-99-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-00-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212499-01-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-

10/572,343 (RCE)


dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-quinolinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-02-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-03-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-04-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-05-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-quinolynylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212499-06-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 212499-07-5 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3-aminophenyl)methoxy]-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212499-09-7 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-11-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-[(2,5-dimethoxyphenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-13-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-(cyanomethoxy)-1,2-dihydro-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-15-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-7-(1-isoquinolinylmethoxy)-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl



RN 212499-17-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-19-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[9H-fluoren-9-ylmethoxy]carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212499-20-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-diaminophenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:3) (CA INDEX NAME)



●3 HCl

RN 212499-21-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212499-22-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-[[4-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212499-23-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[4-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212499-25-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-[3-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212499-27-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(4-carboxyphenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212499-29-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[(3-carboxyphenyl)methoxy]-2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)



RN 212499-31-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3-carboxyphenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212499-32-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 212499-33-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 212499-34-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[3-(methylamino)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



● 2 HCl

RN 212499-35-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[2-(hydroxymethyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-36-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[3-(hydroxymethyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-37-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[4-(hydroxymethyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212499-38-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetamino)phenyl]-1,2-dihydro-1-oxo-7-(2-(pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212499-39-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-([(1,1-dimethylethoxy)carbonyl]amino)phenyl]-1,2-dihydro-7-[(1-oxido-2-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-40-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(1-oxido-2-


10/572,343 (RCE)

pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212499-41-7 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 7-[(3-aminophenyl)methoxy]-1,2-dihydro-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-42-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 7-(1H-benzimidazol-2-yl)methoxy)-1,2-dihydro-2-(4-morpholinyl)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212499-43-9 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-8-hydroxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212499-44-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212499-45-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212499-46-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212499-47-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(2-quinolinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



RN 212499-48-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(2-phenylethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)


10/572,343 (RCE)



● HCl1

RN 212499-49-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-(1H-imidazol-5-ylmethoxy)-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl1

RN 212499-50-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-[[4-(aminomethyl)phenyl]methoxy]-1,2-dihydro-2-[4-[(methylsulfonyl)amino]phenyl]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-51-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(1H-benzimidazol-2-

10/572,343 (RCE)

ylmethoxy)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 212499-52-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● HCl

RN 212499-53-1 CAPLUS

10/572,343 (RCE)


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-54-2 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-55-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-7-(2-furanylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212499-56-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[4-
 [[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(
 phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212499-57-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-
 methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(phenylmethoxy)-, methyl
 ester, hydrochloride (1:1) (CA INDEX NAME)




RN 212499-58-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[4-
 [[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-7-hydroxy-6-
 methoxy-1-oxo-, methyl ester (CA INDEX NAME)




RN 212499-59-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-hydroxy-6-methoxy-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



RN 212499-60-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




RN 212499-61-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-

10/572,343 (RCE)

methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


IT	212499-62-2P	212499-64-4P	212499-67-7P
	212499-70-2P	212499-73-5P	212499-76-8P
	212499-79-1P	212499-80-4P	212499-81-5P
	212499-82-6P	212499-84-8P	212499-85-9P
	212499-88-2P	212499-90-6P	212499-92-8P
	212499-94-0P	212499-96-2P	212499-98-4P
	212500-00-0P	212500-02-2P	212500-03-3P
	212500-05-5P	212500-07-7P	212500-10-2P
	212500-13-5P	212500-15-7P	212500-17-9P
	212500-19-1P	212500-21-5P	212500-23-7P
	212500-25-9P	212500-27-1P	212500-28-2P
	212500-30-6P	212500-31-7P	212500-32-8P
	212500-34-0P	212500-36-2P	212500-37-3P
	212500-38-4P	212500-39-5P	212500-40-6P
	212500-41-9P	212500-42-0P	212500-43-1P
	212500-44-2P	212500-45-3P	212500-46-4P
	212500-47-5P	212500-48-6P	212500-49-7P
	212500-50-0P	212500-51-1P	212500-52-2P
	212500-53-3P	212500-54-4P	212500-57-7P
	212500-60-2P	212500-64-6P	212500-66-8P
	212500-67-9P	212500-68-0P	212500-69-1P
	212500-70-4P	212500-73-5P	212500-72-6P
	212500-73-7P	212500-74-8P	212500-75-9P
	212500-76-0P	212500-77-1P	212500-78-2P
	212501-80-9P	212501-90-1P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-isoquinolinone-3-carboxylates as PDE V inhibitors)

RN 212499-62-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



● 2 HCl

RN 212499-64-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-quinolinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 212499-67-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212499-70-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-

10/572,343 (RCE)


methylphenyl)-1,2-dihydro-1-oxo-7-(phenylmethoxy)-, methyl ester,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212499-73-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3,5-dimethoxy-4-methylphenyl)-2-[4-
[[(1,1-dimethylethoxy)carbonyl]aminophenyl]-1,2-dihydro-7-hydroxy-1-oxo-,
methyl ester (CA INDEX NAME)



RN 212499-76-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-
methylphenyl)-1,2-dihydro-7-hydroxy-1-oxo-, methyl ester, hydrochloride
(1:1) (CA INDEX NAME)



● HCl

RN 212499-79-1 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-80-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




●2 HCl

RN 212499-81-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



●2 HCl

RN 212499-82-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-quinolinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-84-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-(1-isoquinolinylmethoxy)-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl


RN 212499-85-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-diaminophenyl)methoxy]-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-

10/572,343 (RCE)

, methyl ester, hydrochloride (1:3) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● 3 HCl

RN 212499-88-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[6-(hydroxymethyl)-2-pyridinyl]methoxy]-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)




● 2 HCl

RN 212499-90-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[3-(methylamino)phenyl]methoxy]-1-oxo-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)


10/572,343 (RCE)



●2 HCl

RN 212499-92-8 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-([2-(hydroxymethyl)phenyl]methoxy)-1-oxo-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 212499-94-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 212499-96-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212499-98-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212499-96-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 212500-00-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 212499-96-2

CMF C32 H29 N3 O7



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 212500-02-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212500-03-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7

10/572,343 (RCE)



CM 2

CRN 7664-93-9

CMF H2 O4 S




RN 212500-05-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2


CRN 75-75-2

CMF C H4 O3 S




RN 212500-07-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo- (CA INDEX NAME)




RN 212500-10-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-bromo-4,5-dimethoxyphenyl)-1,2-dihydro-6,7-dimethoxy-1-oxo-, methyl ester (CA INDEX NAME)



RN 212500-13-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-4-(3-hydroxy-4,5-dimethoxyphenyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 212500-15-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-4-(4-hydroxy-3,5-dimethoxyphenyl)-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212500-17-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-19-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-21-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-2-(4-morpholinyl)-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-23-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-25-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-27-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6-methoxy-1-oxo-2-phenyl-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-28-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-((3-aminophenyl)methoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-30-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-31-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-(1H-benzimidazol-2-ylmethoxy)-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-32-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-diaminophenyl)methoxy]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212500-34-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212500-36-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-


10/572,343 (RCE)

dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(3-pyridinylmethoxy)-,
methyl ester (CA INDEX NAME)




RN 212500-37-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3-
dimethoxyphenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(4-pyridinylmethoxy)-,
methyl ester (CA INDEX NAME)




RN 212500-38-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(3-
pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX
NAME)




RN 212500-39-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(2,5-
dimethoxyphenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-,
methyl ester (CA INDEX NAME)




RN 212500-40-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-dimethoxyphenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212500-41-9 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)



RN 212500-42-0 CAPLUS


10/572,343 (RCE)

- CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




- RN 212500-43-1 CAPLUS

- CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




- RN 212500-44-2 CAPLUS

- CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3-aminophenyl)methoxy]-4-(4-bromo-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-, methyl ester (CA INDEX NAME)




- RN 212500-45-3 CAPLUS

- CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212500-46-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)



RN 212500-47-5 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[[3-(dimethylamino)phenyl]methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212500-48-6 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)

10/572,343 (RCE)




RN 212500-49-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-diaminophenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-50-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[(6-(hydroxymethyl)-2-pyridinyl)methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-51-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(4-carboxyphenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 212500-52-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3-carboxyphenyl)methoxy]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester (CA INDEX NAME)




RN 212500-53-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-54-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-57-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[3-(methylamino)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-60-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-7-[[2-(hydroxymethyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-64-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-66-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(3-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-67-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-8-(4-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212500-68-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-7-[(6-(hydroxymethyl)-2-pyridinyl)methoxy]-1-oxo-, methyl ester (CA INDEX NAME)




RN 212500-69-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212500-70-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212500-71-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(3-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212500-72-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212500-73-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-7-[(3,5-diaminophenyl)methoxy]-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-, methyl ester (CA INDEX NAME)




RN 212500-74-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[(6-(hydroxymethyl)-2-pyridinyl)methoxy]-1-oxo-, methyl ester (CA INDEX NAME)




RN 212500-75-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[(3-(methylamino)phenyl)methoxy]-1-oxo-, methyl ester (CA INDEX NAME)




RN 212500-76-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-7-[[2-[(hydroxymethyl)amino]phenyl]methoxy]-1-oxo-, methyl ester (CA INDEX NAME)




RN 212500-77-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(3,5-dimethoxy-4-methylphenyl)-1,2-dihydro-1-oxo-7-(2-pyrazinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212500-78-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-4-(4-chloro-3,5-dimethoxyphenyl)-1,2-dihydro-1-oxo-7-(4-pyridinylmethoxy)-, methyl ester (CA INDEX NAME)




RN 212501-80-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212501-90-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-carboxyphenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, 3-methyl ester, sodium salt (1:1) (CA INDEX NAME)



● Na

IT 212501-73-0P 212501-74-1P 212501-75-2P

212501-77-4P 212501-78-5P 212501-79-6P


212501-81-0P 212501-83-2P 212501-84-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1-isoquinolinone-3-carboxylates as PDE V inhibitors)


RN 212501-73-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[(1,1-dimethylethoxy)carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212501-74-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-6-methoxy-1-oxo-7-(2-thienylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212501-75-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-phenyl-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 212501-77-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-(4-piperidinyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 212501-78-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-(acetylamino)phenyl]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212501-79-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 212501-81-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-2-[4-((phenylmethoxy)carbonyl)-1-piperazinyl]-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)




RN 212501-83-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-7-[[4-(methoxycarbonyl)phenyl]methoxy]-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



RN 212501-84-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 7-(cyanomethyl)-2-[4-[[[1,1-dimethylethoxy]carbonyl]amino]phenyl]-1,2-dihydro-6-methoxy-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



OSC.G 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 21 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1998:398243 CAPLUS Full-text

DN 129:81741

OREF 129:16880h,16881a

TI Preparation of pyridines as antiasthmatics

IN Ukita, Tatsuzo; Sugahara, Masakatsu; Ikezawa, Katsuo; Kikkawa, Hideo;
 Naito, Kazuaki

PA Tanabe Seiyaku Co., Ltd., Japan

SO Eur. Pat. Appl., 59 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 848000	A1	19980617	EP 1997-309947	19971210 <--

10/572,343 (RCE)

EP 848000 B1 20020612
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 US 5965730 A 19991012 US 1997-985042 19971204 <--
 TW 429257 B 20010411 TW 1997-86118300 19971205 <--
 AT 219075 T 20020615 AT 1997-309947 19971210 <--
 PT 848000 E 20020930 PT 1997-309947 19971210
 ES 2178741 T3 20030101 ES 1997-309947 19971210
 CA 2224635 A1 19980613 CA 1997-2224635 19971211 <--
 CA 2224635 C 20060131
 CN 1184813 A 19980617 CN 1997-125491 19971212 <--
 CN 1127498 C 20031112
 JP 10226685 A 19980825 JP 1997-342352 19971212 <--
 JP 3951395 B2 20070801
 HK 1012505 A1 20021025 HK 1998-113891 19981217
 PRAI JP 1996-333357 A 19961213

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 129:81741
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A = II-VI (wherein R1, R2 = H, (un)protected OH; R31, R41, R42 = (un)protected CH2OH; R32 = H, lower alkyl, (un)protected CH2OH; R33 = (un)substituted lower alkyl; the dotted line means the presence or absence of a double bond); R5, R6 = H, (un)protected NH2, or NR5R6 = (un)substituted heterocycle], which show excellent bronchoconstriction inhibitory activity and/or anti-inflammatory activity of airways, and therefore are useful in the prophylaxis or treatment of asthma, were prepared. Thus, reaction of 4-(3-pyridyl)phthalazin-1(2H)-one with 2-bromo-4-[6,7-dimethoxy-2-(4-pyridyl)methyl]phthalazin-1(2H)-on-4-ylpyridine in the presence of K2CO3 and CuI in DMF afforded the title compound VII. Compds. I are effective at 0.003-3 mg/kg/day.

IT 209262-34-QP 209262-35-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyridines as antiasthmatics)

RN 209262-34-0 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(4-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 209262-35-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-4-(4-pyridinyl)-, methyl ester (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 22 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1997:706935 CAPLUS [Full-text](#)

DN 128:3591

OREF 128:779a,782a

TI Potent NK1 receptor antagonists: synthesis and antagonistic activity of various heterocycles with an N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoyl substituent

AU Ikeura, Yoshinori; Tanaka, Toshimasa; Kiyota, Yutaka; Morimoto, Shinji; Ogino, Masaki; Ishimaru, Takenori; Kamo, Izumi; Doi, Takayuki; Natsugari, Hideaki

CS Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532, Japan

SO Chemical & Pharmaceutical Bulletin (1997), 45(10), 1642-1652


CODEN: CPBTAL; ISSN: 0009-2363

FB Pharmaceutical Society of Japan

DT Journal

LA English

GI



I

AB Various N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoyl heterocycles modified at rings A and B in the isoquinolone and pyrido[3,4-b]pyridine nuclei were prepared and evaluated for NK1 receptor antagonistic activities. The structure-activity relationship studies on this series, along with conformational anal., showed that for ring A, 6-membered heterocycles are preferable to 5-membered heterocycles (a ca. 300-fold difference in potency), the 6-membered ring seems to function as an anchor by fixing the pendant Ph group in a desirable orientation for receptor binding, and since compds. with

aromatic rings and those with aliphatic rings as ring B both show good potency, this ring does not seem to be essential for receptor recognition. Among the compds. synthesized, the tetrahydropyridine derivs. I [RR1 = NMe(CH2)3, CH2NMeCH2CH2, (CH2)3NMe] exhibited excellent inhibitory effects both in vitro and in vivo, with potent activity upon oral administration (ED50-0.20-0.27 mg/kg) (capsaicin-induced plasma extravasation in guinea pig trachea).


IT 159817-70-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoylpyridinone analogs as potent NK1 receptor antagonists)

RN 159817-70-6 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-1,2-dihydro-N,2-dimethyl-1-oxo- (CA INDEX NAME)



OSC.G 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 23 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1997:151429 CAPLUS Full-text

DN 126:157495

OREF 126:30459a

TI Preparation of pyridopyridine derivatives as tachykinin antagonists

IN Natsukari, Hideaki; Ishimaru, Takenori; Doi, Takayuki

PA Takeda Chemical Industries Ltd, Japan

SO Jpn. Kokai Tokkyo Koho, 43 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08337583	A	19961224	JP 1996-115519	19960412 <--
PRAI	JP 1995-113594	A	19950413		
OS	MARPAT 126:157495				

GI For diagram(s), see printed CA Issue.

AB The title compds. I (ring A, B = homocyclic ring, heterocyclic ring; at least one of rings A and B is a heterocyclic ring; Z = heterocyclic ring, etc.; R = H, hydrocarbon; one of X and Y is NR1 or O, the other is CO or CS; or one of X and Y is N, the other is CR2; R1 = H, hydrocarbon; R2 = H, halo, etc.; n = 1 - 4), useful as tachykinin antagonists (no data), are prepared For example, 7,8-dihydro-7-methyl-5-(4-methylphenyl)-8-oxo-N-(2-pyridylmethyl)-6-pyrido[3,4-b]pyridinecarboxamide was prepared

IT 168542-27-6P 168542-47-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of pyridopyridine derivs. as tachykinin antagonists)


RN 168542-27-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 168542-47-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-4-(2-thienyl)- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L11 ANSWER 24 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1997:67283 CAPLUS Full-text

DN 126:89355

OREF 126:17255a,17258a

TI Preparation of heterocyclecarboxamide derivatives as tachykinin receptor antagonists

IN Natsukari, Hideaki; Ishimaru, Takenori; Doi, Takayuki; Ishichi, Juji

PA Takeda Chemical Industries Ltd, Japan

SO Jpn. Kokai Tokyo Koho, 22 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08301849	A	19961119	JP 1995-132761	19950501 <--
PRAI	JP 1995-132761		19950501		
OS	MARPAT 126:89355				

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; the ring A = (un)substituted homo- or heterocyclic ring; the ring b = (un)substituted NH2 or OH; R1 = (un)substituted homo- or heterocyclic ring; one of X and Y = NR1 or O and the other one = CO or CS; wherein R1 = H, (un)substituted hydrocarbyl; or one of X and Y = N and the other one = CR2; wherein R2 = H, halo, (un)substituted hydrocarbyl, NH2, or OH; R = H, (un)substituted hydrocarbyl; n = 0-3] or salts thereof, which have


tachykinin receptor antagonism, in particular substance P receptor antagonism, and are reduced in toxicity, are prepared Thus, 1,2-dihydro-2-methyl-1-oxo-4-pyrrolidino-3-isoquinolinecarboxylic acid (preparation given) was stirred with oxalyl chloride CH₂Cl₂ containing one drop of DMF at room temperature for 1 h and after distilling off the solvent, the residue was dissolved in CH₂Cl₂, treated with 520 mg N-[3,5-bis(trifluoromethyl)benzyl]methylamine hydrochloride and 1.2 mL Et₃N, and stirred at room temperature for 2 h to give the title compound, pyrrolidinoisoquinoline-N-benzylcarboxamide (II). II in vitro showed IC₅₀ of 0.66 nM for antagonizing the binding of [¹²⁵I]-labeled substance P to human lymphocyte IM-9 cells.

IT 185446-59-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclecarboxamide derivs. as tachykinin receptor antagonists)

RN 185446-59-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-N,2-dimethyl-1-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)




IT 185446-63-3P 185446-66-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclecarboxamide derivs. as tachykinin receptor antagonists)


RN 185446-63-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-4-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 185446-66-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-4-(1-pyrrolidinyl)-, ethyl ester (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L11 ANSWER 25 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1995:835514 CAPLUS [Full-text](#)

DN 123:256684

OREF 123:45911a,45914a

TI Preparation of pyridopyridinecarboxamides, thienopyridinecarboxamides, and related compounds as tachykinin antagonists and inhibitors of plasma extravasation.

IN Natsugari, Hideaki; Ishimaru, Takenori; Doi, Takayuki

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 72 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 652218	A1	19950510	EP 1994-117576	19941108 <--
	EP 652218	B1	20010711		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	NO 9404252	A	19950511	NO 1994-4252	19941108 <--
	AT 203024	T	20010715	AT 1994-117576	19941108 <--
	CA 2135440	A1	19950511	CA 1994-2135440	19941109 <--
	FI 9405281	A	19950511	FI 1994-5281	19941109 <--
	AU 9477738	A	19950518	AU 1994-77738	19941109 <--
	AU 678295	B2	19970522		
	BR 9404403	A	19950718	BR 1994-4403	19941109 <--
	JP 08067678	A	19960312	JP 1994-274699	19941109 <--
	RU 2135471	C1	19990827	RU 1994-40174	19941109 <--
	HU 68810	A2	19950519	HU 1994-3230	19941110 <--
	CN 1107476	A	19950830	CN 1994-113866	19941110 <--
	CN 1052004	C	20000503		
	US 5585385	A	19961217	US 1994-338762	19941110 <--
	BR 9501976	A	19960430	BR 1995-1976	19950509 <--
PRAI	JP 1993-281178	A	19931110		
	JP 1993-337488	A	19931228		
	JP 1994-33637	A	19940303		
	JP 1994-138551	A	19940621		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 123:256684; MARPAT 123:256684

GI For diagram(s), see printed CA Issue.

AB Title compds. [I; ring A, ring B = (substituted) homo- or heterocyclyl, ≥1 of them = (substituted) heterocyclyl; ring C = (substituted) benzene ring; R = H, (substituted) hydrocarbyl; 1 of X, Y = NR1, O; the other = CO, CS; or 1 of them = N; and the other = CR2; R1 = H, (substituted) hydrocarbyl; R2 = H, halo, (substituted) hydrocarbyl, amino, OH; n = 1, 2], were prepared Thus, 5-(4-fluorophenyl)-7,8-dihydro-7-methyl-8-oxo-6-pyrido[3,4-b]pyridinecarboxylic acid (preparation given) was refluxed with SOCl2 in benzene and ther residue

10/572,343 (RCE)

in THF was refluxed with N-[3,5-bis(trifluoromethyl)benzyl]methylamine and Et3N to give N-[3,5-bis(trifluoromethyl)benzyl]-5-(4-fluorophenyl)-7,8-dihydro-N,7-di methyl-8-oxo-6-pyrido[3,4-b]pyridinecarboxamide (II). II inhibited substance P binding to IM-9 human lymphoblasts with IC50 = 0.08 nM. Tablets containing II were prepared


IT 168541-22-8P 168541-23-9P 168541-87-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridopyridinecarboxamides, thienopyridinecarboxamides, and related compds. as tachykinin antagonists and inhibitors of plasma extravasation)


RN 168541-22-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-methyl-1-oxo-4-(2-thienyl)- (CA INDEX NAME)




RN 168541-23-9 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[(2-methoxyphenyl)methyl]-N,2-dimethyl-1-oxo-4-(2-thienyl)- (CA INDEX NAME)



RN 168541-87-5 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-N,2-dimethyl-1-oxo-4-(2-thienyl)- (CA INDEX NAME)



IT 168542-27-6P 168542-47-0P


10/572,343 (RCE)

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyridopyridinecarboxamides, thienopyridinecarboxamides, and related compds. as tachykinin antagonists and inhibitors of plasma extravasation)


RN 168542-27-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-4-(2-thienyl)-, ethyl ester (CA INDEX NAME)



RN 168542-47-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-4-(2-thienyl)- (CA INDEX NAME)



OSC.G 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (51 CITINGS)

L11 ANSWER 26 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1995:789121 CAPLUS Full-text

DN 123:198640

OREF 123:35457a,35460a

TI Preparation of phenylisoquinolinone derivatives as calcium- and substance P antagonists for treating cerebrovascular disorders.

IN Natsugari, Hideaki; Imamoto, Tetsuji; Ichimori, Yuzo

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 52 pp.

CODEN: EPXXDW

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 634402	A1	19950118	EP 1994-110774	19940712 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07076573	A	19950320	JP 1994-161350	19940713 <--
	US 5527811	A	19960618	US 1994-274263	19940713 <--
	CA 2128055	A1	19950115	CA 1994-2128055	19940714 <--
PRAI	JP 1993-173918	A	19930714		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 123:198640; MARPAT 123:198640
GI



I

- AB Title compds. [I; Q = O, S; Ar = (substituted) aryl, heterocyclyl; R = H, (substituted) hydrocarbaryl, OH, amino; X = O, NR1; R1, R2 = H, (substituted) hydrocarbaryl; Y = O, NR2; m = 1-3; n = 0-2; rings A and B may be substituted], were prepared. Thus, Et3N was added dropwise to a mixture of 6-chloro-1,2-dihydro-2-methyl-1-oxo-4-phenyl-3-isoquinolineacetic acid and diphenylphosphoryl azide in benzene; the mixture was refluxed, treated with 3-(1-phthalimidomethyl)aniline, and again refluxed. The resulting product was treated with N2H4 to give N-[3-(aminomethyl)phenyl]-N'-[(6-chloro-1,2-dihydro-2-methyl-1-oxo-4-phenylisoquinolin-3-yl)methyl]urea (II). II.HCl at 5 mg/kg i.p. gave 100% survival in gerbils subjected to global cerebral ischemia for 15 min.
- IT 142256-44-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylisoquinolinone derivs. as calcium- and substance P antagonists for treating cerebrovascular disorders)
- RN 142256-44-8 CAPLUS
- CN 3-Isoquinolinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

- L11 ANSWER 27 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
- AN 1995:699369 CAPLUS [Full-text](#)
- DN 123:340006
- OREF 123:61019a,61022a
- TI Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyrido[3,4-b]pyridine
- AU Natsugari, Hideaki; Ikeura, Yoshinori; Kiyota, Yutaka; Ishichi, Yuji; Ishimaru, Takenori; Saga, Osamu; Shirafuji, Hideo; Tanaka, Toshimasa;

Kamo, Izumi; et al.

CS Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Osaka, 532, Japan

SO Journal of Medicinal Chemistry (1995), 38(16), 3106-20

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English


AB A series of 4-phenylisoquinolone derivs. were synthesized and evaluated for NK1 (substance P) antagonist activity. Highly potent antagonists, 4-phenylisoquinolone-N-benzylcarboxamides, were discovered from the structure-activity relationship studies on N-(1,2-dihydro-2,6,7-trimethyl-1-oxo-4-phenyl-3-isoquinolinyl)-N'-(3-methylphenyl)urea. Optimization of the activity in this series resulted in the development of 5-phenylpyrido[3,4-b]pyridine-N-benzylcarboxamides which are highly potent orally active NK1 antagonists. Among the compds. synthesized, N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-N,7-dimethyl-8-oxo-5-(substituted phenyl)-6-pyrido[3,4-b]pyridinecarboxamides showed excellent antagonist activities with IC50 values (in vitro inhibition of [125I]BH-SP binding in human IM-9 cells) of 0.21-0.34 nM and ED50 values (in vivo inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea, i.v.) of 0.017-0.030 mg/kg. These compds. exhibited significantly potent activity upon oral administration with ED50 values of 0.068-0.17 mg/kg. Conformational studies on N-[3,5-bis(trifluoromethyl)benzyl]-7,8-dihydro-N,7-dimethyl-8-oxo-5-(substituted phenyl)-6-pyrido[3,4-b]pyridinecarboxamides indicated that the two stable conformers are quite similar to those of CP-99,994.

IT 159817-05-7P 159817-06-8P 159817-07-9P
 159817-08-0P 159817-09-1P 159817-10-4P
 159817-11-5P 159817-18-2P 159817-70-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (isoquinolinecarboxamides and pyrido[3,4-b]pyridines as substance P antagonists)


RN 159817-05-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-06-8 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-07-9 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-08-0 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[(2-methoxyphenyl)methyl]-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-09-1 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(2-chlorophenyl)methyl]-1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-10-4 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(3,5-dimethylphenyl)methyl]-1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-11-5 CAPLUS

CN 3-Isoquinolinecarboxamide, N-ethyl-1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-18-2 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-70-6 CAPLUS


CN 3-Isoquinolinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-4-(4-fluorophenyl)-1,2-dihydro-N,2-dimethyl-1-oxo- (CA INDEX NAME)




IT 142256-44-8P 152818-52-5P 170639-95-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (isoquinolinecarboxamides and pyrido[3,4-b]pyridines as substance P
 antagonists)
 RN 142256-44-8 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-
 oxo- (CA INDEX NAME)



RN 152818-52-5 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-
 oxo- (CA INDEX NAME)



RN 170639-95-9 CAPLUS
 CN 3-Isoquinolinecarboxamide, 1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo-
 (CA INDEX NAME)



OSC.G 66 THERE ARE 66 CAPLUS RECORDS THAT CITE THIS RECORD (66 CITINGS)

L11 ANSWER 28 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 1995:257714 CAPLUS [Full-text](#)
 DN 122:56051
 OREF 122:10863a,10866a
 TI Condensed heterocyclic compounds, their production and use


IN Natsugari, Hideaki; Ikeda, Hitoshi; Ishimaru, Takenori; Doi, Takayuki
 PA Takeda Chemical Industries, Ltd., Japan
 SO Eur. Pat. Appl., 161 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 585913	A2	19940309	EP 1993-114024	19930902 <--
	EP 585913	A3	19940525		
	EP 585913	B1	19971229		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	NO 9303133	A	19940307	NO 1993-3133	19930902 <--
	NO 179904	B	19960930		
	NO 179904	C	19970108		
	US 5482967	A	19960109	US 1993-114841	19930902 <--
	AT 161530	T	19980115	AT 1993-114024	19930902 <--
	CA 2105518	C	19940305	CA 1993-2105518	19930903 <--
	CA 2105518	A1	19940305		
	AU 9346132	A	19940310	AU 1993-46132	19930903 <--
	AU 667739	B2	19960404		
	FI 9303857	A	19940517	FI 1993-3857	19930903 <--
	JP 07010844	A	19950113	JP 1993-220333	19930903 <--
	JP 3724818	B2	20051207		
	HU 67284	A2	19950328	HU 1993-2499	19930903 <--
	CN 1090274	A	19940803	CN 1993-118986	19930904 <--
	US 5700810	A	19971223	US 1995-540913	19951011 <--
PRAI	JP 1992-237481	A	19920904		
	JP 1993-103328	A	19930428		
	US 1993-114841	A3	19930902		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 122:56051; MARPAT 122:56051

GI



I

AB Novel compds. represented by I were prepared; ring A may be substituted; ring B represents an optionally substituted benzene ring; either X or Y represents -NR1- (R1 represents a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxyl group or an optionally substituted amino group), -O- or -S-, the other representing -CO-, -CS-, or -C(R2)R2a- (R2 and R2a independently represent a hydrogen atom or an optionally substituted hydrocarbon group), or either X or Y represents -N=, the other representing =CR3- (R3 represents a hydrogen atom, a halogen atom, an optionally substituted hydrocarbon group, an optionally substituted amino group, a substituted hydroxyl group or a mercapto group substituted by an optionally

substituted hydrocarbon group); --- represents a single or double bond; when --- is a single bond, Z represents -CR4- (R4 represents a hydrogen atom, hydroxyl group or an optionally substituted hydrocarbon group) or a nitrogen atom, or (ii) when --- is a double bond, Z represents a carbon atom. D represents a C1-3 alkylene group which may be substituted by an oxo group or a thio group, or D and Y, taken together, may form a 5- to 7-membered ring which may be substituted by an oxo group or a thio group; E represents -NR5- (R5 represents a hydrogen atom or an optionally substituted hydrocarbon group), -O- or -S(O)n- (n is 0, 1 or 2), or R5 and Y, taken together, may form a 5- to 7-membered ring which may be substituted by an oxo group or a thio group. G represents a bond or a C1-3 alkylene group. Ar represents an optionally substituted aryl or heterocyclic group. Some representative prepared compds. were benzopyran-, quinoline-, isoquinoline- and quinoxalinecarboxamides. I and its salts have an excellent activity of inhibiting ACAT, lowering cholesterol in blood and inhibiting tachykinin receptor (test data given).


IT	159816-13-4P	159817-05-7F	159817-06-8F
	159817-07-9P	159817-09-0P	159817-09-1F
	159817-10-4P	159817-11-5P	159817-18-2F
	159817-19-3P	159817-20-6P	159817-21-7F
	159817-22-8P	159817-23-9P	159817-24-0P
	159817-25-1P	159817-26-2P	159817-27-3P
	159817-28-4P	159817-29-5P	159817-43-3P
	159817-44-1P	159817-45-5P	159817-46-6P
	159817-47-7P	159817-48-8P	159817-49-9P
	159817-50-2P	159817-51-3P	159817-55-7F
	159817-56-8P	159817-57-9P	159817-58-0P
	159817-59-1P	159817-62-6P	159817-63-7F
	159817-64-8P	159817-65-9P	159817-66-0P
	159817-67-1P	159817-68-2P	159817-69-3P
	159817-70-6P	159817-71-7P	159817-72-8P
	159817-73-9P	159817-79-5P	159817-80-8P
	159817-82-0P	159817-85-3P	159817-86-4P
	159817-92-2P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and biol. activity of)


RN 159816-13-4 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[2,6-bis(1-methylethyl)phenyl]-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 159817-05-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-06-8 CAPLUS

CN 3-Isoquinolinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-07-9 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)



RN 159817-08-0 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[(2-methoxyphenyl)methyl]-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-09-1 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(2-chlorophenyl)methyl]-1,2-dihydro-N,2-


10/572,343 (RCE)

dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-10-4 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(3,5-dimethylphenyl)methyl]-1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-11-5 CAPLUS

CN 3-Isoquinolinecarboxamide, N-ethyl-1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-18-2 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-19-3 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(2-chlorophenyl)methyl]-1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-20-6 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(3,5-dimethylphenyl)methyl]-1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-21-7 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-22-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[(4-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-23-9 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-24-0 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(2-ethylphenyl)-1,2-dihydro-2-methyl-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-25-1 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(2-ethylphenyl)-1,2-dihydro-N-[(4-methoxyphenyl)methyl]-2-methyl-1-oxo- (CA INDEX NAME)




RN 159817-26-2 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2,6-dimethylphenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 159817-27-3 CAPLUS

CN 3-Isoquinolinecarboxamide, N-([3,5-bis(trifluoromethyl)phenyl]methyl)-4-(2,6-dimethylphenyl)-1,2-dihydro-N,2-dimethyl-1-oxo- (CA INDEX NAME)




RN 159817-28-4 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(2,6-dimethylphenyl)-1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-methyl-1-oxo- (CA INDEX NAME)




RN 159817-29-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(2,6-dimethylphenyl)-1,2-dihydro-N-[(2-methoxyphenyl)methyl]-N,2-dimethyl-1-oxo- (CA INDEX NAME)




RN 159817-43-3 CAPLUS

CN 3-Isoquinolinecarboxamide, 6-chloro-1,2-dihydro-N-[(4-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-44-4 CAPLUS

CN 3-Isoquinolinecarboxamide, 6-chloro-1,2-dihydro-N-[(4-methoxyphenyl)methyl]-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-45-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 6-chloro-1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-46-6 CAPLUS

CN 3-Isoquinolinecarboxamide, 7-chloro-1,2-dihydro-N-[(4-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-47-7 CAPLUS

CN 3-Isoquinolinecarboxamide, 7-chloro-1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-48-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 6-chloro-1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-49-9 CAPLUS

CN 3-Isoquinolinecarboxamide, 7-chloro-1,2-dihydro-N-[(2-methoxyphenyl)methyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-50-2 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N,2,6,7-tetramethyl-4-(2-methylphenyl)-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-51-3 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(2,6-dimethylphenyl)-1,2-dihydro-N,2,6,7-tetramethyl-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-55-7 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[(4-methoxyphenyl)methyl]-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-56-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[2-(2-methoxyphenyl)ethyl]-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-57-9 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-[2-(2-methoxyphenyl)ethyl]-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-58-0 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N-(2-methoxyphenyl)-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 159817-59-1 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo-N-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




RN 159817-62-6 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-4-(2-methoxyphenyl)-2-methyl-1-oxo- (CA INDEX NAME)




RN 159817-63-7 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-1,2-dihydro-4-(2-methoxyphenyl)-N,2-dimethyl-1-oxo- (CA INDEX NAME)




RN 159817-64-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-4-(2-methoxyphenyl)-N-[(2-methoxyphenyl)methyl]-2-methyl-1-oxo- (CA INDEX NAME)




RN 159817-65-9 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-4-(2-methoxyphenyl)-N-[(2-methoxyphenyl)methyl]-N,2-dimethyl-1-oxo- (CA INDEX NAME)




RN 159817-66-0 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(2-ethylphenyl)-1,2-dihydro-N,2-dimethyl-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-67-1 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(2-ethylphenyl)-1,2-dihydro-N-[(4-methoxyphenyl)methyl]-N,2-dimethyl-1-oxo- (CA INDEX NAME)




RN 159817-68-2 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(2-ethylphenyl)-1,2-dihydro-N,2,6,7-tetramethyl-1-oxo-N-(phenylmethyl)- (CA INDEX NAME)




RN 159817-69-3 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 159817-70-6 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-1,2-dihydro-N,2-dimethyl-1-oxo- (CA INDEX NAME)




RN 159817-71-7 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo-N-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 159817-72-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo-N-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 159817-73-9 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-2-methyl-4-(2-methylphenyl)-N-[(4-methylphenyl)methyl]-1-oxo- (CA INDEX NAME)




RN 159817-79-5 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 159817-80-8 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-1,2-dihydro-N,2-dimethyl-1-oxo- (CA INDEX NAME)




RN 159817-82-0 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-1,2-dihydro-N-methyl-1-oxo- (CA INDEX NAME)




RN 159817-85-3 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-2-methyl-1-oxo-4-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 159817-86-4 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,2-dihydro-N,2-dimethyl-1-oxo-4-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 159817-92-2 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-fluoro-4-(4-fluorophenyl)-1,2-dihydro-N,2-dimethyl-1-oxo- (CA INDEX NAME)



IT 142256-48-2P 152818-43-4P 152818-49-6P

152818-50-3P 152818-51-4P 152818-52-5P

152818-53-6P 152818-54-7P 152818-55-8P


159819-80-4P 159819-85-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of biol. active condensed heterocyclic compds.)


RN 142256-48-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2,6,7-trimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 152818-43-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 5-fluoro-4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 152818-49-0 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-2,6,7-trimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)



RN 152818-50-3 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(2,6-dimethylphenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)



RN 152818-51-4 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 4-(4-fluoro-2-methylphenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 152818-52-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 152818-53-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2-ethylphenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 152818-54-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2-ethylphenyl)-1,2-dihydro-2,6,7-trimethyl-1-oxo- (CA INDEX NAME)




RN 152818-55-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2,6-dimethylphenyl)-1,2-dihydro-2,6,7-trimethyl-1-oxo- (CA INDEX NAME)




RN 159819-80-4 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2-fluorophenyl)-1,2-dihydro-2,6,7-trimethyl-1-oxo- (CA INDEX NAME)



RN 159819-85-9 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-1-oxo-4-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 159820-23-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of biol. active condensed heterocyclic compds.)

RN 159820-23-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)



OSC.G 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (70 CITINGS)

L11 ANSWER 29 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1994:134310 CAPLUS [Full-text](#)

DN 120:134310

OREF 120:23651a,23654a

TI Isoquinolone tachykinin and substance P receptor antagonists

IN Natsugari, Hideaki; Shirafuji, Hideo; Doi, Takayuki

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 51 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 566069	A1	19931020	EP 1993-106015	19930414 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AU 9335663	A	19931021	AU 1993-35663	19930401 <--
	AU 657045	B2	19950223		
	US 5523305	A	19960604	US 1993-45219	19930413 <--
	NO 9301364	A	19931018	NO 1993-1364	19930414 <--
	NO 179550	B	19960722		
	NO 179550	C	19961030		
	JP 06321906	A	19941122	JP 1993-87054	19930414 <--
	HU 70148	A2	19950928	HU 1993-1080	19930414 <--
	CA 2094117	A1	19931016	CA 1993-2094117	19930415 <--
	CN 1083054	A	19940302	CN 1993-105950	19930415 <--
PRAI	JP 1992-95291	A	19920415		
	JP 1993-55272		19930316		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 120:134310


GI




I

10/572,343 (RCE)


- AB The title compds. I [R, R1 = H, (un)substituted alkyl; R2 = (un)substituted hydrocarbon group; rings A and B may be substituted; NR1R2 may form a heterocyclic ring], which are substance P and tachykinin receptor antagonists, are prepared and I-containing formulations presented. Thus, 4-phenyl-2,6,7-trimethyl-1(2H)-isoquinolinone-3-carboxylic acid was reacted with diphenylphosphoryl azide and MeNHCH2Ph, producing N-benzyl-N'-(1,2-dihydro-2,6,7-trimethyl-1-oxo-4-phenylisoquinolin-3-yl)-N-methylurea (II), m.p. 174-176°. II demonstrated 50% inhibitory concentration for radioligand receptor binding [human lymphoblast cells (IM-9)] of 0.016 μ M.
- IT 142256-48-2P 152818-41-2P 152818-43-4P
 152818-49-0P 152818-50-3P 152818-51-4P
 152818-52-5P 152818-53-6P 152818-54-7P
 152818-55-8P
- RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of isoquinolone tachykinin and substance P receptor antagonists)
- RN 142256-48-2 CAPLUS
- CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2,6,7-trimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)



- RN 152818-41-2 CAPLUS
- CN 3-Isoquinolinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-2,6,7-trimethyl-1-oxo- (CA INDEX NAME)




- RN 152818-43-4 CAPLUS
- CN 3-Isoquinolinecarboxylic acid, 5-fluoro-4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 152818-49-0 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-2,6,7-trimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 152818-50-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2,6-dimethylphenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)



RN 152818-51-4 CAPLUS


CN 3-Isoquinolinecarboxylic acid, 4-(4-fluoro-2-methylphenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)



RN 152818-52-5 CAPLUS


10/572,343 (RCE)

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 152818-53-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2-ethylphenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 152818-54-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2-ethylphenyl)-1,2-dihydro-2,6,7-trimethyl-1-oxo- (CA INDEX NAME)



RN 152818-55-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(2,6-dimethylphenyl)-1,2-dihydro-2,6,7-trimethyl-1-oxo- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L11 ANSWER 30 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1992:448326 CAPLUS Full-text

DN 117:48326

OREF 117:8615a,8618a

TI Preparation of N-(4-phenyl-3-isocoumarinyl)-N'-phenylureas and analogs as anticholesteremics

IN Natsugari, Hideaki; Tawada, Hiroyuki; Ikeda, Hitoshi

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 481383	A1	19920422	EP 1991-117442	19911012 <--
	EP 481383	B1	19950628		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2053477	A1	19920417	CA 1991-2053477	19911015 <--
	CA 2053477	C	20020129		
	JP 05132463	A	19930528	JP 1991-266339	19911015 <--
	JP 3211065	B2	20010925		
	US 5198462	A	19930330	US 1991-777169	19911016 <--
	US 5300646	A	19940405	US 1992-995016	19921222 <--
PRAI	JP 1990-278038	A	19901016		
	JP 1991-237983	A	19910918		
	US 1991-777169	A3	19911016		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 117:48326

GI



I



II

AB Title compds. [I; R = (substituted) Ph; R₂ = (substituted) hydrocarbyl; X = O, S, NR₁; R₁ = H, alkyl; Y = NH, O, bond, CH₂, CH₂CH₂; Z = CO, CS, CH₂], cholesterol acyltransferase inhibitors, were prepared. Thus, 2-MeC₆H₄COPh was brominated and the product condensed with HSCH₂CO₂Et to give 2-(PhCO)C₆H₄CH₂SCH₂CO₂Et which was cyclized and the saponified product condensed with 4-acetoxy-3,5-dimethylaniline to give title compound II (R₃ = H, X = S). II (R₃ = MeO, X = O) at 0.14 mg/kg/day in feed gave 87.6 mg/dL lowering of serum cholesterol in cholesterol-fed rats.

IT 142256-44-8P 142256-47-1P 142256-48-2P


142256-54-0P 142256-57-3P 142256-67-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of anticholesteremics)


RN 142256-44-8 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)




RN 142256-47-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2,6,7-trimethyl-4-(2-methylphenyl)-1-oxo-, ethyl ester (CA INDEX NAME)




RN 142256-48-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-2,6,7-trimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 142256-54-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-(2-methoxyphenyl)-2-methyl-1-oxo- (CA INDEX NAME)




RN 142256-57-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)



RN 142256-67-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,2-dihydro-2-methyl-1-oxo-, ethyl ester (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L11 ANSWER 31 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1991:679782 CAPLUS Full-text

DN 115:279782

OREF 115:47539a,47542a

TI Synthesis and anticonvulsant activity of
3-carbamoyl-4-arylisoquinolin-1(2H)-onesAU Unverferth, Klaus; Doerre, Ronald; Koerner, Brunhild; Scheibe, Heike;
Morgenstern, Eve

CS Sect. Biowiss., Univ. Leipzig, Leipzig, O-7010, Germany

SO Archiv der Pharmazie (Weinheim, Germany) (1991), 324(10), 809-14


CODEN: ARPMA5; ISSN: 0365-6233

DT Journal


LA German

OS CASREACT 115:279782

GI



I



II


AB Title compds. I (R = H, Me, Bu, cyclohexyl, CH₂Ph, CHMe₂, R₁, R₂ = H; R = CHMe₂, R₁ = 2-Me, 3-Me, 2-Cl, 3-Cl, 4-F, 4-Cl, 4-Br, R₂ = H; R = CHMe₂, R₁ = H, R₂ = 6-Cl, 6-Br, 7-Cl) were prepared by cyclization of the nitriles II. I have anticonvulsant activity in the maximum electroshock test, I (R = CHMe₂, R₁ = 4-Cl, R₂ = H) having an i.p. ED₅₀ of 2.1 + 10⁻⁴ mol/kg.

IT 134563-31-8P 137537-54-3P 137537-55-4P
137537-56-5P 137537-57-6P 137537-58-7P
137537-59-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and anticonvulsant activity of)


RN 134563-31-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(4-fluorophenyl)-1,2-dihydro-2-(1-methylethyl)-1-oxo- (CA INDEX NAME)




RN 137537-54-3 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-2-(1-methylethyl)-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 137537-55-4 CAPLUS

CN 3-Isoquinolinecarboxamide, 1,2-dihydro-2-(1-methylethyl)-4-(3-methylphenyl)-1-oxo- (CA INDEX NAME)




RN 137537-56-5 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(2-chlorophenyl)-1,2-dihydro-2-(1-methylethyl)-1-oxo- (CA INDEX NAME)




RN 137537-57-6 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(3-chlorophenyl)-1,2-dihydro-2-(1-methylethyl)-1-oxo- (CA INDEX NAME)




RN 137537-58-7 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(4-chlorophenyl)-1,2-dihydro-2-(1-methylethyl)-1-oxo- (CA INDEX NAME)



RN 137537-59-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(4-bromophenyl)-1,2-dihydro-2-(1-methylethyl)-1-oxo- (CA INDEX NAME)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L11 ANSWER 32 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1991:429146 CAPLUS [Full-text](#)

DN 115:29146

OREF 115:5125a,5128a

TI Preparation of 3-carbamoyl-4-aryl-1,2-dihydroisoquinolin-1-ones

IN Unverferth, Klaus; Doerre, Ronald; Koerner, Brunhild; Scheibe, Heike; Lohmann, Dieter; Laban, Gunter

PA Karl-Marx-Universitaet Leipzig, Germany

SO Ger. (East), 6 pp.


CODEN: GEXXA8

DT Patent


LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DD 287032	A5	19910214	DD 1989-331246	19890728 <--
PRAI	DD 1989-331246		19890728		
OS	CASREACT 115:29146; MARPAT 115:29146				
GI					



I



II


AB Anticonvulsant (no data) title compds. I (R = alkyl, alkaryl; R1 = CONH2; R2 = H, alkyl, amino, F, Cl, Br; R3 = H, F, Cl, Br, NO2) were prepared by treating RNHCH2CN with benzoyl chlorides II, cyclizing the amides with base, and hydrolyzing I (R1 = cyano). Thus, Me2CHNHCH2CN was treated with 2-BzC6H4COC1, followed by MeONa to give I (R = CHMe2, R1 = cyano, R2 = R3 = H) which was hydrolyzed with KOH to give I (R = CHMe2, R1 = CONH2, R2 = R3 = H).

IT 134563-31-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 134563-31-8 CAPLUS

CN 3-Isoquinolinecarboxamide, 4-(4-fluorophenyl)-1,2-dihydro-2-(1-methylethyl)-1-oxo- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L11 ANSWER 33 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1990:158072 CAPLUS Full-text

DN 112:158072

OREF 112:26719a,26722a

TI Preparation and formulation of isoquinolinones as anticholesteremics

IN Ashton, Michael John; Bridge, Andrew William; Chambers, Robert Keith;
Dron, Donald Ian; Fenton, Garry; Harris, Neil Victor; Lythgoe, David John;
McFarlane, Ian Michael; Newton, Christopher Gregory; Et, Al.

PA May and Baker Ltd., UK

SO Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DT Patent

LA English



FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 326386	A2	19890802	EP 1989-300759	19890126 <--
	EP 326386	A3	19900425		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AU 8928882	A	19890727	AU 1989-28882	19890126 <--
	DK 8900337	A	19890728	DK 1989-337	19890126 <--
	FI 8900393	A	19890728	FI 1989-393	19890126 <--
	JP 01242570	A	19890927	JP 1989-17406	19890126 <--
	ZA 8900645	A	19891025	ZA 1989-645	19890126 <--
	HU 50783	A2	19900328	HU 1989-341	19890126 <--
	HU 202842	B	19910429		
	US 5004747	A	19910402	US 1990-494956	19900315 <--
PRAI	GB 1988-1772	A	19880127		
	GB 1988-19221	A	19880812		
	US 1989-302389	B1	19890126		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 112:158072

GI




- AB Title compds. I [R1, R2 = cycloalkyl, alkyl, alkenyl, alkynyl, aryl, heteroaryl, etc.; R3-R6 = H, halo, alkyl, alkenyl, alkynyl, aryl, heteroaryl, alkoxy, etc.; X = (CH2)2, CH2CH; R7 = YCH2CH(OH)CH2CO2R8, Q; R8 = H, (substituted) alkyl; Y = CHOH, CO, C(OR)2 (R = alkyl; RR = alkylene); Z = CO, CHOH] are prepared Reduction of I [R1 = Ph; R2 = Me; R3-R6 = H; XR7 = CH:CHCH(OH)CH2COCH2CO2Et] (preparation given) with NaBH4 gave I [XR7 = CH:CH[CHCOH]CH2]2CO2Et], followed by saponification of the latter with aqueous NaOH to give I [XR7 = CH:CH[CH(OH)CH2]2CO2Na] (II). II at 20.0 µg/mL showed 65% inhibition of 3-hydroxy-3-methylglutaryl CoA reductase. A capsule formulation was given.
- IT 125064-64-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction of, in preparation of isoquinolinone anticholesteremics)
- RN 125064-64-4 CAPLUS
- CN 3-Isoquinolinecarboxylic acid, 4-(4-fluorophenyl)-1,2-dihydro-2-(1-methylethyl)-1-oxo- (CA INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

- L11 ANSWER 34 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN
- AN 1979:420286 CAPLUS [Full-text](#)
- DN 91:20286
- OREF 91:3389a,3392a
- TI Synthesis of heterocyclic compounds using isocyno compounds. 5.
 One-step synthesis of 1-oxo-1,2-dihydroisoquinoline-3-carboxylic acid derivatives
- AU Nunami, Kenichi; Suzuki, Mamoru; Yoneda, Naoto
- CS Res. Lab. Appl. Biochem., Tanabe Seiyaku Co. Ltd., Osaka, Japan
- SO Journal of Organic Chemistry (1979), 44(11), 1887-8
 CODEN: JOCEAH; ISSN: 0022-3263
- DT Journal
- LA English
- OS CASREACT 91:20286
- GI




AB Isoquinolinones I (R = H, Me, Ph, 4-MeC₆H₄, 4-MeOC₆H₄; R₁ = OMe, 1-pyrrolidinyl, piperidino) were prepared in good yields in one step by the reaction of 2-RCOC₆H₄CO₂Me with NCCH₂COR₁ in the presence of NaH.

IT 69454-49-5P 69454-50-3P 69454-51-9P
69454-52-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 69454-49-5 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-(4-methylphenyl)-1-oxo-,
methyl ester (CA INDEX NAME)




RN 69454-50-8 CAPLUS

CN 1(2H)-Isoquinolinone, 4-(4-methylphenyl)-3-(1-pyrrolidinylcarbonyl)- (CA
INDEX NAME)




RN 69454-51-9 CAPLUS

CN 1(2H)-Isoquinolinone, 4-(4-methoxyphenyl)-3-(1-pyrrolidinylcarbonyl)- (CA
INDEX NAME)



RN 69454-52-0 CAPLUS
 CN 1(2H)-Isoquinolinone, 4-(4-methoxyphenyl)-3-(1-piperidinylcarbonyl)- (CA
 INDEX NAME)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L11 ANSWER 35 OF 35 CAPLUS COPYRIGHT 2010 ACS on STN

AN 1971:488499 CAPLUS Full-text

DN 75:88499

OREF 75:14013a,14016a

TI Imidazolinyisoquinolinones and pyrimidinylisoquinolinones as central
 nervous system depressants

IN Sulkowski, Theodore S.

PA American Home Products Corp.

SO U.S., 3 pp.

CODEN: USXXAM

DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3594380	A	19710720	US 1969-800275	19690218 <--
PRAI	US 1969-800275	A	19690218		

GI For diagram(s), see printed CA Issue.

AB Isoindolineacetic acid esters (I), prepared by interaction of an acid chloride with an alkyl glycinate in C₅H₅N at 50-110°, are refluxed with a diamine, H₂N(CH₂)_nNH₂ (II) in an inert solvent and simultaneously converted via the intermediate oxoisoquinolinecarboxamides (III) to the cyclized title isoquinolinones (IV, R₁ = phenyl, alkylphenyl, alkoxyphenyl, halophenyl, phenalkyl, furyl, thienyl, naphthyl; R₂, R₃ = H, halogen, amino, alkyl, alkoxy; n = 2,3). Thus, o-(p-ClC₆H₄CO)C₆H₄COCl in C₆H₆ added over 20 min to H₂NCH₂CO₂Et.HCl in C₅H₅N and the mixture refluxed 2 hr gave I (R = Et, R₁ = p-ClC₆H₄, R₂ = R₃ = H) (V). V and II (n = 2) refluxed 17 hr in PhMe gave IV (R₁ = p-ClC₆H₄, R₂ = R₃ = H, n = 2). V and II (n = 3) refluxed 18 hr gave IV (R₁ = p-ClC₆H₄, R₂ = R₃ = H, n = 3) (VI). III (R₁ = p-ClC₆H₄, R₂ = R₃ = H), converted by refluxing in C₅H₅N 17 hr into VI.

IT 33260-01-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 33260-01-4 CAPLUS
 CN 3-Isoquinolinecarboxamide, N-(3-aminopropyl)-4-(4-chlorophenyl)-1,2-dihydro-1-oxo- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

=> s l9 not l11
 L12 33 L9 NOT L11
 => dis l12 1-33 bib abs fhitstr

L12 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2009:1566750 CAPLUS Full-text
 DN 152:67621
 TI β -Adrenergic receptor agonists for the treatment of B-cell
 proliferative disorders
 IN Rickles, Richard; Lee, Margaret S.
 PA CombinatorX, Inc., USA
 SO PCT Int. Appl., 111 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009151569	A2	20091217	WO 2009-US3449	20090608
	WO 2009151569	A3	20100225		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20100009934	A1	20100114	US 2009-480034	20090608
PRAI	US 2008-60064P	P	20080609		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention discloses a method for treating a B-cell proliferative disorder by administering to a patient a β -Adrenergic receptor (BAR) agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or i.v. administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may be administered as a monotherapy or in combination with one or more other agents, e.g., a PDE inhibitor, an A2A receptor agonist, or an antiproliferative compound, in ams. that together are effective to treat the B-cell proliferative disorder. The invention further discloses pharmaceutical compns. and kits including a BAR agonist, alone or in combination with addnl. agents, for the treatment of a B-cell proliferative disorder.

IT 212500-03-3, T 1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(β -Adrenergic receptor agonists for treatment of B-cell proliferative disorders, and use with other agents)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S




L12 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:1180279 CAPLUS [Full-text](#)

DN 152:6936

TI Ck1 ϵ / δ -dependent phosphorylation is a temperature-insensitive, period-determining process in the mammalian circadian clock

- AU Isojima, Yasushi; Nakajima, Masato; Ukai, Hideki; Fujishima, Hiroshi; Yamada, Rikuhiko G.; Masumoto, Koh-Hei; Kiuchi, Reiko; Ishida, Mayumi; Ukai-Tadenuma, Maki; Minami, Yoichi; Kito, Ryotaku; Nakao, Kazuki; Kishimoto, Wataru; Yoo, Seung-Hee; Shimomura, Kazuhiro; Takao, Toshifumi; Takano, Atsuko; Kojima, Toshio; Nagai, Katsuya; Sakaki, Yoshiyuki; Takahashi, Joseph S.; Ueda, Hiroki R.
- CS Comparative Systems Biology Team, Genomic Science Center, RIKEN, 1-7-22, Suehiro-cho, Tsurumi, Yokohama, 230-0045, Japan
- SO Proceedings of the National Academy of Sciences of the United States of America (2009), 106(37), 15744-15749, S15744/1-S15744/74
CODEN: PNASA6; ISSN: 0027-8424
- PB National Academy of Sciences
- DT Journal
- LA English
- AB A striking feature of the circadian clock is its flexible yet robust response to various environmental conditions. To analyze the biochem. processes underlying this flexible-yet-robust characteristic, we examined the effects of 1260 pharmacol. active compds. in mouse and human clock cell lines. Compds. that markedly (>10 s.d.) lengthened the period in both cell lines, also lengthened it in-central clock tissues and peripheral clock cells. Most compds. inhibited casein kinase I α (CKI α) or CKI δ phosphorylation of the PER2 protein. Manipulation of CKI α / δ -dependent phosphorylation by these compds. lengthened the period of the mammalian clock from circadian (24 h) to circadian (48 h), revealing its high sensitivity to chemical perturbation. The degradation rate of PER2, which is regulated by CKI α / δ -dependent phosphorylation, was temperature-insensitive in living clock cells, yet sensitive to chemical perturbations. This temperature-insensitivity was preserved in the CKI α / δ -dependent phosphorylation of a synthetic peptide in vitro. Thus, CKI α / δ -dependent phosphorylation is likely a temperature-insensitive period-determining process in the mammalian circadian clock.
- IT 212500-03-3, T-1032
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)
(CKI α / δ -dependent phosphorylation is temperature-insensitive, period-determining process in mammalian circadian clock)
- RN 212500-03-3 CAPLUS
- CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)
- CM 1
- CRN 212500-02-2
- CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:623850 CAPLUS [Full-text](#)

DN 152:185060

TI A cell-based β -lactamase reporter gene assay for the CREB signaling pathway

AU Xia, Menghang; Guo, Vicky; Huang, Ruili; Inglese, James; Nirenberg, Marshall; Austin, Christopher P.

CS NIH Chemical Genomics Center, National Institutes of Health, Bethesda, MD, 20892, USA

SO Current Chemical Genomics (2009), 3, 7-12

CODEN: CCGUAQ; ISSN: 1875-3973

URL: <http://www.bentham.org/open/tochgenj/openaccess2.htm>

PB Bentham Science Publishers Ltd.

DT Journal; (online computer file)

LA English

AB The Cyclic-AMP Response Element Binding (CREB) proteins comprise a family of transcription factors that stimulate or repress the expression of a wide variety of genes by binding to nucleotide sequences known as cAMP response elements. CREB-mediated transcription has been implicated in a wide variety of important physiol. processes, including long-term memory, and enhancement of CREB signaling has been suggested as an attractive therapeutic strategy for human memory disorders. To identify small mol. compds. that enhance CREB pathway signaling, we have optimized and validated a cell-based β -lactamase reporter gene CREB pathway assay in 1536-well plate format. The LOPAC library of 1280 compds. was screened in triplicate in this assay on a quant. high throughput screening (qHTS) platform. A variety of compds. which affect known members of the CREB pathway were identified as active, including twelve known phosphodiesterase (PDE) inhibitors, and forskolin, a known activator of adenylate cyclase, thus validating the assay's performance. This qHTS platform assay will facilitate identification of novel small mol. CREB signaling enhancers, which will be useful for chemical genetic dissection of the CREB pathway and as starting points for potentially memory-enhancing therapeutics.

IT 212500-03-3, T-1032

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (cell based β -lactamase reporter gene assay for CREB signaling pathway)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
 (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:506805 CAPLUS [Full-text](#)

DN 151:519

TI Revisiting Automated G-Protein Coupled Receptor Modeling: The Benefit of Additional Template Structures for a Neurokinin-1 Receptor Model

AU Kneissl, Benny; Leonhardt, Bettina; Hildebrandt, Andreas; Tautermann, Christofer S.

CS Center for Bioinformatics, Saarland University, Saarbruecken, 66123, Germany

SO Journal of Medicinal Chemistry (2009), 52(10), 3166-3173

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society


DT Journal

LA English

AB The feasibility of automated procedures for the modeling of G-protein coupled receptors (GPCR) is investigated on the example of the human neurokinin-1 (NK1) receptor. We use a combined method of homol. modeling and mol. docking and analyze the information content of the resulting docking complexes regarding the binding mode for further refinements. Moreover, we explore the impact of different template structures, the bovine rhodopsin structure, the human β_2 adrenergic receptor, and in particular a combination of both templates to include backbone flexibility in the target conformational space. Our results for NK1 modeling demonstrate that model selection from a set of decoys can in general not solely rely on docking expts. but still requires addnl. mutagenesis data. However, an enrichment factor of 2.6 in a nearly

fully automated approach indicates that reasonable models can be created automatically if both available templates are used for model construction. Thus, the recently resolved GPCR structures open new ways to improve the model building fundamentally.

IT 159817-09-1
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (revisiting automated G-protein coupled receptor modeling and benefit of addnl. template structures for neurokinin-1 receptor model)
 RN 159817-09-1 CAPLUS
 CN 3-Isoquinolinecarboxamide, N-[(2-chlorophenyl)methyl]-1,2-dihydro-N,2-dimethyl-4-(2-methylphenyl)-1-oxo- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:362566 CAPLUS Full-text

DN 150:515009

TI Chlorosulfonic acid-mediated cyclization of
 4-phenyl-3-isocoumarincarboxylic acids and
 4-phenyl-3-isoquinolinonecarboxylic acids: an efficient synthesis of
 3-oxoindeno[2,1-c]isocoumarins and 3-oxoindeno[2,1-c]isoquinolinones

AU Jagtap, Prakash G.; Chen, Zhiyu; Southan, Garry J.

CS Inotek Pharmaceuticals Corporation, Lexington, MA, 02421, USA

SO Tetrahedron Letters (2009), 50(18), 2057-2059

CODEN: TELEAY; ISSN: 0040-4039

PB Elsevier Ltd.

DT Journal

LA English

OS CASREACT 150:515009

AB A highly efficient and clean method has been developed for the synthesis of 3-oxoindeno[2,1-c]isocoumarins and 3-oxoindeno[2,1-c]isoquinolinones from 4-phenyl-3-isocoumarincarboxylic acids and 4-phenyl-3-isoquinolinonecarboxylic acids, resp.


IT 1151797-86-2F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-oxoindeno[2,1-c]isocoumarins and
 3-oxoindeno[2,1-c]isoquinolinones by chlorosulfonic acid-mediated
 cyclization of 4-phenyl-3-isocoumarincarboxylic acids and
 4-phenyl-3-isoquinolinonecarboxylic acids)

RN 1151797-86-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-4-(4-methylphenyl)-1-oxo- (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2009:86451 CAPLUS Full-text

DN 150:160095

TI Use of adenosine A2A receptor agonists and phosphodiesterase (PDE) inhibitors for the treatment of B-cell proliferative disorders, and combinations with other agents

IN Rickles, Richard; Lee, Margaret S.

PA CombinatoRx, Incorporated, USA

SO PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009011893	A2	20090122	WO 2008-US8758	20080717
	WO 2009011893	A3	20090319		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2008276451	A1	20090122	AU 2008-276451	20080717
	CA 2694983	A1	20090122	CA 2008-2694983	20080717
	US 20090053168	A1	20090226	US 2008-175219	20080717
PRAI	US 2007-950307P	P	20070717		
	US 2007-965587P	P	20070821		
	WO 2008-US8758	W	20080717		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The invention provides comps. and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and comps. may further include an antiproliferative compound

IT 213500-03-3, T 1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(adenosine A2A receptor agonists and phosphodiesterase inhibitors for treatment of B-cell proliferative disorders, and combinations with

other agents)
 RN 212500-03-3 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
 (CA INDEX NAME)
 CM 1
 CRN 212500-02-2
 CMF C32 H29 N3 O7



CM 2
 CRN 7664-93-9
 CMF H2 O4 S



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L12 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2010 ACS ON STN
 AN 2009:83374 CAPLUS [Full-text](#)
 DN 150:160094
 TI Combinations for the treatment of B-cell proliferative disorders
 IN Rickles, Richard; Pierce, Laura; Lee, Margaret S.
 PA Combinatorx, Incorporated, USA
 SO PCT Int. Appl., 79pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009011897	A1	20090122	WO 2008-US8764	20080717
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,				

10/572,343 (RCE)

TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU	2008276455	A1	20090122	AU	2008-276455	20080717
CA	2694987	A1	20090122	CA	2008-2694987	20080717
US	20090047243	A1	20090219	US	2008-175121	20080717
PRAI	US 2007-959877P	P	20070717			
	US 2007-965595P	P	20070821			
WO	2008-US8764	W	20080717			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention features comps. and methods employing combinations of an A2A receptor agonist and a PDE (phosphodiesterase) inhibitor for the treatment of a B-cell proliferative disorder, e g, multiple myeloma. In at least one embodiment, the comps. of the invention comprise a PDE inhibitor active against at least two of PDE 2, 3, 4, and 7. In at least one embodiment, the comps. of the invention comprises further administering an antiproliferative compound

IT 212500-03-3, T 1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combinations for treatment of B-cell proliferative disorders using PDE inhibitors and A2A receptor agonists and antiproliferative comps.)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:1009534 CAPLUS Full-text

DN 149:282995

TI Modulation of nitric oxide signaling to normalize tumor vasculature

IN Jain, Rakesh K.; Fukumara, Dai; Kashiwagi, Satoshi

PA The General Hospital Corp., USA

SO PCT Int. Appl., 61pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008100591	A2	20080821	WO 2008-US2004	20080214
	WO 2008100591	A3	20081204		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20100087370	A1	20100408	US 2009-525186	20091130
PRAI	US 2007-901144P	P	20070214		
	WO 2008-US2004	W	20080214		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cGMP or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(modulation of nitric oxide signaling to normalize tumor vasculature and treatment with antitumor therapy)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7




CM 2

CRN 7664-93-9

CMF H2 O4 S



L12 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2008:495445 CAPLUS [Full-text](#)
 DN 149:44277
 TI Discovery, synthesis and biological evaluation of isoquinolones as novel
 and highly selective JNK inhibitors (1)
 AU Asano, Yasutomi; Kitamura, Shuji; Ohra, Taiichi; Aso, Kazuyoshi; Igata,
 Hideki; Tamura, Tomoko; Kawamoto, Tomohiro; Tanaka, Toshimasa; Sogabe,
 Satoshi; Matsumoto, Shin-ichi; Yamaguchi, Masashi; Kimura, Hiroyuki; Itoh,
 Fumio
 CS Medicinal Chemistry Research Laboratories, Pharmaceutical Research
 Division, Takeda Pharmaceutical Company, Ltd, 17-85, Jusohonmachi 2-chome,
 Yodogawa-ku, Osaka, 532-8686, Japan
 SO Bioorganic & Medicinal Chemistry (2008), 16(8), 4715-4732
 CODEN: BMECEP; ISSN: 0968-0896
 PB Elsevier Ltd.
 DT Journal
 LA English
 OS CASREACT 149:44277
 GI




AB A novel series of 4-phenylisoquinolones were synthesized and evaluated as c-Jun N-terminal kinase (JNK) inhibitors. Initial modification at the 2- and 3-positions of the isoquinolone ring of hit compound 4, identified from high-throughput screening, led to the lead compound 6b (I). The optimization was carried out using a JNK1-binding model of 6b and several compds. exhibited potent JNK inhibition. Among them, a (methylsulfonylbenzyl)bromooxoisoquinolinecarboxylate significantly inhibited cardiac hypertrophy in rat pressure-overload models without affecting blood pressure and the concept of JNK inhibitors as novel therapeutic agents for heart failure was confirmed.

IT 583835-48-7P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of aryl-substituted oxoisoquinolinecarboxylates as JNK inhibitors and the kinase inhibition selectivity, pharmacokinetics, and effect on cardiac hypertrophy and blood pressure of one of the isoquinolinones)

RN 583835-48-7 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-4-(3-formylphenyl)-1,2-dihydro-2-[[4-(methylsulfonyl)phenyl]methyl]-1-oxo-, methyl ester (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2008:493012 CAPLUS Full-text

DN 148:509885

TI Compositions and methods for treating neurological disorders or damage

IN Diamandis, Phedias; Tyers, Mike; Dirks, Peter B.

PA Can.

SO Can. Pat. Appl., 3pp.

CODEN: CPXXEB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2606658	A1	20080413	CA 2007-2606658	20071012
	US 20090076019	A1	20090319	US 2007-871562	20071012
PRAI	US 2006-851615P	P	20061013		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to a clonogenic neurosphere assay to carry out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells,

neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). The invention also relates to compns. comprising the identified modulators and methods of using the modulators and compns., in particular to treat neurol. disorders (e.g. brain or CNS cancer) or damage.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(screening for compns. and methods for treating neurol. disorders or damage with modulators of neural stem cells)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L12 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2007:1168711 CAPLUS [Full-text](#)

DN 147:515346

TI Blockade of phosphodiesterase Type 5 enhances rat neurohypophysial excitability and electrically evoked oxytocin release

AU Zhang, Zhenjie; Klyachko, Vitaly; Jackson, Meyer B.

CS Department of Physiology, University of Wisconsin, Madison, WI, USA

SO Journal of Physiology (Oxford, United Kingdom) (2007), 584(1), 137-147

CODEN: JPHYA7; ISSN: 0022-3751

PB Blackwell Publishing Ltd.

DT Journal

LA English

AB Phosphodiesterase type 5 (PDE5) acts specifically on cyclic guanosine monophosphate (cGMP) and terminates cGMP-mediated signaling. PDE5 has a well established role in vascular smooth muscle, where specific inhibitors of PDE5 such as sildenafil correct erectile dysfunction by augmenting cGMP-mediated vascular relaxation. However, the role of PDE5 outside of the vasculature has received little attention. The present study tested PDE5 inhibitors on the cGMP-mediated modulation of K⁺ channels in the neurohypophysis (posterior pituitary). Photolysis of caged-cGMP enhanced current through Ca²⁺-activated K⁺ channels, and this enhancement recovered in about 2 min. Sildenafil essentially eliminated this recovery, suggesting that the reversal of K⁺ current enhancement depends on cGMP breakdown. Activation of nitric oxide synthase during trains of activity in pituitary nerve terminals enhances excitability. When trains of stimulation were applied at regular intervals, sildenafil enhanced the excitability of neurohypophyseal nerve terminals and increased the action potential firing probability. T-1032, a compound with high specificity for PDE5 over PDE6, had a similar action. Voltage imaging in intact neurohypophysis with a voltage sensitive absorbance dye showed that T-1032 reduced the failure of propagating action potentials during trains of activity. This indicates that PDE5 activity limits action potential propagation in neurohypophyseal axons. Immunoassay of oxytocin, a neuropeptide hormone secreted by the posterior pituitary, demonstrated that sildenafil increased elec. evoked release. Thus, PDE5 plays an important role in the regulation of neurohypophyseal function, and blockade of this enzyme can enhance the use-dependent facilitation of neurohypophyseal secretion.

IT 212500-03-3, T-1032

RL: BUU (Biological use, unclassified); PAC (Pharmacological activity);

BIOL (Biological study); USES (Uses)

(phosphodiesterase type 5 blockade enhancement of rat neurohypophyseal excitability and elec. evoked oxytocin release)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:877609 CAPLUS Full-text
 DN 147:315026
 TI Alkaloid as antineoplastic drugs
 IN Zhu, Feng; Chen, Guangying; Lin, Yongcheng; Luo, Jinghui
 PA Zhu Feng, Peop. Rep. China
 SO Faming Zhuanli Shengqing Gongkai Shuomingshu, 7 pp.
 CODEN: CNXXEV
 DT Patent
 LA Chinese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 101012221	A	20070808	CN 2007-10026304	20070115
	CN 100532376	C	20090826		
PRAI	CN 2007-10026304		20070115		

AB The title alkaloid is 4-pyrrole-1-isoquinoline ketone alkaloid and has two kinds. The structural formula is shown in the invention. The alkaloid has significant antitumor activity.

IT 920020-06-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (4-pyrrole-1-isoquinoline ketone alkaloids as antineoplastic drugs)

RN 920020-06-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-4-(1H-pyrrol-2-yl)- (CA INDEX NAME)



L12 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2007:41365 CAPLUS Full-text
 DN 146:115052
 TI Method and compositions using phosphodiesterase 5 inhibitors for modulating neuropeptide hormone secretion
 IN Jackson, Meyer
 PA Wisconsin Alumni Research Foundation, USA
 SO U.S. Pat. Appl. Publ., 11 pp.
 CODEN: USXXCO

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070010525	A1	20070111	US 2006-475010	20060627
PRAI	US 2005-693939P	P	20050627		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods for increasing the release of oxytocin or vasopressin or both from the posterior pituitary of a mammal in need thereof comprises administering to the mammal an effective amount of a cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitor to the mammal. The method is particularly useful to treat pregnant female or postnatal mammal wherein labor, fetal expulsion, or milk let-down or production needs to be induced, enhanced, or augmented. Also provided are pharmaceutical compns. suitable for the method.

IT 212500-03-3, T-1032

RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase 5 inhibitors for modulating neuropeptide hormone secretion)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7




CM 2

CRN 7664-93-9

CMF H2 O4 S



AN 2006:1258651 CAPLUS [Full-text](#)
 DN 146:371885
 TI Reverse fingerprinting, similarity searching by group fusion and fingerprint bit importance
 AU Williams, Chris
 CS Chemical Computing Group Inc., Montreal, H3A 2R7, Can.
 SO Molecular Diversity (2006), 10(3), 311-332
 CODEN: MODIF4; ISSN: 1381-1991
 PB Springer
 DT Journal
 LA English
 AB Recent research has shown that using data fusion rules in fingerprint-based similarity searching can improve results over traditional searches. Group fusion scores, which use multiple reference compds., have in particular been shown to be quite effective in increasing enrichment rates over single reference structure based searches. In this paper, the effectiveness of using data fusion with multiple reference compds. to increase similarity search recall rates was investigated using 44 biol. targets and four different 2D fingerprinting systems, including a new 2D typed triangle fingerprinting system introduced here. Scaffold-hopping abilities using data fusion rules were investigated using eight (8) different classes of scaffolds active against cGMP phosphodiesterase isoform 5 (PDE5). An approach to using the reference group for ranking and visualizing important fingerprints bits, or reverse fingerprinting, was presented, and used to score and visualize important pharmacophore features within sample active mols. Finally, similarity statistics within the reference groups were investigated and compared to recall rates.
 IT 212489-27-5
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
 (reverse fingerprinting, similarity searching by group fusion and fingerprint bit importance)
 RN 212489-27-5 CAPLUS
 CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-6,7-dimethoxy-1-oxo-2-(phenylmethyl)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
 RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2006:1045855 CAPLUS [Full-text](#)
 DN 145:410050
 TI Further Studies on Imidazo[4,5-b]pyridine AT1 Angiotensin II Receptor Antagonists. Effects of the Transformation of the 4-Phenylquinoline Backbone into 4-Phenylisoquinolinone or 1-Phenylindene Scaffolds
 AU Cappelli, Andrea; Mohr, Galla Pericot; Giuliani, Germano; Galeazzi,

Simone; Anzini, Maurizio; Mennuni, Laura; Ferrari, Flora; Makovec, Francesco; Kleinrath, Eva M.; Langer, Thierry; Valoti, Massimo; Giorgi, Gianluca; Vomero, Salvatore

CS Dipartimento Farmaco Chimico Tecnologico and European Research Centre for Drug Discovery and Development, Universita di Siena, Siena, 53100, Italy

SO Journal of Medicinal Chemistry (2006), 49(22), 6451-6464

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

OS CASREACT 145:410050

AB The 4-phenylquinoline fragment of novel AT1 receptor antagonists 4 based on imidazo[4,5-b]pyridine moiety was replaced by 4-phenylisoquinolinone (compds. 5) or 1-phenylindene (compds. 6) scaffolds to investigate the structure-activity relationships. Binding studies showed that most of the synthesized compds. display high affinity for the AT1 receptor. Because of the in vitro high potency of carboxylic acids 5b,f, they were evaluated in permeability (in Caco-2 cells) and in pharmacokinetic studies in comparison with quinoline derivs. 4b,i,j,k. The studies showed that these compds. are characterized by rapid excretion, low membrane permeability, and low oral bioavailability. The structure optimization of the indene derivs. led to compds. 6e,f possessing interesting AT1 receptor affinities. Optimization produced polymerizing AT1 receptor ligand 6c, which forms a thermoreversible polymer (poly-6c) and is released from the latter by a temperature-dependent kinetics. The results suggest the possibility of developing novel polymeric prodrugs based on a new release mechanism. Finally, a set of 34 AT1 receptor antagonists was used as a new test for the evaluation of the predictive capability of the previously published qual. and quant. pharmacophore models.


IT 912564-32-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Further Studies on Imidazo[4,5-b]pyridine AT1 Angiotensin II Receptor Antagonists. Effects of the Transformation of the 4-Phenylquinoline Backbone into 4-Phenylisoquinolinone or 1-Phenylindene Scaffolds)

RN 912564-32-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-[4-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]phenyl]-1,2-dihydro-2-methyl-1-oxo- (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2006:947366 CAPLUS [Full-text](#)

DN 145:483236

TI Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35

AU Taniguchi, Yasuhito; Tonai-Kachi, Hiroko; Shinjo, Katsuhiko

CS Magoya Laboratories, Discovery Biology Research, Pfizer Global Research and Development, Pfizer Inc., Aichi, 470-2393, Japan

SO FEBS Letters (2006), 580(21), 5003-5008
CODEN: FEBLAL; ISSN: 0014-5793

PB Elsevier B.V.

DT Journal

LA English

AB We found that zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, acted as an agonist for a G protein-coupled receptor, GPR35. In our intracellular calcium mobilization assay, zaprinast activated rat GPR35 strongly (geometric mean EC50 value of 16 nM), whereas it activated human GPR35 moderately (geometric mean EC50 value of 840 nM). We also demonstrated that GPR35 acted as a Gai/o- and Ga16-coupled receptor for zaprinast when heterologously expressed in human embryonic kidney 293 (HEK 293) cells. These findings will facilitate the research on GPR35 and the drug discovery of the GPR35 modulators.

IT 212500-03-3, T-1032
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)
(zaprinast, well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is agonist for GPR35)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2006:637348 CAPLUS [Full-text](#)

DN 146:158889

TI Marinamide, a novel alkaloid and its methyl ester produced by the application of mixed fermentation technique to two mangrove endophytic fungi from the South China Sea

AU Zhu, Feng; Lin, Yongcheng

CS Department of Chemistry and Chemical Engineering, Foshan University, Foshan, 528000, Peop. Rep. China

SO Chinese Science Bulletin (2006), 51(12), 1426-1430

CODEN: CSBUEF; ISSN: 1001-6538

PB Science in China Press

DT Journal

LA English

AB A novel 1-isoquinolone analog designated as marinamide (A) and its Me ester (B), were produced by the application of mixed fermentation technique to two mangrove endophytic fungi (strains Nos. 1924 and 3893) from the South China Sea. Their structures were elucidated by comprehensive spectra methods (mainly by 2D NMR) as 4-(2-pyrrolyl)-1-isoquinolone-3-carboxylic acid (A) and Me 4-(2-pyrrolyl)-1-isoquinolone-3-carboxylate (B), resp. Compds. A and B were not obtained when either strain was cultured individually under the same conditions. The results showed that the application of mixed fermentation technique may represent a potentially important approach to discover novel metabolites.

IT 920020-06-0P

RL: BSU (Biological study, unclassified); NPO (Natural product occurrence); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)


(marinamide, a novel alkaloid and its Me ester, were produced by the application of mixed fermentation technique to two mangrove endophytic

fungi

from the South China Sea)

RN 920020-06-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 1,2-dihydro-1-oxo-4-(1H-pyrrol-2-yl)- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2006:213386 CAPLUS [Full-text](#)

DN 144:286183

TI Endothelin A receptor (eta) antagonists in combination with
phosphodiesterase 5 inhibitors (pde5) and uses thereof
IN Keyser, Donald Jeffrey; Dixon, Richard
PA Encysive Pharmaceuticals, USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006026395	A1	20060309	WO 2005-US30342	20050826
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 20060205733	A1	20060914	US 2005-211099	20050825
	AU 2005280077	A1	20060309	AU 2005-280077	20050826
	CA 2578044	A1	20060309	CA 2005-2578044	20050826
	EP 1789051	A1	20070530	EP 2005-792498	20050826
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
	CN 101072564	A	20071114	CN 2005-80034468	20050826
	JP 2008510830	T	20080410	JP 2007-530143	20050826
	BR 2005014666	A	20080617	BR 2005-14666	20050826
	MX 2007002311	A	20080310	MX 2007-2311	20070226
	ZA 2007002132	A	20081126	ZA 2007-2132	20070313
	NO 2007001446	A	20070326	NO 2007-1446	20070316
	KR 2007074552	A	20070712	KR 2007-706248	20070319
	IN 2007KN01040	A	20070713	IN 2007-KN1040	20070323
PRAI	US 2004-604462P	P	20040826		
	US 2005-211099	A	20050825		
	WO 2005-US30342	W	20050826		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates generally to combination therapies comprising an endothelin A receptor (ETA) antagonist and a phosphodiesterase 5 (PDE5) inhibitor, pharmaceutical compns. comprising ETA antagonist and PDE5 inhibitor and methods of treating various disorders comprising administering an ETA antagonist and a PDE5 inhibitor. In particular, the combination therapies and pharmaceutical compns. are useful for the treatment and/or prevention of cardiac disorders such as pulmonary arterial hypertension (PAH). No significant pharmacokinetic interactions between sitaxsentan and sildenafil were demonstrated in healthy volunteers.

IT 212500-03-3, T-1032
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ETA antagonists and PDE5 inhibitors for treating vascular disorders)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2006:167023 CAPLUS [Full-text](#)

DN 144:247226

TI Use of a phosphodiesterase 5 (PDE5) inhibitor for treating and preventing
 hypopigmentary disorders

IN Peuker, Heidemarie

PA Switch Biotech A.-G., Germany

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006018088	A1	20060223	WO 2005-EP7747	20050715
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,			

10/572,343 (RCE)

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

EP 1759700 A1 20070307 EP 2004-19695 20040819
EP 1759700 B1 20090805
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK
AT 438403 T 20090815 AT 2004-19695 20040819
ES 2330934 T3 20091217 ES 2004-19695 20040819
AU 2005274546 A1 20060223 AU 2005-274546 20050715
CA 2619779 A1 20060223 CA 2005-2619779 20050715
JP 2008509944 T 20080403 JP 2007-526325 20050715
US 20080051408 A1 20080228 US 2007-660351 20070705
PRAI EP 2004-19695 A 20040819
US 2004-603069P P 20040819
WO 2005-EP7747 W 20050715

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention discloses the use of PDE5 inhibitors, preferably sildenafil or
tadalafil, optionally in combination with a further active ingredient, for
treating and/or preventing hypopigmentary disorders.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(phosphodiesterase 5 inhibitor for treatment and prevention of
hypopigmentary disorder)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-
pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S




RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
AN 2005:405379 CAPLUS Full-text
DN 142:441853
TI HSP90 inhibitor-phosphodiesterase inhibitor combination for treating or preventing neoplasia
IN Masferrer, Jaime L.; Penning, Thomas D.; Wang, Xing; Heuvelman, Deborah M.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005041879	A2	20050512	WO 2004-US35949	20041028
	WO 2005041879	A3	20051006		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2543503	A1	20050512	CA 2004-2543503	20041028
	EP 1682143	A2	20060726	EP 2004-817484	20041028
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	BR 2004015896	A	20070109	BR 2004-15896	20041028
	JP 2007509968	T	20070419	JP 2006-538292	20041028
	MX 2006004657	A	20060627	MX 2006-4657	20060426
PRAI	US 2003-515021P	P	20031028		
	WO 2004-US35949	W	20041028		
OS	MARPAT 142:441853				
AB	A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising an HSP90 inhibitor and a phosphodiesterase inhibitor, and optionally a COX-2 inhibitor. Preparation of, e.g. 4[2-(4-fluorophenyl)phenyl]benzenesulfonamide, is described.				
IT	212500-03-3, T-1032				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(HSP90 inhibitor-phosphodiesterase inhibitor combination for treating or preventing neoplasia)				
RN	212500-03-3 CAPLUS				
CN	3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)				
CM	1				
CRN	212500-02-2				

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2005:300410 CAPLUS [Full-text](#)

DN 142:373700

TI Preparation of isoquinoline derivatives as potassium channel inhibitors
 IN Isaacs, Richard; Dinsmore, Christopher J.; McIntyre, Charles J.; Payne,
 Linda S.; Claremon, David A.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030727	A1	20050407	WO 2004-US30944	20040922
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276267	A1	20050407	AU 2004-276267	20040922


10/572,343 (RCE)

CA 2539541	A1	20050407	CA 2004-2539541	20040922
EP 1667977	A1	20060614	EP 2004-788883	20040922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1856473	A	20061101	CN 2004-80027378	20040922
JP 2007506748	T	20070322	JP 2006-528110	20040922
IN 2006DN01129	A	20070817	IN 2006-DN1129	20060302
US 20060270704	A1	20061130	US 2006-572343	20060317
PRAI US 2003-505138P	P	20030923		
WO 2004-US30944	W	20040922		


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:373700; MARPAT 142:373700

GI



I



II

AB Title compds. represented by the formula I [wherein ring A = (un)substituted (hetero)aryl; R1 = H, (cyclo)alkyl, (alkyl)amino, etc.; R2, R8-R10 = independently H, halo, aminocarbonyl, etc.; R5 = carbonylamino, carboxy, carbonylheterocyclic, etc.; and pharmaceutically acceptable salts, crystal forms or hydrates thereof] were prepared as potassium channel inhibitors. For example, II was given in a multi-step synthesis starting from (2-hydroxy-4-methoxyphenyl)(phenyl)methanone. I provide ≥ 20 % inhibition at a concentration of 33 μ M or less in the high throughput Kv1.5 planar patch clamp assay and ≥ 25 % inhibition at a concentration of 25 μ M or less in the AAS (Atomic Absorption Spectroscopy) assay. Thus, I and their pharmaceutical compns. are useful as potassium channel inhibitors for the treatment of cardiac arrhythmias, and the like.


IT 1027989-45-2

RL: PRPH (Prophetic)

(Preparation of isoquinoline derivatives as potassium channel inhibitors)

RN 1027989-45-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 4-(3-fluorophenyl)-1,2-dihydro-6-methoxy-2-methyl-1-oxo- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN
 AN 2005:136521 CAPLUS Full-text
 DN 142:225784
 TI Nanoparticulate sildenafil free base compositions
 IN Ryde, Tuula A.; Hovey, Douglas C.; Bosch, H. William
 PA Elan Pharma International Ltd., Ire.
 SO PCT Int. Appl., '76 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013937	A2	20050217	WO 2004-US19106	20040723
	WO 2005013937	A3	20050616		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20050042177	A1	20050224	US 2004-895405	20040721
	CA 2533163	A1	20050217	CA 2004-2533163	20040723
	EP 1658053	A2	20060524	EP 2004-786037	20040723
	EP 1658053	B1	20080227		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	JP 2006528176	T	20061214	JP 2006-521069	20040723
	AT 387186	T	20080315	AT 2004-786037	20040723
	ES 2302035	T3	20080701	ES 2004-786037	20040723
PRAI	US 2003-489101P	P	20030723		
	WO 2004-US19106	W	20040723		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention is directed to nanoparticulate comps. comprising sildenafil free base. The sildenafil free base particles have an effective average particle size of <2000 nm. Thus, 30 g the nanoparticulate sildenafil free base dispersion was added to 3.0 g mannitol and 1.5 g pullulan. A wafer tray was then filled by adding 0.5 g the diluted sildenafil free base dispersion to each 0.5-mL well and the wafer tray was then placed in a lyophilizer for 48 h to produce the final lyophilized wafer dosage form.


IT 212500-03-3, T-1032

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nanoparticulate sildenafil free base comps.)

RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
 (CA INDEX NAME)

CRN 212500-02-2
CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9
CMF H2 O4 S



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2004:1124642 CAPLUS [Full-text](#)

DN 142:79915

TI Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases

IN Wollin, Stefan-Lutz

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110450	A1	20041223	WO 2004-EP51120	20040615
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RM:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,			

SN, TD, TG
 CA 2529007 A1 20041223 CA 2004-2529007 20040615
 EP 1638567 A1 20060329 EP 2004-741805 20040615
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR
 JP 2006527737 T 20061207 JP 2006-516154 20040615
 US 20060148693 A1 20060706 US 2005-560116 20051209
 US 7238664 B2 20070703
 PRAI EP 2003-13615 A 20030616
 WO 2004-EP51120 W 20040615

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to the combined administration of a pulmonary surfactant and a PDE5 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental. For example, a suspension for intrabronchial instillation contained Sildenafil 0.79mg and Lusupultide 15.34g.


IT 212500-02-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pharmaceutical composition comprising pulmonary surfactants in combination with phosphodiesterase 5 inhibitors for the treatment of lung diseases)

RN 212500-02-2 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2004:1036929 CAPLUS [Full-text](#)

DN 142:16825

TI Composition comprising a PDE4 inhibitor and a PDE5 inhibitor

IN Dunkern, Thorsten; Hatzelmann, Armin; Schudt, Christian; Grimminger, Friedrich; Ghofrani, Hossein Ardeschir

PA Altana Pharma A.-G., Germany

SO PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004103407	A2	20041202	WO 2004-EP50869	20040519
	WO 2004103407	A3	20050217		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			

10/572,343 (RCE)

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

AU 2004241749	A1	20041202	AU 2004-241749	20040519
AU 2004241749	B2	20100325		
CA 2525946	A1	20041202	CA 2004-2525946	20040519
EP 1628682	A2	20060301	EP 2004-766017	20040519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010326	A	20060523	BR 2004-10326	20040519
CN 1791429	A	20060621	CN 2004-80013349	20040519
JP 2006528229	T	20061214	JP 2006-530210	20040519
NZ 544040	A	20090331	NZ 2004-544040	20040519
ZA 2005008116	A	20070131	ZA 2005-8116	20051007
MX 2005012302	A	20060130	MX 2005-12302	20051115
US 20060094723	A1	20060504	US 2005-556888	20051115
IN 2005MN01393	A	20070706	IN 2005-MN1393	20051213
NO 2005005941	A	20051214	NO 2005-5941	20051214
PRAI EP 2003-11609	A	20030522		
WO 2004-EP50869	W	20040519		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 GI



AB The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) activity is detrimental. Patients were administered orally one tablet of Roflumilase and once daily a tablet of Viagra. An example of another selected PDE4 inhibitor is I.


IT 212500-03-3, T-1032
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition comprising a PDE4 inhibitor and a PDE5 inhibitor)

RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
 (CA INDEX NAME)

CM 1

CRN 212500-02-2
CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9
CMF H2 O4 S



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2004:885197 CAPLUS [Full-text](#)

DN 141:360422

TI Long-Term Treatment with a Phosphodiesterase Type 5 Inhibitor Improves
Pulmonary Hypertension Secondary to Heart Failure through Enhancing the
Natriuretic Peptides-cGMP Pathway

AU Yamamoto, Takashi; Wada, Atsuyuki; Tsutamoto, Takayoshi; Ohnishi, Masato;
Horie, Minoru

CS Department of Cardiovascular and Respiratory Medicine, Shiga University of
Medical Science, Otsu, Shiga, Japan

SO Journal of Cardiovascular Pharmacology (2004), 44(5), 596-600

CODEN: JCPCDT; ISSN: 0160-2446

PB Lippincott Williams & Wilkins

DT Journal

LA English

AB In advanced heart failure (HF), the compensatory pulmonary vasodilation is attenuated due to the relative insufficiency of cGMP despite increased secretion of natriuretic peptides (NPs). Phosphodiesterase type 5 (PDE5) inhibitors prevent cGMP degradation, and thus may potentiate the effect of the NPs-cGMP pathway. The authors orally administered a specific PDE5 inhibitor, T-1032 (1 mg/kg; twice a day, n = 7) or placebo (n = 7) for 2 wk in dogs with HF induced by rapid pacing (270 bpm, 3 wk) and examined the blood plasma levels of atrial natriuretic peptide (ANP), cGMP, and hemodynamic parameters. The authors also examined the hemodynamic changes after injection of a specific NPs receptor antagonist, HS-142-1 (3 mg/kg), under treatment with T-

1032. T-1032 significantly increased plasma cGMP levels compared with the vehicle group despite low plasma ANP levels associated with improvement in cardiopulmonary hemodynamics. HS-142-1 significantly decreased plasma cGMP levels in both groups, whereas it did not change all hemodynamic parameters in the vehicle group. In contrast, in the T-1032 group, HS-142-1 significantly increased pulmonary arterial pressure and pulmonary vascular resistance. These results indicated that long-term treatment with a PDE5 inhibitor improved pulmonary hypertension 2ndary to HF and the NPs-cGMP pathway contributed to this therapeutic effect.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phosphodiesterase type 5 inhibitor improves pulmonary hypertension 2ndary to heart failure)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1)
(CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2004:534178 CAPLUS [Full-text](#)


DN 141:71461

TI Preparation of isoquinolinone derivatives as JNK inhibitors

IN Itoh, Fumio; Kitamura, Shuji; Kimura, Hiroyuki; Igata, Hideki

PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004054979	A1	20040701	WO 2003-JP16159	20031217
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003289386	A1	20040709	AU 2003-289386	20031217
	JP 2004210772	A	20040729	JP 2003-421268	20031218
PRAI	JP 2002-366257	A	20021218		
	WO 2003-JP16159	W	20031217		
OS	MARPAT 141:71461				
GI					



AB JNK inhibitors characterized by containing compds. represented by the following general formula, or salts or prodrugs thereof; wherein A is an optionally substituted benzene ring; R1 is an optionally substituted cyclic hydrocarbon group or an optionally substituted heterocyclic group; R2 is hydrogen, a hydrocarbon group which may be substituted with optionally substituted hydroxyl, cyano, acyl, optionally esterified carboxyl, optionally substituted carbamoyl, or optionally substituted amino; X is an optionally substituted divalent linear hydrocarbon group; and Y is an optionally substituted nonarom. hydrocarbon group, an optionally substituted heterocyclic group, optionally substituted hydroxyl, or optionally substituted amino. Title compds. I [wherein ring A = (un)substituted Ph; R1 = (un)substituted cyclic hydrocarbon group or heterocycle; R2 = H, (un)substituted hydrocarbon group; X = (un)substituted bivalent linear hydrocarbon group; Y = (un)substituted nonarom. hydrocarbon group, heterocyclyl, hydroxyl, amino; and their salts or prodrug thereof] were prepared For example, II was prepared by


the coupling reaction of 6-chloro-2-(4-methoxycarbonylbenzyl)-1-oxo-4-trifluoromethanesulfonyloxy-1,2-dihydroisoquinolin-3-carboxylic Me ester with 2-formyl-3-thiophene boronic acid in 20% yield. II showed inhibition of JNK1 with the IC50 value of 0.025µM. The formulation of I were also presented. Thus, I and their pharmaceutical compns. are useful as JNK inhibitors for the prevention and treatment of JNK related diseases, such as diabetes mellitus, etc. (no data).

IT 706758-91-0P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of isoquinolinone derivs. as JNK inhibitors)

RN 706758-91-0 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-4-[5-(hydroxymethyl)-2-thienyl]-2-[[4-(methoxycarbonyl)phenyl]methyl]-1-oxo-, methyl ester (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2004:98963 CAPLUS [Full-text](#)

DN 140:246624

TI T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-mediated muscle haemodynamic effects and glucose uptake in vivo

AU Mahajan, Hema; Richards, Stephen M.; Rattigan, Stephen; Clark, Michael G.
CS Biochemistry, Medical School, University of Tasmania, Tasmania, 7001, Australia

SO British Journal of Pharmacology (2003), 140(7), 1283-1291
CODEN: BJPCBM; ISSN: 0007-1188

PB Nature Publishing Group

DT Journal

LA English

AB 1 cGMP phosphodiesterase-5 inhibitors have been shown to alter blood flow in specific tissues by potentiating local NO-dependent vasodilatory mechanisms. Since the haemodynamic effects of physiologic insulin, particularly capillary recruitment, may be critical for muscle glucose uptake in vivo and are blocked by inhibitors of nitric oxide synthase, we have explored the acute effects of the specific cGMP phosphodiesterase-5 inhibitor T-1032 on physiologic insulin action in anesthetized healthy rats in vivo. 2 Whole-body glucose infusion (GIR), femoral blood flow (FBF), hind leg vascular resistance (VR), hind leg glucose uptake (HGU), 2-deoxyglucose uptake into muscles of the lower leg (R'g), hind leg metabolism of infused 1-methylxanthine (1-MX), a measure of capillary recruitment, and muscle cGMP were determined. The exptl. groups were T-1032 (10 µg min⁻¹ kg⁻¹) infused for 1 h before and during a euglycemic

10/572,343 (RCE)

insulin clamp (3 mU min⁻¹ kg⁻¹ + 2 h), T-1032 infused for 3 h with saline, T-1032 during a 2 h clamp, T-1032 with saline for 2 h, and a 2 h saline control. 3 Insulin increased GIR from zero to 13 mg min⁻¹ kg⁻¹, HGU from 0.1±0.01 to 0.43±0.05 µmol min⁻¹, R'g and 1-MX, marginally increased FBF, and had no effect on blood pressure or heart rate. T-1032 alone had no effect on blood pressure, heart rate, FBF, VR, HGU, R'g or 1-MX, but increased muscle cGMP. T-1032 1 h before and during insulin completely blocked GIR (1 h), HGU (2 h), R'g (2 h), and 1-MX (2 h). T-1032 commenced with insulin had only partial blocking activity against insulin. 4 We conclude that T-1032 is a potent acutely acting inhibitor of the muscle effects of physiol. insulin on capillary recruitment and glucose uptake in vivo. These, together with inhibition of whole-body glucose infusion during insulin, may caution against the use of isoenzyme-5-specific cGMP phosphodiesterase inhibitors as therapeutic agents.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiol. insulin-mediated muscle haemodynamic effects and glucose uptake in vivo)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2003:656749 CAPLUS Full-text

DN 139:197386

TI Preparation of isoquinolinone derivatives as JNK inhibitors

IN Itoh, Fumio; Kimura, Hiroyuki; Igata, Hideki; Kawamoto, Tomohiro; Sasaki, Mitsuru; Kitamura, Shuji

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 369 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003068750	A1	20030821	WO 2003-JP1429	20030212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2476162	A1	20030821	CA 2003-2476162	20030212
	AU 2003211931	A1	20030904	AU 2003-211931	20030212
	EP 1484320	A1	20041208	EP 2003-705075	20030212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2004143134	A	20040520	JP 2003-35096	20030213
	US 20050148624	A1	20050707	US 2004-504132	20040811
	US 7402595	B2	20080722		
PRAI	JP 2002-35073	A	20020213		
	JP 2002-251997	A	20020829		
	WO 2003-JP1429	W	20030212		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:197386

AB Claimed are JNK (c-Jun N-terminal kinase) inhibitors containing isoquinolinones or salts thereof. The second claim specifies that said isoquinolinones are 1-isoquinolinones. Comps. of this invention in vitro showed IC50 values of 0.0067 μ M to 0.095 μ M against JNK1. Formulations are given.


IT 583831-78-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of isoquinolinone derivs. as JNK inhibitors)

RN 583831-78-1 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 6-chloro-1,2-dihydro-2-(methylamino)-4-(4-methylphenyl)-1-oxo-, methyl ester (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2003:652131 CAPLUS Full-text

DN 139:214237

TI Preparation of nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases

IN Scaramuzzino, Giovanni

PA Italy

SO Eur. Pat. Appl., 313 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1336602	A1	20030820	EP 2002-425075	20020213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	EP 2002-425075		20020213		
GI					



AB New pharmaceutical compds. of general formula F-(X)q (I) [q = 1-5, preferably 1; F is chosen among drugs such as δ -tocopherol, clidanac, diethylhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt, nitrite ester, ONO, thioinitrite, SNO, etc., T = OR1-M, OR1OR1-M, SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc., R1 = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl,

optionally heterosubstituted 3-7 carbon aryl; R1, R2 = OH, SH, F, Cl, Br, OP(=O)H2, CO2H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M2, OZ-M2, NR2Z-M2, R1Z-M2, OR1-M2, OR1Z-M2, M2 = M, R1-M, OR1-M, SR1-M, NR2R1-M; ZM2 = COCH2CH(M2)CH2NMe3, COCH2CH2COM2, COCH(NHR2)CH2M2, etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2, etc.] were prepared For example, α -tocopherol reacted with 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

IT 586349-90-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nitrate prodrugs for treating or preventing inflammatory, ischemic, degenerative, and proliferative diseases)


RN 586349-80-6 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, nitrate (1:?) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7697-37-2


CMF H N O3



OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 2003:633415 CAPLUS Full-text
 DN 139:159956
 TI Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate
 CNS nerve regeneration
 IN Bunge, Mary Bartlett; Pearse, Damien Daniel
 PA University of Miami, USA
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003065994	A2	20030814	WO 2003-US3513	20030207
	WO 2003065994	A3	20040212		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, IJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2476275	A1	20030814	CA 2003-2476275	20030207
	AU 2003210869	A1	20030902	AU 2003-210869	20030207
	US 20030220280	A1	20031127	US 2003-359554	20030207
	EP 1482916	A2	20041208	EP 2003-737656	20030207
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005516988	T	20050609	JP 2003-565420	20030207
	US 20090136463	A1	20090528	US 2009-363388	20090130
PRAI	US 2002-354306P	P	20020207		
	US 2003-359554	A1	20030207		
	WO 2003-US3513	W	20030207		
AB	The use of a composition that elevates intracellular levels of cyclic nucleotide cyclases in combination with phosphodiesterase inhibitors and cell grafts to restore function after CNS injury are disclosed.				
IT	212500-03-3, T-1032 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (stimulation of CNS nerve regeneration by phosphodiesterase inhibitors and Schwann cell bridge implants)				
RN	212500-03-3 CAPLUS				
CN	3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)				
CM	1				
CRN	212500-02-2				
CMF	C32 H29 N3 O7				



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 31 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2003:491029 CAPLUS Full-text

DN 139:63337

TI Use of selective phosphodiesterase 5 (PDE5) inhibitors in the treatment of
 pulmonary diseases having a ventilation-perfusion mismatch

IN Ghofrani, Ardeschir; Grimminger, Friedrich Josef; Schudt, Christian

PA Altana Pharma AG, Germany

SO PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051346	A2	20030626	WO 2002-EP14279	20021214
	WO 2003051346	A3	20040212		
	W:	AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, HU, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, TN, UA, US, VN, YU, ZA, ZW			
	RW:	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR			
	CA 2470210	A1	20030626	CA 2002-2470210	20021214
	AU 2002361417	A1	20030630	AU 2002-361417	20021214
	EP 1461022	A2	20040929	EP 2002-796635	20021214
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	JP 2005513060	T	20050512	JP 2003-552279	20021214
	US 20050107394	A1	20050519	US 2005-499215	20050104
PRAI	EP 2001-129951	A	20011217		
	EP 2002-9555	A	20020426		

EP 2002-23936 A 20021025
 WO 2002-EP14279 W 20021214

- AB The invention discloses the use of PDE5 inhibitors for the treatment of patients having a pulmonary disorder in which a pulmonary ventilation-pulmonary perfusion mismatch is present.
- IT 212500-02-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phosphodiesterase 5 inhibitors for treatment of pulmonary disease with ventilation-perfusion mismatch)
- RN 212500-02-2 CAPLUS
- CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



- OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
- RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2003:90630 CAPLUS [Full-text](#)

DN 139:46973

TI Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons

AU Nakamizo, Tomoki; Kawamata, Jun; Yoshida, Kohei; Kawai, Yuko; Kanki, Rie; Sawada, Hideyuki; Kihara, Takeshi; Yamashita, Hirofumi; Shibasaki, Hiroshi; Akaike, Akinori; Shimohama, Shun

CS Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan

SO Journal of Neuroscience Research (2003), 71(4), 485-495

CODEN: JNREDK; ISSN: 0360-4012

PB Wiley-Liss, Inc.

DT Journal

LA English

- AB We have previously reported that cyclic guanosine-3',5'-monophosphate (cGMP) protects spinal motor neurons against acute reactive oxygen species (ROS)-induced toxicity but not against chronic ROS-induced or glutamate (Glu)-induced toxicity. In this study, we investigated the effects of phosphodiesterase (PDE) inhibitors on the survival of cultured spinal motor neurons. Selective PDE5 inhibitors (dipyridamole, T-1032, and zaprinast) as well as a nonselective PDE inhibitor (aminophylline) protected motor and non-motor neurons against both acute ROS-induced and chronic Glu-induced neurotoxicity, whereas selective inhibitors of PDE1-4 offered no protection. 8-Bromo-cGMP (8Br-cGMP), a cGMP analog, protected both motor and non-motor neurons against acute ROS-induced toxicity but protected only non-motor neurons against chronic Glu-induced toxicity. This neuroprotection was blocked by KT5823, a cGMP-dependent protein kinase (PKG) inhibitor. Immunohistochem.

staining confirmed that PDE5 and PKG are located in almost all rat lumbar spinal neurons. Furthermore, semiquant. anal. of the immunostaining intensity revealed that PDE5 was more abundant in motor neurons than in non-motor neurons. Our results suggest that this difference in the amount of PDE5 may be responsible for the vulnerability of motor neurons to chronic excitotoxicity. In addition, the results of this study raise the possibility that PDE5 inhibitors might be used as a treatment for amyotrophic lateral sclerosis.

IT 212500-03-3, T-1032

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phosphodiesterase inhibitors are neuroprotective to spinal motor neurons)


RN 212500-03-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-(4-aminophenyl)-1,2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-, methyl ester, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 212500-02-2

CMF C32 H29 N3 O7



CM 2

CRN 7664-93-9

CMF H2 O4 S



OSC.G 24 THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2010 ACS on STN

AN 2002:902258 CAPLUS [Full-text](#)

DN 137:379992

TI Method of inhibiting neoplastic cells with isoquinolinonecarboxylates


IN Pamukcu, Rifat; Piazza, Gary A.

PA Cell Pathways, Inc., USA

SO U.S., 119 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6486155	B1	20021126	US 1998-198413	19981124
PRAI	US 1998-198413		19981124		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 137:379992
 GI




I

AB A method is claimed for inhibiting neoplasia (no data), particularly cancerous and precancerous lesions, by exposing the affected cells to 1-isoquinoline-3-carboxylates. Such compds. are effective in modulating apoptosis and eliminating and inhibiting the growth of neoplasias such as precancerous lesions, but are not characterized by the severe side reactions of conventional non-steroidal antiinflammatory drugs or other chemotherapeutics. Although the methods of preparation are not claimed, example preps. of 429 isoquinolines and 107 intermediates are included; these examples are referenced to PCT application WO 98/38168. Although the claims indicate I (ring A and ring B are the same or different and each a (un)substituted benzene ring, R1 is morpholine, R2 is -COOR3, and R3 is alkyl; e.g. 7-benzyloxy-6-methoxy-3-methoxycarbonyl-2-morpholino-4- (3,4,5-trimethoxyphenyl)-1(2H)-isoquinolinone) or pharmaceutically acceptable salt thereof, the examples include a much broader variety of 1-isoquinoline-3-carboxylates.

IT 260407-20-3
 RL: PRPH (Prophetic)
 (Method of inhibiting neoplastic cells with isoquinolinonecarboxylates)

RN 260407-20-3 CAPLUS

CN 3-Isoquinolinecarboxylic acid, 2-[[[(1,1-dimethylethoxy)carbonyl](2-hydroxyethyl)amino]-1,2-dihydro-1-oxo-4-(3,4,5-trimethoxyphenyl)-, methyl ester (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 171 THERE ARE 171 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y
 STN INTERNATIONAL LOGOFF AT 08:06:26 ON 14 APR 2010